
==== Front
Signal Transduct Target Ther
Signal Transduct Target Ther
Signal Transduction and Targeted Therapy
2095-9907
2059-3635
Nature Publishing Group UK London

1936
10.1038/s41392-024-01936-8
Review Article
Pharmacokinetic characteristics of mesenchymal stem cells in translational challenges
http://orcid.org/0000-0002-6954-364X
Shan Yunlong immunometabolism@163.com

1
Zhang Mengying 1
Tao Enxiang 1
Wang Jing 2
Wei Ning 12
Lu Yi 1
Liu Qing 2
Hao Kun haokun@cpu.edu.cn

1
Zhou Fang zf1113@163.com

1
Wang Guangji guangjiwang@hotmail.com

1
1 grid.254147.1 0000 0000 9776 7793 Key Laboratory of Drug Metabolism and Pharmacokinetics, Haihe Laboratory of Cell Ecosystem, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China
2 Jiangsu Renocell Biotech Co. Ltd., Nanjing, China
13 9 2024
13 9 2024
2024
9 24210 1 2024
4 7 2024
23 7 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Over the past two decades, mesenchymal stem/stromal cell (MSC) therapy has made substantial strides, transitioning from experimental clinical applications to commercial products. MSC therapies hold considerable promise for treating refractory and critical conditions such as acute graft-versus-host disease, amyotrophic lateral sclerosis, and acute respiratory distress syndrome. Despite recent successes in clinical and commercial applications, MSC therapy still faces challenges when used as a commercial product. Current detection methods have limitations, leaving the dynamic biodistribution, persistence in injured tissues, and ultimate fate of MSCs in patients unclear. Clarifying the relationship between the pharmacokinetic characteristics of MSCs and their therapeutic effects is crucial for patient stratification and the formulation of precise therapeutic regimens. Moreover, the development of advanced imaging and tracking technologies is essential to address these clinical challenges. This review provides a comprehensive analysis of the kinetic properties, key regulatory molecules, different fates, and detection methods relevant to MSCs and discusses concerns in evaluating MSC druggability from the perspective of integrating pharmacokinetics and efficacy. A better understanding of these challenges could improve MSC clinical efficacy and speed up the introduction of MSC therapy products to the market.

Subject terms

Translational research
Stem-cell research
https://doi.org/10.13039/501100001809 National Natural Science Foundation of China (National Science Foundation of China) 82104184 82373949 82073928 Shan Yunlong Wang Guangji issue-copyright-statement© West China Hospital, Sichuan University 2024
==== Body
pmcIntroduction

Mesenchymal stem/stromal cell (MSC), which can be harvested and expanded from various adult and perinatal tissues, such as adipose tissue, bone marrow (BM), dental pulp, and umbilical cord (UC),1 exhibits diverse pharmacological effects, including immunomodulation, angiogenesis, and regenerative properties, rendering them promising for therapeutic applications.2 MSC therapy, which exerts the therapeutic potential of living cell preparations, has experienced explosive growth in both clinical deployment and expansion within the pharmaceutical marketplace for decades.3,4 Several MSC therapies approved by regulatory agencies and introduced to the commercial market have attracted increasing public attention. These include the successful approval of Prochymal (Remestemcel-L) in 2012 for treating graft-versus-host disease (GvHD) in Canada and Alofisel in 2018 for the treatment of Crohn’s disease in Europe (Table 1). The significant clinical benefits of MSC therapies are inspiring for further exploration and development.Table 1 MSC products approved in different countries

Product	Origin	Therapeutic disease	Approved time	Approved region	
Queencell	Autologous adipose tissue	Subcutaneous tissue injury	2010	Korea	
Cellgram	Autologous BM	Acute myocardial infarction	2011	Korea	
Cartistem	Allogeneic umbilical cord blood	Degenerative osteoarthrosis	2012	Korea	
Cupistem	Autologous adipose tissue	Crohn’s Disease, Perianal fistulae	2012	Korea	
Prochymal	Allogeneic BM	Graft-versus-host disease	2012	Canada, New Zealand	
TEMCELL	Allogeneic BM	Graft-versus-host disease	2015	Japan	
NeuroNata-R	Autologous BM	Amyotrophic lateral sclerosis	2014	Korea	
Stempeucel	Allogeneic BM	Critical limb ischemia, Angiitis	2015, 2020	European Union, India	
Stemirac	Autologous BM	Spinal cord injury	2018	Japan	
Alofisel	Allogeneic adipose tissue	Crohn’s Disease, Perianal fistulae	2018, 2021	European Union, Japan	

Many previous studies disconnected basic biomedical research and the potential druggability of MSCs. A limited understanding of the dynamic biodistribution and fate of MSCs within the body threatens the development of MSC therapies. The evaluation of the safety and efficacy of MSC therapy is limited by its unfavorable pharmacokinetic (PK) and pharmacodynamic (PD) properties.5 Pharmacokinetics, which describes how the body interacts with a drug, involves the processes of absorption, distribution, metabolism, and excretion, detailing the drug’s movement into, through, and out of the body over time.6 Unlike conventional drugs, MSCs can naturally migrate, localize, and even proliferate in specific tissues or compartments.7 In this review, we can consider the biodistribution of MSCs within the body as “distribution” and their fate as “metabolism and excretion”. Furthermore, MSCs are typically distinct from other cell therapies because their therapeutic efficacy depends not only on cell-to-cell contact but also on what is often referred to as a “hit-and-run” (or “touch and go”) mechanism—that is, through their rapid migration to damaged tissues and subsequent clearance following the release of paracrine effectors from their secretome, including soluble cytokines, growth factors, hormones, and miRNAs8,9 or the transfer of mitochondria to target cells through tunneling nanotubes,10,11 potentially leading to long-lasting effects.12 Thus, the lack of control over the localization, migration, and fate of MSCs is a translational challenge for MSC therapies.13

Numerous studies have shown that secretome-derived bioproducts containing bioactive molecules (such as proteins, lipids, and nucleic acids) and MSC-derived extracellular vesicles (EVs) retain the biological activity of parent MSCs and demonstrate similar therapeutic effects.14 The characteristics of secretome-derived bioproducts and MSC-derived exosomes have been comprehensively reviewed elsewhere.15–17 In this review, we first outline the key molecules involved in the motility of MSCs. We then provide a brief introduction to the various methods for tracking MSCs in vivo, highlighting their advantages and limitations. The core of the article focuses on the biodistribution and fate of MSCs in vivo, assessing the relationship between the kinetic characteristics and druggability of MSCs. Finally, we discuss the prospects of future opportunities for the clinical and commercial use of MSCs.

The landscape in clinical MSC therapies

The success of clinical trials depends on understanding the mechanisms of drugs, but the clinical application of MSCs has frequently surpassed the understanding of their underlying mechanisms. A search using the keyword “mesenchymal stem/stromal cell” on ClinicalTrials.gov revealed more than 1600 related clinical trials, with more than 1500 clinical trials employing MSCs as a therapeutic intervention. With over 500 clinical trials of MSCs expected to be conducted by 2023, there is a wealth of information that can be leveraged to enhance our understanding of the factors influencing their successful implementation in human subjects (Table 2). These clinical trials are mostly in phase I, phase II, or combined phase I/II trials. Only a small percentage of trials are in phase III (comparing newer treatment approaches with standard or most well-known treatments) or phase II/III. Overall, MSCs appear to be well tolerated, with the majority of trials reporting no adverse reactions in the midterm. Only a few trials indicated mild and transient adverse reactions during the injection period. While MSCs exhibit a favorable safety profile, they often struggle to demonstrate significant efficacy in humans.18 Notably, no MSC therapies have received approval from the National Medical Products Administration (NMPA) of China or the U.S. Food and Drug Administration.Table 2 Representative clinical trials of MSC therapies

General indication	Clinical indication	Cell source	Administration route	Clinical efficacy	Engineered	Phase	Trial number	
Autoimmune diseases	Rheumatoid arthritis	Allogeneic mesenchymal precursor cells	Systemic	Yes	No	2	NCT03186417	
Systematic lupus erythematous	Allogeneic UC	Systemic	Promising	No	2	NCT03171194	
Arthropathy	Osteoarthritis, knee	Autologous BM	Local	Yes	No	1/2	NCT01183728	
Osteoarthritis, knee	Autologous BM	Local	Yes	No	1/2	NCT01586312	
Osteoarthritis, knee	Autologous BM	Local	Yes	No	2	NCT02958267	
Focal cartilage lesions of the knee	Allogeneic BM	Local	Yes	No	1/2	NCT02037204	
Blood disorder	Nonmalignant red blood cell disorders	Allogeneic BM	Systemic	No	No	2	NCT00957931	
Cancer	Advanced gastrointestinal cancer	Autologous BM	Systemic	No	Yes	1/2	NCT02008539	
Metastases solid tumors	Autologous BM	Systemic	Unknown	Yes	1/2	NCT01844661	
Cardiovascular diseases	Acute myocardial infarction	Allogeneic BM	Systemic	Yes	No	2	NCT00877903	
Chronic heart failure	Allogeneic mesenchymal precursor cells	Local	Yes	No	3	NCT02032004	
Heart failure	Autologous UC	Systemic	Yes	No	3	NCT05043610	
Ischemic stroke	Allogeneic BM	Systemic	No	No	2	NCT01436487	
Non-ischemic heart failure	Autologous BM	Systemic	No	No	2	NCT02467387	
Undergoing cardiac surgery	Autologous BM	Local	Yes	No	1/2	NCT00587990	
Cardiomyopathy due to anthracyclines	Allogeneic BM	Systemic	Yes	No	1	NCT02509156	
Chronic ischemic left ventricular dysfunction	Autologous BM	Local	No	No	1/2	NCT01087996	
Chronic ischemic left ventricular dysfunction	Autologous BM	Local	Yes	No	2	NCT02013674	
Nonischemic dilated cardiomyopathy	Autologous/Allogeneic BM	Systemic	Yes	No	1/2	NCT01392625	
Ventricular dysfunction, left	Autologous BM	Systemic	Yes	No	1/2	NCT00768066	
Dilated cardiomyopathy	Autologous BM	Systemic	Yes	No	2	NCT00629018	
Heart failure	Allogeneic BM	Local	Unknown	No	2	NCT00927784	
Dental diseases	Periapical periodontitis	Allogeneic UC	Local	Yes	No	1/2	NCT03102879	
Eye diseases	Advanced glaucoma	Autologous BM	Local	Unknown	No	1	NCT02330978	
GvHD	Acute GvHD	Allogeneic BM	Local	Yes	No	1/2	NCT02379442	
Chronic GvHD	Allogeneic BM	Local	Unknown	No	2/3	NCT01526850	
Grade B to D acute GvHD	Allogeneic BM	Systemic	Yes	No	3	NCT02336230	
Grade B to D acute GvHD	Allogeneic BM	Systemic	Yes	No	3	NCT00366145	
IBD	Crohn’s disease	Allogeneic adipose tissue	Local	Yes	No	3	NCT01541579	
Crohn’s disease	Allogeneic BM	Systemic	Yes	No	3	NCT00482092	
Ulcerative colitis	Allogeneic BM	Systemic	To be determined	No	2	NCT01240915	
Kidney disorders	Acute kidney injury	Allogeneic BM	Systemic	No	No	2	NCT01602328	
Diabetic nephropathy	Allogeneic mesenchymal precursor cells	Systemic	Yes	No	1/2	NCT01843387	
Kidney failure	Allogeneic BM	Systemic	No	No	1/2	NCT01429038	
Renal transplantation	Autologous BM	Systemic	Yes	No	N/A	NCT00658073	
Neurological disorders	Alzheimer’s disease	Allogeneic UC	Systemic	Unknown	No	1/2	NCT01547689	
Amyotrophic lateral sclerosis	Autologous BM	Local	Yes	Yes	2	NCT02017912	
Chronic progressive multiple sclerosis	Autologous BM	Local	To be determined	Yes	2	NCT03799718	
Diabetic peripheral neuropathy	Autologous BM	Systemic	Yes	No	N/A	NCT02387749	
Multiple sclerosis	Autologous BM	Systemic	To be determined	No	2	NCT02239393	
Spinal cord injury	Autologous BM	Local	No	No	1	NCT01909154	
Spinal cord injury	Allogeneic UC	Local	Yes	No	1/2	NCT02481440	
Spinal cord injury	Autologous BM	Local	Yes	No	1	NCT02165904	
Respiratory disorders	Acute respiratory distress syndrome	Allogeneic BM	Systemic	N/A	No	1	NCT01775774	
Chronic obstructive pulmonary disease	Allogeneic BM	Systemic	No	No	2	NCT00683722	
Lung adenocarcinoma	Allogeneic UC	Systemic	To be determined	Yes	1/2	NCT03298763	
Acute respiratory distress syndrome	Allogeneic BM	Systemic	Yes	No	2	NCT02097641	
Idiopathic pulmonary fibrosis	Allogeneic UC	Systemic	Yes	No	1	NCT01385644	
Respiratory distress syndrome, adult	Autologous BM	Systemic	Unknown	No	2	NCT02112500	
Skin disorder	Psoriasis vulgaris	Allogeneic UC	Systemic	Yes	No	1/2	NCT02491658	

Representative registered clinical trials of MSC therapies

Many completed clinical trials have demonstrated the efficacy of MSC infusion in treating a variety of diseases, such as GvHD, multiple sclerosis (MS), Crohn’s disease (CD), amyotrophic lateral sclerosis (ALS), myocardial infarction (MI), and acute respiratory distress syndrome (ARDS), among others (Table 2). Kabat et al. classified the indications for clinical trials into 14 groups, with those that could not be classified or had too few cases classified as “Other“.19 Among these clinical trials, MSC therapies for “neurological” diseases (17%) and “joint” diseases (15%) are the most common in registered indications. Cardiovascular disease (8.8%) and GvHD (8.3%) are closely related to this disease, with a higher percentage of phase III clinical trials. Only 84% explicitly specify the route of administration in MSC clinical trials.

Clinical comparison of MSC therapy and cell-free therapy

Compared to MSC therapy, cell-free therapy utilizing the MSC secretome involves the delivery of multiple bioactive molecules rather than intact cells.20 Assessing the safety and efficacy of MSC-conditioned medium will be considerably less complicated.21 Furthermore, the production of conditioned medium is more economical, as it can be scaled up for mass production utilizing existing MSC populations under current good manufacturing practice conditions. Nonetheless, cell-free therapy products share similarities with conventional drugs in that they may necessitate prolonged administration and could result in the development of drug resistance and adverse reactions.22 However, cell therapy offers the distinct advantage of potentially conferring enduring effects with a single treatment that can last for several months, reducing the need for frequent medication and enhancing the resilience of the treatment regimen.23 Additionally, to enhance the efficacy of MSC therapy and their homing ability, the singular or combined application of bioengineering techniques shows promising potential to significantly overcome the current clinical challenges.

Impact of different administration routes

The pharmacokinetics and biological properties of infused MSCs may be influenced by the route of administration.13,24 The administration routes in MSC clinical trials mainly include intravenous, intracardiac, intra-articular, intramuscular, intraosseous, intrathecal, intra-arterial, and implantation. Among the eight most frequently employed routes, intravenous infusion accounts for 43%.19 This preference for intravenous infusion is attributed to its ease of administration, low invasiveness, and high repeatability, making it the most frequently utilized method in treatment.25

Local administration is commonly employed because it allows direct delivery to the disease site. Forty-nine percent of registered MSC clinical trials utilized local delivery by 2018.26 Many MSC therapies are locally administered for various diseases, including lumbar pain, anal fistula, and chronic heart failure, in late-stage clinical trials.27 Local administration of MSCs is a more controllable approach, making it easier to access disease sites and often yielding better therapeutic responses.28 However, in certain cases, less than 5% of the administered cells have been observed to remain at the injection site just hours after transplantation.29 Moreover, local administration of MSCs also results in secondary distribution but is limited to locally vascularized areas such as the heart.30 The poor persistence of MSCs after local administration is due to several factors, such as cell death from the inhospitable microenvironment at the disease site and ineffective integration into the tissue.31 Compared to systemic administration, direct injection of MSCs into damaged tissue sites lacks systemic homing processes, but the persistence of MSCs in target tissues remains similar to that of systemic administration.

Systemic administration of MSCs is more minimally invasive and can avoid tissue calcification issues compared with local injection.32 Among the approved MSC products, treatments for GvHD and spinal cord injury are administered systemically. Although many studies in animals and humans have shown that intravenously infused MSCs tend to stick to the lungs,33 systemic administration of MSC therapy has been used in most clinical trials by 2023. Due to nonspecific uptake by blood vessels in nontarget tissues, higher doses are needed for MSCs to achieve effective treatment levels in target organs and tissues. The administration of 105–107 MSCs per kilogram is required based on patient weight,34,35 leading to widespread biodistribution in tissues and organs such as the lung, liver, and gastrointestinal tract.36 An increasing number of MSC clinical trials are using systemic administration, highlighting the need for a comprehensive understanding of the pharmacokinetics of MSCs in the body. The detailed process of systemic administration of MSCs in vivo can be found in the next section.

Molecules of governing MSC motile potency during homing

After systemic administration, MSCs enter the blood circulation and cross the vascular endothelium at lesion sites through four steps: (1) tethering and rolling, (2) activation, (3) adhesion, and (4) transmigration (Fig. 1). This process involves various proteins that regulate MSC motility and interactions with endothelial cells (ECs). The ligands expressed on the surface of MSCs mediate their rolling action on the vascular wall upon binding to selectins. The G protein-coupled chemokine receptors on MSCs receive activation signals, leading to integrin-dependent adhesion to the endothelium. Finally, MSCs secrete proteases to break down the EC barrier, completing the homing process.7,37,38Fig. 1 Multiple steps in mesenchymal stem cells (MSCs) homing. The homing processes of MSCs are dependent on a series of molecules of motile potency, including selectins, integrins, chemokine receptors, and proteases. Selectins, which are expressed on endothelial cells (ECs), capture MSCs by interacting with their ligands and then mediating the rolling of MSCs. MSCs can thus be activated by exposure to chemokines, consequently leading to integrin-dependent firm adhesion to the endothelium. At the appropriate location, MSCs cross the endothelial barrier by secreting different proteases before continuing chemokine-mediated migration

Selectin ligands

The homing process is initiated through tethering events mediated by selectin ligands on MSCs and selectins on ECs (Table 3), with MSCs rolling after attaching to ECs.39 Hematopoietic cell E-selectin/L-selectin ligand (HCELL), a functional form of CD44 containing an sLex-like epitope, binds to E-selectin/L-selectin and functions as a marker of MSC motility.40,41 P-selectin also plays a role in mediating the rolling of MSCs through interacting with P-selectin glycoprotein ligand (PSGL-1),42 and blocking P-selectin decreases the binding of MSCs to ECs.39 Suila et al. reported that Galectin-1, rather than PSGL-1, tends to serve as a marker of MSC motility, as MSCs preferentially interact with P-selectin on ECs through Galectin-1, which is independent of the sLex epitope.43 The complex interplay of various selectin ligands is crucial for the efficient adhesion of MSCs to ECs.Table 3 Molecules governing MSC motility during homing

Molecule	Ligand/Receptor/Substrate	Ligand/Receptor source	Function	MSC organism	Cell source	Strategies to improve MSCs homing	Homing target	Ref.	
Galectin-1	P-selectin	Endothelium	Tethering and rolling	Human	Umbilical cord blood	Enzymatic modification (pronase)	Injury area	43,333	
CD44 (α-1,3-gamma glycosylation)	E-selectin	Endothelium; Ischemic kidney	Shear-resistant adhesion	Human; Mouse	Adipose; BM	Enzymatic modification (fucosyltransferases)	Inflammatory sites; Kidney	41,334–336	
L-selectin	Endothelium	Human	Adipose; BM	Enzymatic modification (fucosyltransferases)	BM	41,334,335	
VLA-4	VCAM-1	Endothelium	Firm adhesion and rolling	Human	BM; Placentas	Priming (LLP2A)	BM; Fetal tissue	40,46,337	
CCR1	CCL2	Hippocampus	Homing to the cortices and hippocampus	Human	Nasal olfactory mucosae	Genetic modification (overexpression: lentivirus)	Myocardial infarction area	65	
CCL5	Infarct adjacent border zone area of the heart	Homing to the heart infraction sites	Mouse	BM	Genetic modification (overexpression: lentivirus)	/	63	
Granulation tissue of the ear	Homing to the ear wound sites	Human	Periodontal ligament	Genetic modification (overexpression: Kaposi’s sarcoma-associated herpesvirus)	Inflamed ears	73	
CCL7	Urethral	Homing to the muscle bundles in the urethra	Rat	BM	Genetic modification (overexpression: lentivirus)	CCL7 injection site	64	
CCR2	CCL2	Skin wound tissues	Homing to the skin wound sites	Human	UC	Genetic modification (overexpression: lentivirus)	Injured skin tissues	67	
Liver	Homing to the liver lesions	Human	UC	Genetic modification (overexpression: lentivirus)	Injured liver	68	
Hemisphere	Homing to hemisphere ischemic sites	Human	BM	Genetic modification (overexpression: lentivirus)	Ischemic hemisphere	69	
CD133+ glioblastoma stem cells	Homing to the brain	Human	UC	Genetic modification (overexpression: lentivirus)	Brain injury	70	
Hippocampus	Homing to the cortices and hippocampus	Human	Nasal olfactory mucosae	Genetic modification (overexpression: lentivirus)	Lesioned hippocampus	65	
CCL7	Cardiac fibroblasts	Homing to the heart infraction sites	Rat	BM	Genetic modification (overexpression: plasmid)	Injured myocardium	71	
CCR3	CCL5	Injured and inflammatory sites	Homing to the wound sites	Human	Periodontal ligament	Genetic modification (overexpression: Kaposi’s sarcoma-associated herpesvirus)	Injured and inflammatory sites	73	
CCR4	CCL2	Astroglia cell	Homing to the hemisphere lesions	Human	BM	Priming (polyethylenimine)	Brain injury	74	
CCR5	CCL5	Glioma-associated microglia	Homing to the retina	Mouse	BM	Genetic modification (overexpression: lentivirus)	Degenerating retina	96	
CCR6	CCL20	Epithelial cells	Homing to skin	Mouse	BM	Genetic modification (overexpression: plasmid)	Skin wounds	75,338	
CCR7	CCL21	Keratinocytes	Homing to the skin wound sites	Mouse	BM	Priming (culture media additives)	Wounds	78	
High endothelial venules of secondary lymphoid organs	Homing to the secondary lymphoid organs	Mouse	BM	Genetic modification (Overexpression: plasmid)	Secondary lymphoid organs	77	
Lung	Homing to the lung	Rat	BM	Genetic modification (overexpression: lentivirus	Injured lung	339	
CCR9	CCL25	Thymic dendritic cells	Homing to the thymic	Mouse	BM	Genetic modification (overexpression: lentivirus)	Thymus	80,340	
CCR10	CCL2	Hippocampus	Homing to the cortices and hippocampus	Human	Nasal olfactory mucosae	Genetic modification (overexpression: lentivirus)	Lesioned hippocampus	65	
CCL27	Epidermis, dermis	Homing to the interfollicular dermis	Mouse	BM	Genetic modification (overexpression: plasmid)	Normal skin	82	
CXCR1	CXCL8	Glioma cells	Homing to the hemisphere	Human	Umbilical cord blood	Genetic modification (overexpression: plasmid)	Gliomas	85	
CXCR2	CXCL2	Colon	Homing to the colon inflamed sites	Human	BM	Genetic modification (overexpression: mRNA transfection)	Inflammatory bowel	87	
Tongue	Homing to the inflamed mucosa of the tongue	Human	BM	Genetic modification (overexpression: lentivirus)	Radiation-induced oral mucositis	88	
CXCL5	Colon	Homing to the colon inflamed sites	Human	BM	Genetic modification (overexpression: mRNA transfection)	Inflammatory bowel	87	
CXCR3	CXCL10	Ear	Homing to the ear inflamed sites	Human	BM	Genetic modification (overexpression: lentivirus)	Inflamed lesions	341	
CXCR4	CXCL12	Brain	Homing to the brain	Human	UC; BM	Genetic modification (overexpression: lentivirus; adenovirus)	Brain injury	70,130	
Ovary	Homing to the ovary	Human	Amnion	/	Injured ovaries	92	
BM	Homing to the cortical and trabecular bone	Rat	BM; Adipose	Genetic modification (overexpression: adenovirus)	BM	342,343	
Osteoblast	Homing to the fracture sites	Rat	BM	Short-Wave	Fracture site	344	
Liver	Homing to the liver ischemic sites	Human	BM	Hypoxia	Injured liver	345	
Liver	Homing to the liver ischemic sites	Human	UC	Priming (rapamycin))	Injured liver	170	
Heart	Homing to the heart infraction sites	Rat	BM	Genetic modification (overexpression: lentivirus)	Heart of ischemia/perfusion injury	146	
Lung	Homing to the alveoli	Rat	BM	Genetic modification (overexpression: lentivirus)	Injured lung	346	
Lung epithelial cells	Homing to the lung	Human	BM	Genetic modification (overexpression: lentivirus)	Alveolar epithelial cells	91	
Lung metastatic tumor cells	Homing to the lung	Rat	BM	Genetic modification (overexpression: plasmid)	Lung tumors	347	
Intestinal tissue	Homing to the intestine inflamed sites	Mouse	BM	Genetic modification (overexpression: lentivirus); priming (IL-1β)	Intestine	138,140	
Kidney	Homing to the glomeruli and tubulointerstitium	Rat	BM	Hypoxia	Ischemic acute kidney	348	
Renal tubules cells	Homing to the kidney ischemic sites	Mouse	BM	Hypoxia	Renal ischemia/reperfusion	349	
Basal layer of the epidermis, hair follicles	Homing to the epidermis and hair follicles of wounds	Mouse	BM	/	Burn wounds	350	
CXCR5	CXCL13	Ear	Homing to the ear inflamed sites	Human	BM	Genetic modification (overexpression: lentivirus)	Inflamed ears	97	
CXCR6	CXCL16	Skin wound tissues	Homing to the skin wound sites	Mouse	BM	Genetic modification (overexpression: plasmid)	Skin wounds	75	
CX3CR1	CX3CL1	Intestinal epithelial cells	Homing to the colon	Rat	BM	Genetic modification (overexpression: lentivirus)	Inflammatory bowel	99	
MMP-1	Collagen, gelatin, laminin	/	Breakdown the endothelial basement membrane	Human	BM	Priming (IL-1β; IL-6)	Damaged tissues	106,112	
MMP-2	Collagen, gelatin, laminin	/	Breakdown the endothelial basement membrane	Human	BM	Priming (TGFβ; IL-1β; TNFα; IL-6)	Inflammatory sites	106,109,112	
MMP-13	Collagen, gelatin, laminin	/	Breakdown the endothelial basement membrane	Human	BM	Priming (IL-1β; IL-6)	Inflammatory sites	106,112	
MT1-MMP	Collagen fibrils	/	Breakdown the interstitial stroma	Human	BM	Priming (TGFβ; IL-1β; TNFα; PDGF)	Inflammatory sites	106,107,109	
TIMP-1	MMPs	/	Inhibit MMPs	Human	BM	Genetic modification (knock down: siRNA)	Inflammatory sites	106,109,112,351	
TIMP-2	MMPs	/	Inhibit MMPs; MMP-2 proenzyme activation	Human	BM	Antibody conjugation (TIMP antibodies)	Damaged tissues	106,109,112,351	
TIMP-3	MMPs	/	Inhibit MMPs	Human	BM	Antibody conjugation (TIMP antibodies)	Inflammatory sites	104	
TIMP-4	MMPs	/	Inhibit MMPs	Human	BM	Antibody conjugation (TIMP antibodies)	Damaged tissues	112	
Sialyl Lewis X	P-selectin	/	Promote rolling response	Human	BM	Protein conjugation (Sialyl Lewis X)	Inflamed tissues	352	
P-selectin binding peptide	P-selectin	/	Enhance their targeting to vascular injury sites	Rat	Adipose	Protein conjunction (Peptides: DAEWVDVS)	Vascular injury sites	353	
Peptides	Cysteine-rich protein 2	/	Improving the homing efficiency	Human	BM	Protein-conjunction (Peptides: CRPPR)	Myocardial infarction	151	

Integrins

Integrins are transmembrane receptors that act as interfaces between extracellular and intracellular compartments and facilitate cell-extracellular matrix (ECM) adhesion.44 MSCs express a broad spectrum of integrins, including β1, β2, β3, β5, α1, α2, α3, α4, α5, α6, α7, α8, α9, αX, αV, and αD45 (Table 3). The integrin VLA-4 (α4β1), which is composed of CD49d (α4) and CD29 (β1), is highly expressed on human MSCs46 and plays a crucial role in the adhesion and rolling of MSCs. Vascular cell adhesion molecule-1 (VCAM-1) is an immobilized protein expressed on ECs that can bind to CD29, resulting in fast-rolling interactions under appropriate shear stress.47 Blocking CD29 or VCAM-1 abolishes MSC rolling, indicating that these rolling interactions depend on adhesion. This subsequently diminishes MSC migration to the injured liver and ischemic myocardium.40 Compared to that of CD29, the amount of CD49d on MSCs is insufficient, which may limit the homing ability of MSCs.48 Overexpression of CD49d enhances transendothelial migration in vitro and increases homing to the BM in vivo,49 demonstrating that VLA-4 is a suitable marker for MSC motility. Notably, MSCs also express intercellular cell adhesion molecule (ICAM-1, the ligand for αLβ2) naturally, but the significance of ICAM-1 in MSC homing still needs to be clarified. Integrin, a significant molecule involved in MSC motility, can generate actin-based forces to pull the cell body forward through more stable interactions between MSCs and ECs.

Chemokine receptor family

Chemokines and their receptors are now recognized as important mediators of MSC homing. Human chemokines are a superfamily of 48 ligands that bind to 19 different G protein-coupled chemokine receptors, regulating cell proliferation, differentiation, chemotaxis, and other physiological processes.50 They can be categorized into several groups depending on their functions.51,52 Inflammatory chemokines are upregulated during inflammation, promoting leukocyte recruitment and migration toward injury or infection sites.53 Homeostatic chemokines regulate adaptive immune responses and contribute to stem cell systemic migration.51 MSC activation is triggered by G protein-coupled chemokine receptors that respond to inflammatory signals, with chemokines binding to chemokine receptors on MSCs, leading to integrin recruitment and increased adhesiveness.54 In addition, the increased integrin affinity is attributed to rapid lateral mobility triggered by chemokines.55 MSCs express a broad panel of chemokine receptors, including CCR1-7, CCR9-10, CXCR1-6, and CX3CR1,56–60 but the expression of most these receptors is low and decreases after in vitro expansion, which limits studies on MSC homing and therapeutic efficacy.61 The chemokine-chemokine receptor network also plays significant roles in the tropism of MSCs from the bloodstream toward different organs or tissues in response to inflammation or injury (Table 3).

CCR1

CCR1 on MSCs is a key marker of motile potency, with a broad spectrum of chemokines acting as natural ligands. CCL3, which is produced by lymphocytes, monocytes, and macrophages in response to proinflammatory agents/cytokines, can accelerate MSC migration by interacting with CCR1 on MSCs.62 Stimulating CCR1-overexpressing MSCs with CCL5 increased the ability of MSCs to home to injured sites and restored cardiac function.63 CCL7, which is significantly expressed in the urethras of rats during stimulated birth injury, is a ligand for CCR1, and pretreatment combined with CCR1-MSC overexpression increases MSC engraftment to the mid-urethra.64 The lesioned hippocampus expresses increased CCL2, which recruits human olfactory ectomesenchymal stem cells (OE-MSCs) in vitro.65 CCL2 may bind to and activate CCR1 and CCR10 in OE-MSCs through an unknown migration pathway.

CCR2

Previous studies have shown that CCL2 (the ligand of CCR2) is widely present in certain inflammatory diseases and monocyte recruitment in injured tissue mainly depends on CCR2.66 Therefore, CCR2 on MSCs may also play an important role in migration. CCL2 induces MSC migration by activating CCR2 in vitro, and the CCL2-CCR2 axis promotes the homing of MSCs to various organs or tissues, including the heart, liver, brain, skin, and tumor.67–71 Huang et al. showed that CCR2 overexpression on MSCs enhanced their homing to the ischemic hemisphere and improved therapeutic outcomes.69 Moreover, CCR2 also plays a crucial role in regulating the motility of MSCs and promoting their recruitment to liver injury sites.72 CCL7, another ligand for CCR2, could induce MSCs to migrate toward the injured myocardium, resulting in beneficial remodeling in the infarct zone.71

CCR3 and CCR4

MSCs typically do not express CCR3, but following infection with Kaposi’s sarcoma-associated herpesvirus (KSHV), they exhibit increased CCR3 expression and enhanced migration ability in vitro. Knockdown of CCR3 or blockade of its ligand CCL5 can partially suppress MSC migration, suggesting that the CCL5-CCR3 axis may promote MSC homing.73 Treatment with the cationic molecule polyethylenimine (PEI) dose-dependently increased CCR4 expression on MSCs, and the brain homing efficiency of MSCs significantly increased after intravenous administration of PEI in a rat model of brain injury.74

CCR6 and CCR7

Overexpressing CCR6 enhances MSC migration to skin wound sites.75 BM-MSCs expressing CCR6 can transmigrate across ECs in response to CCL20.76 Transfected MSCs with enhanced CCR7 expression showed improved migration to secondary lymphoid organs in response to SLC/CCL21, leading to prolonged survival in GvHD mice.77 Additionally, injection of CCL21 into the periphery of wounded skin significantly increased MSC recruitment to wound sites and accelerated wound closure in skin wound models.78

CCR9 and CCR10

CCL25 acts as a chemoattractant for various immune cells and is a ligand for CCR9.79 CCL25 has been found to mediate the migration of MSCs expressing different levels of CCR9 in vitro.80 In addition, CCL27 (the ligand of CCR10), a skin-specific chemokine, is predominantly expressed by keratinocytes in the epidermis of skin (injured/uninjured/exudates), and its upregulation recruits MSCs to migrate toward wounded skin.81 In vivo studies have shown that systemically administered MSCs overexpressing CCR10 migrate to the skin in response to CCL27.82

CXCR1 and CXCR2

CXCL8 (also known as interleukin 8, IL-8) is an inflammatory chemokine that can interact with CXCR1 and CXCR2.83 Ringe et al. found that MSCs migrate to zones with high concentrations of CXCL8 in a dose-dependent manner through in vitro chemotaxis assays.83 This process was observed in gliomas, in which CXCL8 was identified as an inducer of human umbilical cord blood-derived MSC migration toward glioma cells both in vitro and in vivo.84,85

CXCR2, a molecule with various ligands, is crucial for leukocyte migration toward inflamed BM sites.86 Genetic modification can upregulate CXCR2 expression on MSCs, enhancing their mobilization and accelerating healing.87,88 CXCL7 recruits human BM-MSCs in vitro and may influence their migration through the IL-8 receptor signaling pathway. The activation of chemokines that stimulate CXCR1 and CXCR2 suggests a synergistic mechanism for CXCL7-driven MSC migration.89

CXCR4

CXCL12 (SDF-1)-CXCR4 has already been the most widely studied MSC chemotactic axis.90 CXCL12 is secreted from various tissues, including the tumor, intestine, skin, ovary, bone marrow, liver, lung, kidney, and heart, and has been confirmed to recruit intravenously injected MSCs expressing CXCR4.70,91,92 Recent studies have investigated various methods for enhancing the migration and therapeutic efficacy of MSCs by increasing CXCR4 expression, such as hypoxia, chemical compounds, or cytokines, during MSC expansion in vitro.93 Notably, hypoxic pretreatment has been found to increase CXCR4 expression, promote migration, and reduce the apoptosis of MSCs in vitro.94 In addition to its role in migration and survival, the CXCL12-CXCR4 axis is also critical for MSC cytokine secretion.95

Others

MSCs overexpressing CCR5 exhibit enhanced migration following transplantation into the degenerating retina.96 In mice with allergic contact dermatitis, CXCL10 and CXCL13 mRNA levels were upregulated in inflamed ears. The number of MSCs overexpressing CXCR3 or CXCR5 increased in these ears, indicating that the CXCL10-CXCR3 and CXCL13-CXCR5 axes enhance MSC migration.97 Transwell assays revealed that CXCR6 is involved in the transmigration of MSCs across the EC layer in response to CXCL9.76 Exposure of MSCs to hypoxia increased CX3CR1 expression and migration in vitro.98 Intravenous injections of CX3CR1-overexpressing MSCs led to the generation of long-lasting MSCs in the inflamed colon of mice, even more so than in the liver and lung.99

Matrix metalloproteinase family

Traversing the protein fibers of the ECM, which is present in all tissue types, is crucial for cells to reach target sites in circulation. Basement membranes separate the epithelium or endothelium from the stroma.100 MSCs break down basement membranes by secreting matrix metalloproteinases (MMPs), which are involved in various physiological and pathological processes because of their capacity to degrade ECM components.101,102 MMPs can also function as motility markers of MSCs, influencing their homing efficiency (Table 3). Gelatinases, MMP-2, and MMP-9 are major contributors to the breakdown of basement membranes.103 However, MSCs secrete MMP-2 but not MMP-9, identifying MMP-2 as the key player involved in MSC transmigration and invasion.101 Knocking down MMP-2 significantly reduced the transendothelial migration ability of these cells.104 Chemerin, a chemoattractant produced by the liver, adipocytes, and lung, manipulates the transmigration of intravascularly administered MSCs by upregulating MMP-2 expression.105 MT1-MMP, a membrane-tethered metalloenzyme, not only regulates MSC trafficking through the interstitial ECM both in vitro and in vivo but also directs MSC differentiation programs.106 PDGF-BB stimulates MSC migration and proliferation, upregulating MT1-MMP expression on MSCs.107

The expression of four tissue inhibitors of metalloproteinases (TIMPs), which inhibit the active form of all MMPs, is induced by inflammatory cytokines or chemokines.108 Silencing of TIMP-1 enhanced MSC migration, indicating that both TIMP-1 and TIMP-2 play opposing roles in the homing process.109 Additionally, TIMP-1 activity is responsible for the antiangiogenic effects of MSCs in inflamed lymph nodes of mice.110 TIMP-3, produced by MSCs, has been recognized as a soluble factor that positively impacts EC function in a mouse model of traumatic brain injury.111 TIMP-4 has been found to be expressed at very low levels in BM-MSCs.112

Strategies to improve MSC homing

The success of MSC therapies is facilitated by the effective delivery of living cells to injured tissues to carry out their biological functions. Beyond the exclusive use of anticoagulants,26 various bioengineering strategies (Table 3), including magnetic guidance, radiotherapeutic techniques, genetic modification, enzymatic modification, protein/antibody conjugation, and priming, have been extensively developed and applied to enhance MSC homing efficiency.27,38 Genetic modification methods, such as viral or mRNA transfection to transiently or permanently overexpress specific molecules governing MSC motility, have been discussed in the previous sections.

Unlike genetic modifications, cell surface engineering aims to chemically alter the surface of MSCs directly through enzymatic modification and protein/antibody conjugation, resulting in temporary but effective enhancements in homing. One such strategy is the enzymatic modification of CD44, which converts CD44 to HCELL through sugar modifications, thereby enabling MSCs to home to the BM via E-selectin and L-selectin.113 This modification also increases MSC infiltration into pancreatic islets threefold following intravenous administration and durably reverses hyperglycemia.114 Attaching anti-ICAM-1 or anti-VCAM-1 antibodies to MSCs has been shown to improve retention and homing to target tissues.115,116 The conjugation of E-selectin-binding peptides onto MSC membranes is utilized to manipulate cell-microenvironment interactions, particularly for targeting cell delivery to specific tissues.117 Gundlach et al. developed a bispecific antibody designed to bind CD90 on MSCs and myosin light chain 1 on ischemic myocardium.118

Priming MSCs with small molecules or soluble factors is a simple and effective strategy to boost the molecules that regulate MSC motility. The upregulation of CXCR4 and MMP-9 in MSCs treated with valproic acid and lithium results in enhanced MSC homing, improved functional recovery, and reduced infarct volume in the brains of rats in a cerebral ischemia model.119 In addition, individual MSCs were encapsulated in hydrogels or microgels to increase the residence time of MSCs in target tissues. Mao et al. demonstrated that encapsulating MSCs in alginate-poly-d-lysine-alginate microgels significantly improved the delivery efficiency of MSCs to target tissues. Magnetic labeling of MSCs has been explored as a strategy for targeted tissue delivery.120 The enhanced homing ability of MSCs labeled with iron oxide was observed to be ten times greater when these cells were intravenously infused into a rat model. One week post-injection, magnetic MSCs demonstrated improved penetration into both the inner and outer retina in comparison to nonmagnetic MSCs.121

Understanding the roles of various molecules expressed or secreted by MSCs is crucial for MSC engineering. Bioengineering strategies not only improve the efficacy of MSCs but also accelerate their accumulation in target tissues. These strategies can enhance clinical outcomes by overcoming the challenges of limited MSC persistence and inadequate homing to targeted sites.

Target organs of MSC homing after systemic administration

The localization of MSCs within various organs post-administration provides critical insights into their interactions with tissues and target cells, which are pivotal for the efficacy of MSC-based therapies.122 MSCs have the capacity to home to inflammatory or injured sites, and their biodistribution varies due to their diverse pathogenesis in different disease models, where chemokine–chemokine receptor axes play an important role (Fig. 1).

Brain

Although MSCs can cross the blood‒brain barrier (BBB), no signal from cells can be detected by any of the tracking modalities in the healthy brain after intravenous injection.123 The biodistribution of MSCs in injured brains is completely different from that in healthy brains. MSCs migrate to injured brains at 4 h and reside in the brain until day 11, which is the endpoint of detection after intravenous administration.124 The homing efficiency and retention time are diverse due to the application of different tracking techniques and administration routes. Oshra et al. monitored the biodistribution of MSCs by a nanoparticle-based computed tomography (CT) imaging technique after orthotopic injection. Gold nanoparticle-labeled MSCs could be detected at 1 h, 24 h, and one month post-injection. However, another study showed that no signal from MSCs can be tracked only on day 2 after intra-arterial transplantation.125 After using mannitol to enhance the penetrability of the BBB, MSCs could be detected on day 7 and day 28 after infusion compared with those in the control group without mannitol pretreatment.126

The conventional SDF-1/CXCR4 and CCL2/CCR2 chemokine axes can participate in the homing of MSCs to injured brains as well as other organs.127–129 To improve the homing efficiency of MSCs to injured brains, various strategies can be employed for the modification of MSCs prior to administration. The overexpression of CXCR4 or CCR2 in MSCs is used mostly to increase the targeting ability of cells after intracerebroventricular injection and carotid injection.69,130 Shahror et al. demonstrated that MSCs overexpressing growth factor 21 exhibit enhanced homing efficiency in the damaged brain, thereby improving the therapeutic effects on traumatic brain injury.131 Inflammatory cytokines can also improve the homing ability of MSCs. For example, the upregulation of IL-8 in injured brains has been confirmed, which has been shown to improve the homing ability of BM-derived stem cells.132 Furthermore, pretreatment of MSCs with other soluble factors and chemical agents can also enhance their ability to home to injured brains. Valproate and lithium have been shown to boost the accumulation of MSCs in the tissue of injured brains.119 Other factors, such as IL-3, IL-6, IL-1β, and IFNγ, can also promote the migration of MSCs to injured tissues.133 In addition to gene modification and chemical pretreatment, physical modification can improve the therapeutic efficacy of MSCs by enhancing the ability of cells to home to the brain. More polycluster superparamagnetic iron oxide nanoparticle-labeled MSCs accumulate in the injured brain after intravenous injection and have longer retention times in the brain than control MSCs.134

Colon

Numerous studies have shown that MSCs accumulate preferentially in the lungs and do not migrate to the colon after intravenous injection in a normal mouse model.135 However, the homing of MSCs to damaged colons was increased in a dextran sulfate sodium-induced colitis model.136 MSCs were monitored by in vivo optical bioluminescence imaging at 48 h after administration, and imaging revealed an increased number of MSCs in the inflamed colon in colitis mice (1.5–5.5%) in comparison with that in healthy mice (0.3–1%).137

The SDF-1/CXCR4 axis, CXCL2/CXCR2 axis, and CXCL5/CXCR2 axis can play critical roles in the homing of MSCs to the injured colon.87,138 Another study revealed that upregulating CX3CL1 in injured colon tissue and transducing MSCs with lentivirus expressing CX3CR1 markedly enhanced cell accumulation at injured colon sites after 2 h, 24 h, and 8 days intravenous injection.99 Although more MSCs home to damaged colon sites in disease models than in healthy models, the homing efficiency remains insufficient to achieve optimal therapeutic effects. A series of modification strategies could be employed to improve the migration of MSCs to the inflamed colon. Fu et al. constructed dual-functionalized MSCs that overexpress CX3CR1 and IL-25, which can promote the delivery of MSCs to inflamed colons and improve therapeutic effects on inflammatory bowel disease.99 Among the chemokine receptors, CXCR2 plays an important role in regulating the migration of MSCs to damaged tissues, and transient CXCR2 expression on MSCs can enhance the migration of cells to damaged colons.87 When coupled with an anti-VCAM-1 antibody, MSCs had greater migration efficiency than control MSCs and completely attenuated colitis.139 The expression of CXCR4 can be upregulated by pretreating MSCs with IL-1β, which can enhance the migration rate of cells to the colon.140 In addition to IL-1β, IFNγ can also increase the homing of MSCs to injured tissues of the colon.141 The upregulation of ICAM-1 or CXCR4 demonstrated a positive regulatory relationship with the homing efficiency of MSCs to the injured colon.142 Chemical methods for improving the targeting ability of MSCs have been utilized in many studies. Polyribocytidylic acid, the ligand of Toll-like receptor (TLR3), has been confirmed to promote MSC homing by activating TLR3.143

Heart

Intravenously administered MSCs can be detected in infarcted hearts on days 0.5, 1, 2, 4, 8, and 16, peaking on day 1 and then decreasing with time.144 Another study revealed that less than 1% of administered MSCs accumulate in hearts under normal conditions; however, more than 3% of intravenously injected cells could still be monitored in infarcted hearts after 3 months.145 Andrzejewska et al. also demonstrated that MSCs can be tracked in injured heart regions for up to 7 days following intravenous injection.60

Many reports have shown that chemokines, such as SDF-1, CCL7, CCL2, CCL5, CCL25, and CX3CL1, are upregulated in infarcted hearts and are involved in the homing of MSCs to these damaged areas.146–149 Overexpression of protein kinase C ε and monocyte chemotactic protein-3 (MCP-3 or CCL7) can improve both the capacity of MSCs to migrate to infarcted hearts and their therapeutic effects.71,150 In addition, coupling MSCs with a palmitated peptide resulted in an increased number of MSCs in ischemic heart tissue compared with noncoated controls.151

Kidney

Only 5.4% of administered MSCs migrated to healthy kidneys after intravenous injection, but treatment with cis-platinum increased the release of chemokines from injured kidneys, enhancing MSC homing to 6.4%.152 Furthermore, the difference in the distribution of MSCs is partly attributed to the route of administration, with more MSCs accumulating in injured kidneys 15 min after intra-arterial injection than after intravenous injection in a mouse acute kidney injury model. Most MSCs disappeared within 2 days, with only a barely detectable positive signal remaining in both groups.153,154 Another study reported that more MSCs could be detected in injured kidneys than in normal kidneys 2 h after tail vein injection155; these MSCs exhibited longer retention times and primarily accumulated in the glomeruli of the injured kidneys.156

Emerging data show that the CCL2/CCR2 axis and SDF-1/CXCR4 axis participate in the migration of MSCs to the kidney.32,157 The therapeutic efficacy of MSCs is closely associated with the number of MSCs migrating to the injured region of the kidney. Many methods for enhancing the homing efficiency of MSCs have been reported. CXCR4 overexpression significantly increased the migratory capacity of MSCs in injured kidneys and has been used in many disease models.158 When coupled with kidney injury molecule-1, MSCs migrate to ischemic kidneys more and reside in kidneys for a longer time.159 Pretreating MSCs with erythropoietin, the transforming growth factor β, and insulin-like growth factor-1 can improve the homing ability and restore the function of injured kidneys.160–162 Additionally, ultrasound can enhance the homing capacity of MSCs through the use of various nanoparticles in acute kidney injury.163,164

Liver

Compared to the normal model, the injured liver model exhibited greater homing efficiency (28.7–35.3%).165 Furthermore, in a normal mouse model, no MSCs were detectable at 5 days after intravenous injection.122 However, MSCs were detected in CCl4-injured livers 24 h post-injection,166 with the greatest homing observed in the injured liver tissues 1 week after intravenous injection.165,167 Furthermore, compared to intravenous injection, hepatic artery delivery shows greater homing efficiency (20–30%) to injured livers.168

The use of inflammatory cytokines, hypoxia, chemical agents, and genetic modifications could improve the homing of MSCs to injured livers. Cytokines play a critical role in the homing of MSCs to injured livers. The upregulation of cytokines such as stem cell factor-1, hepatocyte growth factor (HGF), MMPs, and chemokines in injured livers accelerates their homing to the liver.169 A previous study revealed that the upregulation of CCL2 in damaged livers and the overexpression of its receptor CCR2 in MSCs can enhance the delivery of MSCs to damaged livers.68,170 Transfecting MSCs with lentivirus overexpressing c-Met can improve the survival rate of rats in an acute liver failure model by enhancing the homing capacity of MSCs.171 Activation of the HGF/c-Met signaling pathway can improve the migration of MSCs to injured sites, so overexpression of HGF is desirable for the targeting of damaged liver sites by MSCs.172 Pretreating MSCs with IFNγ can increase the homing ability of MSCs to damaged liver tissues.173 IL-6 can also improve the homing capacity of MSCs in the fibrotic liver.174 In addition, pretreatment of MSCs with chemical agents such as sodium nitroprusside, preoperative resveratrol, and melatonin accelerates MSC homing, thereby improving therapeutic efficacy through increased localization of MSCs in the injured liver.175–177

Lung

MSCs are initially trapped in the lungs after intravenous injection and then redistributed to other organs with high blood flow, such as the liver, primarily because the structural characteristics of the lung microvasculature cause the majority of MSCs to become sequestered there.33 However, the population of MSCs residing in the lungs diminishes due to increased permeability under injured conditions in the initial stage of injection. Emerging data confirm that transplanted MSCs home more effectively to injured lungs than to normal lungs, as chemokines released from inflammatory sites in the blood system recruit these cells to injured areas.178–180

The regulation of signaling pathways could similarly enhance the homing capacity to injury sites. MSCs with downregulated Hippo signaling, which can promote the migration of cells, attenuate lung injury in ARDS mice.181 With the knockout of vimentin, fewer MSCs colonize injured lungs.182 After transduction with a lentiviral vector carrying the E-prostanoid 2, the capacity of MSCs to home to injured lung tissues improved significantly.183 Pretreating MSCs with granulocyte colony-stimulating factor can promote the ability of MSCs to home to injured lungs by upregulating the expression of CXCR4.184 Furthermore, the retention time of injected MSCs in mice could be increased via radiation.185

Skin

MSCs are not detectable in healthy mouse skin after intravenous injection. However, increased numbers of MSCs can be detected in injured skin, and this process is mediated by multiple chemokine axes. Alexeev et al. demonstrated the upregulation of CCL27 in wounded skin tissue and the importance of the CCL27/CCR10 axis in the homing of MSCs to damaged skin.82 Increased expression of CXCR6 on MSCs enhanced the accumulation of cells in wound sites on the skin, which was assisted by the upregulation of the ligand CXCL16 in damaged skin.75 In addition, the ability of the CCL2/CCR2 axis and CCL27/CCR10 axis to enhance the homing efficiency of MSCs has been confirmed in several studies.67,78,186 After pretreatment with inflammatory cytokines, such as IL-17, and plant-derived components, such as protocatechuic acid, cannabinoids, and icariin, a sufficient number of MSCs can migrate to wounded skin.187,188 Junction adhesion molecule A may accelerate the repair of wounded skin and improve the therapeutic effects of MSCs by increasing their ability to migrate to damaged skin.189

Other organs

The target organs of MSCs also include the ear and ovary. MSCs can be tracked at 24 h after transplantation in the injured ovary.190 Another study showed that MSCs were located in the interstitium of the ovary at 4 weeks after tail vein injection.191 The SDF-1/CXCR4 axis participates in the homing of MSCs to the ovary.92 Hyaluronic acid improves the homing ability of MSCs to the sites of injured ears.192 Moreover, the glycoengineering of MSCs significantly enhances their homing to tumors.193

Overall, after peripheral intravenous injection, MSCs are initially trapped in the lungs,33 with a smaller portion passing through to reach organs with rich blood flow, such as the liver,165 kidney,152 and brain,123 and minimal numbers of MSCs migrating to the skin.82 Most in vivo distribution studies have been conducted in mice or rats, and given the significant differences in vascular diameters between these animals and humans, these results cannot be directly translated to humans. MSCs labeled with 111In-oxine show a gradual decrease in lung retention and an increase in liver and spleen retention over time in humans.194 These findings suggest that MSCs may display unconventional pharmacokinetic characteristics, with the levels of inflammatory cytokines in vivo and molecules regulating MSC motility being crucial parameters for pharmacokinetic evaluation.

The fate of MSC after transplantation

Several preclinical MSC therapy studies have demonstrated that MSCs do not persist in the body long-term and are gradually cleared over time.27,195 There are significant differences in the persistence of MSCs in vivo across various experiments. Some studies indicate that MSCs can survive in the body for only 24–28 h,33,196 whereas other studies have shown that MSCs are still detectable up to 120 days post-administration.197 The long-term persistence of MSCs in vivo carries the risk of tumor formation, while short-term persistence may restrict their therapeutic efficacy. Hence, understanding the fate of MSCs is essential for assessing their safety and efficacy. While metabolism and excretion represent the fate of conventional drugs, apoptosis, autophagy, differentiation, ferroptosis, phagocytosis, and senescence are the fates of MSCs (Fig. 2). An increasing understanding of the fate of MSCs after intravenous injection has advanced further research into the mechanisms underlying their therapeutic effects.Fig. 2 Regulators and effects of different MSC fates. Regulated by a variety of intrinsic or extrinsic factors, MSCs develop into different destinies. MSCs have stem cell properties and diverse differentiation directions under distinct conditions. Phagocytosis of MSCs is mediated mostly by the monocyte‒macrophage system. Autophagy and senescence can be activated in ROS-enriched environments or under other conditions. Many MSCs undergo apoptosis. Changes in the functions and phenotypes of MSCs and their consequent effects can be detected when MSCs progress to different fates

Apoptosis

Apoptosis, a programmed cell death process, is mediated by diverse signaling pathways and is triggered by multiple factors, such as cellular stress, DNA damage, and other proapoptotic agents.198 MSCs undergo apoptosis in different target organs after administration, whether in a physiological or pathological environment. He et al. investigated the apoptosis of MSCs after infusion in a mouse liver and spinal cord injury model and attributed the therapeutic effects to the release of phosphatidylserine from apoptotic cells. Apoptotic MSCs were first detected at 2 h post-injection in the liver and lung and markedly decreased at 12 h and 24 h, respectively.72 Another study revealed that in a GvHD model, MSC apoptosis was induced by perforin released from cytotoxic cells one hour after injection, and the MSCs were primarily localized in the lung and spleen. Subsequently, the phagocytosis of apoptotic MSCs by macrophages is essential for the immunosuppressive effects of MSCs, as it leads to the production of indoleamine 2,3-dioxygenase.8 However, Swee et al. reported that MSC apoptosis occurs not only in a pathological environment but also in a physiological state after infusion. After intravenous injection, MSCs rapidly undergo apoptosis in the lungs of recipient mice. Furthermore, the results suggested that apoptosis is not dependent on host cytotoxic or alloreactive cells.199

The apoptosis of MSCs, a complex process influenced by various factors, is driven by inflammatory cytokines such as IFNγ and TNFα, which induce the upregulation of inducible nitric oxide synthase and the production of nitric oxide through the activation of the STAT1 signaling pathway.200,201 MSCs have been utilized in the treatment of conditions such as ischemia and myocardial infarction, where the proapoptotic effects are primarily orchestrated through the intricate PI3K/AKT signaling cascade due to low oxygen levels and a lack of essential nutrients in the blood.202–205 The overexpression of certain microRNAs under pathological conditions can initiate apoptosis by downregulating antiapoptotic protein expression, as demonstrated by a study in which miRNA-98-5p triggered apoptosis in MSCs by targeting insulin-like growth factor type 2 mRNA-binding protein 1 and modulating the PI3K/AKT and p53 signaling pathways.206 Increasing evidence indicates that enhanced reactive oxygen species (ROS) generation at injury sites, along with high glucose and other contents released from red blood cells, can induce MSC apoptosis.207–211

Autophagy

Autophagy plays an important role in maintaining the therapeutic effects of MSCs.212 As one of the intracellular degradation systems, autophagy is a complex process composed of a variety of signaling pathways that can be triggered by diverse inducers.213 Among the diverse fates of MSCs, autophagy can be activated by various factors, such as cell starvation, inflammation, and oxidative stress.214 MSCs were detected in the lungs at 24 and 48 h post-administration, with a significant increase in the autophagy marker microtubule-associated protein 1 light chain 3 (MAP1LC3). However, MSCs were not detected in the spinal cord until 72 h post-injection, at which time they could still be detected 120 h later, accompanied by a significant increase in MAP1LC3.215 A reduction in IGF-1 expression results in the downregulation of the AKT/mTOR signaling pathway and the upregulation of autophagy in aged MSCs exposed to hypoxic conditions.216 Autophagy also enhances MSC survival in vitro under conditions of starvation, hypoxia, or exposure to ROS.217–219

Differentiation

MSCs, a heterogeneous subset of multipotent stromal stem cells, can differentiate into adipocytes, osteocytes, and chondrocytes. Emerging studies have shown that MSCs can also differentiate into ECs and neurons at injury sites after transplantation.12 Therefore, the differentiation potential of MSCs is vital for their therapeutic effects. Some MSCs express EC-specific markers after intracerebral administration in a rat model of stroke, revealing that the increase in vascular density is mediated by the differentiation of MSCs into ECs.220 Another study revealed that human adult dental pulp MSCs preferentially differentiated into astrocytes after intracerebral transplantation in a focal cerebral ischemia model.221 Only a few MSCs differentiate into other cells, which mainly occur in the bone, brain, and blood vessels after administration via different pathways.222

The differentiation of MSCs is regulated by various signaling pathways that intricately coordinate this complex process. Intraflagellar transport 20 plays a critical role in determining MSC fate, and its depletion results in a marked increase in adipocyte differentiation.223 In contrast, the suppression of sex-determining region Y box 9 protein hinders the adipocyte differentiation of MSCs through the inhibition of the transcription factor CCAAT enhancer binding protein β.224 The interaction between integrator complex subunit 7 and ATP-binding cassette subfamily D member 3, along with the presence of serum IGF-1, facilitates the osteoblast differentiation of MSCs, offering potential for treating osteoporosis.225,226

Ferroptosis

Ferroptosis, which was originally described by Dixon et al. in 2012, represents a distinct form of regulated cell death that is mechanistically different from apoptosis.227 This iron-dependent process is characterized by the accumulation of intracellular iron and increased levels of lipid peroxidation.228,229 Ferroptosis is inhibited by the overexpression of NOP2/Sun RNA methyltransferase 5 or ferritin heavy chain/light-chain in MSCs.230 Conversely, the murine double minute 2-TLR4 axis and the prominin2-BACH1 axis can also participate in ferroptosis in MSCs.231,232 The occurrence of ferroptosis in MSCs after transplantation reduces their efficacy, and intervention strategies are urgently needed to improve their therapeutic effect. Chen et al. demonstrated that increased levels of peroxiredoxin-2 in MSCs can improve therapeutic outcomes in a neurogenic erectile dysfunction rat model by suppressing ferroptosis.233 Strategically modulating metabolic pathways to inhibit ferroptosis in MSCs can substantially increase the therapeutic potential for ameliorating hepatic damage.234–236

Phagocytosis

MSCs have been widely recognized as promising tools for treating autoimmune diseases because of their ability to cross-talk with various immune cells. Several experiments revealed that nearly half of MSCs were subjected to phagocytosis after intravenous injection.237 MSCs are usually trapped in the lungs and disappear within a day under normal conditions. The fate of MSCs after their disappearance from the lungs was elucidated, showing that MSCs were primarily phagocytized by blood-derived monocytes in the lungs and subsequently redistributed to the liver.195 Another study revealed that MSCs are injured upon contact with blood compounds due to the complement system,238,239 and this apoptosis and injury facilitate their phagocytosis by monocytes.8 In addition to monocytes, tissue-resident macrophages can also phagocytize intravenously injected MSCs. In a mouse model of asthma, MSCs were primarily localized in the alveolar and capillary walls 1 h post-injection and were phagocytized by lung-resident macrophages 24 h post-injection.240 Furthermore, MSCs can be phagocytized by splenic macrophages at 3 h and 24 h after intravenous injection in tumor-bearing mice.241

Senescence

MSCs tend to become senescent after injection due to crosstalk with the microenvironment, which hinders their clinical application and leads to undesirable therapeutic effects. MSCs become senescent with increased expression of senescence-associated genes during long-term in vitro culture and due to replicative senescence and their niche after in vivo administration.242 The mechanisms and induction factors of senescence have been described in many studies. ROS not only induce autophagy but also promote the senescence of MSCs.243,244 D-galactose (D-gal) can promote intracellular ROS generation, which markedly induces cell senescence. Coenzyme Q10 and ascorbic acid inhibit the pro-senescence effect of D-gal on MSCs through AKT/mTOR signaling.244,245 In addition to ROS, microRNAs can induce cellular senescence, and inhibiting microRNA-45 and microRNA-155-5p can rejuvenate senescent MSCs.246,247 Overexpression of apelin and Erb-B2 receptor tyrosine kinase 4 could rejuvenate senescent MSCs via the PI3K/AKT and AMPK signaling pathways after administration and enhance the therapeutic efficacy of MSCs in a myocardial infarction model.248,249 Knockdown of CD26 reduces senescence-associated cytokine secretion and potentiates the therapeutic effects of MSCs by delaying the senescence of MSCs in a mouse emphysema model.250

Premature senescence of MSCs, which occurs more frequently during the pre-processing and early post-injection stages than natural senescence, remains a significant hurdle in clinical application.251 Multiple signaling pathways are involved in the regulation of the premature senescence of MSCs, with the ROS/mTOR/4EBP1/p70S6K1/2 pathway and the FoxO3a pathway playing key roles in this process.251,252 Many strategies have been employed in studies to prevent premature senescence as much as possible and improve the therapeutic efficacy of MSCs. Walnut kernel oil and defatted extracts enhance MSC stemness and delay senescence.253 Depletion of GATA binding protein 4 can hinder SASP-dependent senescence in MSCs by suppressing the NF-κB pathway.254

Currently, the apoptosis, autophagy, ferroptosis, and other fates of MSCs have been investigated in vitro. However, many findings on the in vivo fate of MSCs after injection are unknown, which limits the detection and evaluation of MSC efficacy to an extent. In the future, elucidating the fate of MSCs within various target organs in vivo will be crucial, necessitating the development of new probes and biotechnology for such investigations.

The imaging and tracking modalities of MSC

The homing and persistence of transplanted MSCs in vivo remain poorly understood due to technical limitations, which hinders their clinical translation. Precise and effective detection methods are vital for exploring the migration and distribution of MSCs. Current methods for imaging and tracking in vivo include gene quantitative detection, optical imaging, magnetic resonance imaging (MRI), nuclear medicine imaging, ultrasound imaging, and photoacoustic imaging (Fig. 3),255 each of which has advantages and disadvantages (Table 4).256 To precisely and effectively detect the biodistribution of MSCs in vivo, a combination of different approaches is required.Fig. 3 Multimodal tracing strategies for MSCs in vivo. Precise and effective detection methods are vital for exploring the migration and distribution of mesenchymal stem cells (MSCs). Currently, there are various detection techniques available. Nuclear imaging tracks the biodistribution of cells by imaging radiolabeled tracers. Optical imaging, including bioluminescence imaging (BLI) and fluorescence imaging (FLI), plays an important role in researching the biodistribution of MSCs in different disease models. Cell tracking with magnetic resonance imaging (MRI) requires labeling cells with contrast agents. Magnetic particle imaging (MPI) can detect nanoparticle tracers at any time and location in the body with greater spatial and temporal resolution than MRI. Ultrasound imaging and photoacoustic imaging are noninvasive and emerging imaging modalities. The development of multiple-modality imaging is an emerging trend in MSC tracking and clinical research

Table 4 Comparison of technologies for detecting the distribution of MSCs256

Technology	Clinical application	In vivo/In vitro	Single-cell resolution	The lower limit of detection (Number of cells)	Advantages	Disadvantages	
MRI	Yes	In vivo	No	104	Noninvasiveness; High spatial resolution; Whole body scan	Low sensitivity; Unquantifiable	
PET/SPECT	Yes	In vivo	No	104	Noninvasiveness; High sensitivity; Whole body scan; Quantifiable	Low spatial resolution; Short half-life	
BLI	No	In vivo	No	103	Noninvasiveness; High sensitivity; Long-term detection; Distinguish live/dead cells	Limit on detection depth; No single-cell resolution	
FLI	No	In vivo	Yes	103	Distinguish live/dead cells; Single-cell resolution	Invasiveness; Limit on detection depth, High operation requirement	
Flow cytometry	No	In vitro	Yes	103	Distinguish live/dead cells	Multiple antibodies label; Low precision; Low stability	
Q-PCR	Yes	In vitro	No	102	High sensitivity; High specificity; Wide application; Label-free	Unable to distinguish living/dead cells; Limited detection area	
IHC	Yes	In vitro	Yes	102	High sensitivity; High specificity; Single-cell resolution	Limited detection area; Selective imaging of specific protein; No dynamic detection	

Methods for detecting MSC pharmacokinetics

Flow cytometry, immunohistochemistry (IHC), and real-time quantitative polymerase chain reaction (Q-PCR) detection systems are commonly used for the invasive detection of MSCs.257,258 With convenient operation and high sensitivity, Q-PCR can detect and quantify MSCs quickly without labeling, but it cannot distinguish between living and dead cells.259 Flow cytometry is performed by collecting limited tissues for analysis and requires labeling with specific antibodies, which is less accurate and stable than Q-PCR.260 Although IHC can directly detect the distribution of MSCs, it cannot achieve long-term in vivo tracking of cells.261

In vivo tracking of MSCs involves direct and indirect labeling, commonly using radioisotopes, magnetic nanoparticles, and fluorescent dyes for direct labeling. After incubation with the above labeling materials and administration to animals, MSCs can be detected by positron emission tomography (PET)/single-photon emission computed tomography (SPECT), MRI, and in vivo fluorescence imaging. These tracking technologies can noninvasively and continuously monitor the dynamic distribution of MSCs in preclinical and clinical trials.256 In addition, superparamagnetic iron oxide nanoparticles are used most often in MRI technology,262 and the radioisotopes 64Cu-PSTM, 18F-FDG, 111In-oxine, and 99mTc are the primary tracer agents used in PET/SPECT.263 Although the direct labeling method is more convenient, markers are diluted through cell division and shed from cells over time, reducing the accuracy of long-term tracking.

Indirectly labeled MSCs are tracked by detecting fluorescent proteins or specific proteins combined with a nuclide probe, which are transferred into cells by gene modification. Optical imaging technologies, classified as fluorescence imaging and bioluminescence, are popular for tracking living cells. Fluorescence imaging (FLI) detects cells by fluorescence microscopy and mainly monitors the distribution of cells in animals because of limits on detection depth.264 Bioluminescence-based imaging (BLI) is a minimally invasive technique for experimental animals in which luciferase is continuously and stably expressed in MSCs.265

Optical imaging

Based on the detection of light emission from molecules after excitation via an internal charged-coupled device camera, optical imaging, which mainly consists of BLI and FLI, plays an important role in researching the biodistribution of MSCs in different disease models.266 With high accessibility and the possibility of long-term tracking, optical imaging is widely used for tracking MSCs. Compared to nuclear imaging modalities, optical imaging has fewer negative effects on cell proliferation, viability, and differentiation. Furthermore, most of the labeling reagents for optical imaging are suitable for longitudinal detection.267

FLI relies on various fluorophores that can be excited by specific wavelength light sources, with the emitted light collected by fluorescence signaling components and transformed into images by signal detection and amplification components.268 The exogenous labeling of MSCs using fluorescence has been recognized as an important imaging approach in vivo with excellent accessibility and operability. One of the conventional exogenous fluorescent dyes is hloromethyl-dialkylcarbocyanine, which is frequently used to track labeled cells, especially those that bind to the cell membrane.269 In addition, quantum dots are nanomaterials with intense fluorescence and diverse colors that can directly label MSCs, offering advantages over conventional fluorescent agents.270 To enable long-term cell tracking without affecting cell proliferation and potency, novel fluorescent probes are essential. Liu et al. designed a biocompatible and photostable nanoprobe made of polycaprolactone and di(thiophene-2-yl)-diketopyrrolopyrrole that retained strong fluorescence for up to 4 weeks for MSC differentiation tracing.271 However, one drawback of labeling MSCs directly with fluorescent reagents is a false positive signal. When transfected with fluorescent protein plasmids or virus vectors, MSCs have a greater signal-to-noise ratio than when directly labeled with fluorescent agents. The biodistribution of MSCs labeled with green fluorescent protein has been tracked, and the action of these cells post-administration have been characterized.272,273 Compared with other fluorescent reagents, near-infrared (NIR) fluorescent dyes with emission wavelengths ranging from 740 nm to 1700 nm exhibit reduced tissue absorbance, scattering, and autofluorescence, thereby enabling greater depth of penetration. After being labeled with NIR, MSCs can be continuously traced in vivo for up to 21 days, and liver regeneration can be visualized in an acute liver failure model.274

BLI relies on the photon emission generated by the catalytic conversion of luciferase, which facilitates the intramolecular oxidation of luciferin in the presence of ATP and oxygen within luciferase-expressing MSCs.275 All of the studies tracked cells in real time after injection for up to 4 weeks, which is superior to nuclear imaging.276–278 BLI can also avoid interference from background and biological autofluorescence signals during the imaging process.

In summary, optical imaging is widely used for MSC tracking due to its long-term tracking ability, lower cytotoxicity compared to nuclear imaging, diverse fluorescent reagents, and accessibility. However, its poor tissue penetrability and light scattering limit its use in small animal imaging (Table 5).Table 5 Methods for tracking MSCs

Imaging modality	Spatial resolution	Species and tissue of MSCs	Observation time	Labeling methods and agents	Labeling time	Imaging purposes	Imaging sites	Experimental model	Ref.	
BLI	3–5000 μm	hUC-MSC	7 days	Lentiviral vectors	7 days	Biodistribution tracking	Whole body	Normal	196	
hAD-MSC	/	CMV vector	3 days	Real-time tracking of stem cell viability, proliferation, and differentiation	Whole body	Normal	354	
hBM-MSC	4 weeks	Adenoviral vectors	2 days	Distribution of MSCs at tumor sites	Tumor	Tumor-bearing mice	276	
Rat BM-MSC	4 weeks	Lentiviral vectors	7 days	Cell survival evaluation in defect sites	Calvaria defect site	Calvarial critical sized defect model	278	
FLI	1 mm	human embryonic stem cells-derived M-MSCs	28 days	Lentiviral vectors	4 days	Interaction of MSCs with the vessel system of the bladder	Bladder	Interstitial cystitis/bladder pain syndrome	273	
human embryonic stem cells-derived M-MSCs	6 weeks	Lentiviral vectors	/	Monitor the action of multipotent stem cells in real time	Bladder	Interstitial cystitis/bladder pain syndrome	355	
MRI	10–100 μm	hBM-MSC	24 h	Amino-polyvinyl alcohol coated SPIONs	4 h	Biodistribution of MSCs after injection	Whole body	Normal	292	
hUC-MSC	10 days	Ferumoxytol	3 days	MSCs spheroids tracking	Whole body	Normal	356	
Rat BM-MSC	2 days	Perfluorocarbon	24 h	Biodistribution of MSCs after lung injection	Whole body	Normal	290	
PAI	10–100 μm	Murine BM-MSCs	3 days	Citrate-coated prussian blue particles	1, 3, 6, 12, 24, and 48 h	Provide a new noninvasive and high resolution approach to image traumatic brain injury, monitor the recovery process, and especially trace MSCs	Brain	Brain injury	296	
MSCs	10 days	Inert gold nanorods coated with IR775c, a reactive oxygen species sensitive near-infrared dye	6 h	Longitudinal tracking of MSC viability with a high spatial and temporal resolution	Heart	Normal	297	
hBM-MSC	4.6 days	Iron-oxide nanoparticle	24 h	Monitor the transplantation, biodistribution, and clearance of MSCs	Whole body	Normal	295	
PET	1-2 mm	hUC-MSC	7 days	89Zr-oxine	20 min	Biodistribution of MSCs expressing anticancer protein TRAIL	Tumor	Lung mesothelioma	285	
hBM-MSC	1.5 h	2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG)	1 h	Biodistribution of MSCs in a different animal model via different routes of administration	Whole body	Normal	284	
SPECT	1–2 mm	hBM-MSC	24 h	99mTc-HMPAO	15 min	Biodistribution of MSCs	Whole body	Normal	282	
ADS1-hMSCs	21 days	A novel gold nanoparticle (GNP)coated with glucose	3 h	Track the migration and exact localization of GNP-labeled hMSCs	Brain	Depression	357	
BLI + FLI		hBM-MSC	4 weeks	Lentiviral vectors	3 days	Biodistribution tracking	BM	Normal	272	
	BLI: lentiviral vectors/FLI: magnetic nanoparticles (MNP) conjugated with fluorophores	2 days/18 h	Action analysis and tracking of MSCs	Brain	Stroke	277	
BLI + MRI		Rat BM-MSC	10 days	pCMV-Luciferase2-mKate2- PAI/SPION	2 days	Biodistribution of MSCs after injection	Liver	Acute liver failure	358	
	Murine BM-MSCs	2 days	Lentiviral vectors; superparamagnetic iron oxide nanoparticles	5 days;24 h	The viability, whole-body biodistribution, and intrarenal biodistribution of MSCs	Whole body and kidney	Mouse renal injury	154	
FLI + SPECT		hBM-MSC	21 days	Au-Albumin-indocyanine green-poly-L-lysine (AA@ICG@PLL NP)	24 h	Tracking of MSCs	Lung	Lung fibrosis	359	
FLI + PAI		hUC-MSC	21 days	Near-infrared II fluorescent dye-modified melanin nanoparticles (MNP-PEG-H2)	4 h	Biodistribution of MSCs in liver	Liver	Acute liver failure	274	
MPI + MRI		Murine BM-MSCs	6 h	Ferucarbotran; perfluoropolyether	4 h	Assess the cellular sensitivity of MPI and 19 F MRI for detection of MSCs	Whole body	Normal	294	
PAI + SPECT		Rat BM-MSC	7 days	A cobalt protoporphyrin IX-loaded mesoporous silica nanoparticle (CPMSN) into a125I-conjugated/spermine-modified dextran polymer (125I-SD)	8 h	Real-time tracking of MSCs with high spatial resolution	Brain	Transient middle cerebral artery occlusion	299	
BLI + FLI + PET		Murine BM-MSCs	27 days	Adenoviral vectors	3 days	Biodistribution of MSCs in different inflammatory pathologies	Whole body	Diabetes; injury/wound healing; tumor-bearing mice	298	
FLI + MRI + SPECT		Rat BM-MSC	14 days	125I-fSiO4@SPIOs	1 h	Biodistribution of MSCs after injection	Brain	Transient middle cerebral artery occlusion	360	
FLI + PAI + PTT		hUC-MSC	5 days	Mesoporous silica-coated gold nanostars integrated with indocyanine green	24 h	Biodistribution of MSCs in tumor	Tumor	Breast cancer	361	

Nuclear imaging

Nuclear imaging tracks the biodistribution of MSCs by imaging tracers that have been labeled with radionuclides. There are three nuclear imaging techniques: PET, SPECT, and planar gamma scintigraphy.279 PET and SPECT will be summarized in this review since they are used more widely than planar gamma scintigraphy in the tracking of MSCs.

The gamma-ray photons with well-defined energy levels emitted from SPECT radioactive tracers can be captured directly by a gamma camera, where they are eventually digitized to provide 3D information on the biodistribution of MSCs279 Although the SPECT imaging modality offers relatively high sensitivity and quantifiability, its widespread application in the long-term tracking of MSCs is limited due to the use of radiotracers with short half-lives. 99mTc, which has a half-life of only 6 h, can be detected persistently for 3 days in vivo after injection.280 Compared with 99mTc, 111In-labeled MSCs can be detected up to 14 days after intravenous injection because of their long half-life (t1/2 = 2.81 days). Another drawback of SPECT is its cytotoxicity associated with the use of radiotracers. Although it has no impact on the viability or differentiation of human MSCs labeled with 111In, many other experiments have shown that radiotracer labeling can affect MSC viability and differentiation in a dose-dependent manner.281 Owing to the imaging properties of SPECT, the signal of MSCs in deep tissues could also be captured by a detection camera. When human BM-MSCs were labeled with 99mTc, their biodistribution in arthrosis was fully depicted using a gamma camera.282

PET imaging involves capturing the signals of gamma photons emitted in opposite directions by positron-emitting radionuclides using a ring detector, followed by data processing and image reconstruction. In contrast to SPECT, the PET imaging modality has higher spatial and temporal resolution but shorter cell tracking time in vivo. However, similar to SPECT, PET imaging is limited by time-dependent ionizing radiation injury to target cells and the short half-life of tracers, which restricts its use in long-term cell tracking.279 The isotopic tracers commonly used in PET imaging are 18F-fluorodeoxyglucose (FDG) and 18F-FHBG.270,283 Nose et al. tracked the biodistribution of MSCs in multiple animal species using PET imaging with 18F- FDG following various routes of administration.284 While 89Zr, which has a longer half-life (t1/2 = 78.4 h) than 18F (t1/2 = 109.7 min), can also be used for tracking MSCs, Patrick et al. labeled MSCs with 89Zr to show its delivery to the lungs in a mouse lung cancer model up to 7 days post-injection.285 While nuclear imaging offers good tissue penetrability and sensitivity, its limited spatial resolution and short imaging time make it unsuitable for precise and longitudinal MSC imaging (Table 5).

Magnetic resonance imaging

MRI is a powerful imaging tool with superior spatial resolution and tissue penetrability under preclinical and clinical conditions.286 This modality can also provide 3D information on MSC biodistribution as well as nuclear imaging. Tracing cells with MRI requires labeling cells with contrast reagents, such as superparamagnetic iron oxide nanoparticles (SPIONs), paramagnetic metals (Gd3+ and Mn2+/3+) or micron-sized iron oxide particles.287–289 While ferumoxide-labeled MSCs were observed only in the lung, perfluorocarbon-labeled MSCs dispersed to other distant organs.290 Most cell tracking studies use dextran or carboxy dextran-coated SPIONs, which are designed for uptake by phagocytic cells291; however, their impact on MSC proliferation and function must be evaluated. Novel SPIONs coated with amino-polyvinyl alcohol, which offer greater colloidal stability, greater solubility, greater biocompatibility, and lower toxicity, have been developed and are primarily taken up by MSCs.292

Despite its high spatial resolution and tissue penetrability, MRI has low sensitivity and long imaging times, making it difficult to track labeled cells throughout the whole body and determine their migration beyond damaged tissue. Furthermore, the accessibility of MRI is undesirable due to the high cost of imaging instruments (Table 5).

Magnetic particle imaging

Magnetic particle imaging (MPI), which usually involves the use of noncytotoxic SPIONs, is a relatively new tomographic imaging technique (Table 5). MPI can detect nanoparticle tracers at any time and space in the body with greater spatial and temporal resolution than MRI.293 Sehl et al. compared the sensitivity of MPI and MRI using perfluoropolyether-labeled MSCs and revealed that MPI reliably detected 4000 MSCs, while MRI detected 256,000 MSCs at the same time.294 Zheng et al. utilized MPI to dynamically track and quantify the biodistribution of SPION-labeled MSCs following intravenous injection in mice. One hour post-injection, MSCs primarily accumulate in the lungs before gradually migrating to the liver within 1 day.295

Photoacoustic imaging and ultrasound imaging

As a non-invasive and emerging imaging modality, photoacoustic imaging (PAI) offers rich optical contrast, high ultrasonic resolution, and fast data acquisition, making it suitable for real-time imaging (Table 5). Given these advantages, Li et al. demonstrated that Prussian blue particle-labeled MSCs were able to cross the BBB and subsequently migrate to injured brain regions.296 Dhada et al. developed a contrast agent with inert gold nanorods coated with IR775c, a ROS-sensitive near-infrared dye, enabling the measurement of MSC viability and longitudinal location by combining ultrasound imaging with PAI.297

Multiple-modality imaging

With the development of MSC clinical research, real-time, low cytotoxicity, high temporal and spatial resolution, and long-term imaging modalities are required (Table 5). Since a single imaging modality cannot simultaneously meet all these requirements, multiple-modality imaging has emerged in recent years.33 Combining nuclear imaging with bioluminescence-based imaging enables long-term cell tracking and is complemented by anatomical information from CT, effectively offsetting the limitations of each method.298 Ultrasound imaging and PAI offer high contrast, flexibility, and fast acquisition for real-time MSC transplantation guidance, while MRI with anatomical imaging resolution and SPECT with high sensitivity and quantitative capability are ideal for long-term monitoring of cell biodistribution and migration in vivo. Yao et al. combined these modalities to monitor engrafted MSCs in real-time and track their long-term biodistribution.299 The optical-MRI modality can improve the sensitivity of MSC detection in vivo and the resolution of imaging.255

In recent years, in vivo tracking imaging technologies have developed rapidly. Compared with single detection technology, employing multiple methods provides more comprehensive monitoring of MSC distribution in vivo. By combining Q-PCR with various imaging techniques, the dynamic spatial distribution of living cells, along with anatomical structures and molecular phenotypes at single-cell resolution, can be obtained. This approach provides robust data to support the evaluation of the efficacy of MSC therapies. Furthermore, with the advancement of multimodality imaging techniques, it is essential to develop nanoprobes with multiple imaging properties to enable effective imaging of MSCs after transplantation. This is crucial for the clinical tracking and application of MSCs.

Druggability research for clinical translation

Like conventional drugs, MSCs also adhere to the guidelines of safety, effectiveness, and quality controllability. Despite their remarkable efficacy in preclinical animal trials, MSC therapies have faced challenges in clinical translation due to individual variability and the considerable number of non-responsive patients.300 Several factors may lead to suboptimal clinical outcomes, including heterogeneity in MSC product potency, pharmacokinetics across different administration routes and a limited understanding of how host responses post-administration impact therapeutic efficacy.301 Elucidating the relationships among the disease state, biological distribution, and efficacy of MSCs in vivo helps address a significant challenge to their clinical application. Preclinical research on the druggability of MSCs should not only clarify the relationship between their dynamic biodistribution and efficacy but also elucidate their mechanisms of action and develop reliable biomarkers. These efforts will improve patient stratification and facilitate the establishment of precise therapeutic strategies, ultimately optimizing clinical efficacy (Fig. 4).Fig. 4 Druggability of MSCs. Applying the right treatment to the appropriate population, in the correct dosage regimen, and at the appropriate time is the most crucial principle in the druggability process of MSCs. The biodistribution and fate of MSCs at different time points were monitored by various imaging technologies. These parameters were combined with pharmacodynamic data to construct a PK/PD model of MSCs. Prediction of the pharmacokinetic properties of MSCs in patients, appropriate dosage regimens, and individualized treatments can be achieved with the PK/PD model. Therefore, the most crucial step in the druggability of MSCs is constructing an appropriate treatment regimen based on the pharmacokinetic and pharmacodynamic properties of MSCs

Guidelines and consensus

Conventional preclinical and clinical evaluation methods are inadequate for cell-based products due to the differences between cells and conventional pharmaceuticals. The use of MSCs and other cell therapies is under the regulatory oversight of the Center for Biologics Evaluation and Research, specifically the Office of Cellular, Tissue, and Gene Therapies in the United States. MSCs and other cell therapies are categorized under Advanced Therapy Medicinal Products in the European Union. Japan regulates medical products derived from human cells, genes, or tissues under the Pharmaceuticals and Medical Devices Act (PMD Act).302 In China, all cell therapies, including MSC therapy products, immune cell products, and gene-modified cell products, can be found in the Technical Guidelines for Research and Evaluation of Cell Therapy Products issued by the NMPA in 2017. The NMPA updated the Biological Products Appendix of the GMP for Drugs in 2020 and drafted the Appendix for Cell Therapy Products in the draft version of the GMP for Drugs. Furthermore, the NMPA drafted the Technical Guidance Principles for Clinical Trials of Human Stem Cells and Their Derived Cell Therapy Products on August 4, 2020. New drug development must adhere to the current Chinese Pharmacopoeia and other national drug standards.303 The guidelines and consensus on new drug applications for MSCs or other cell therapy products have been comprehensively reviewed elsewhere.264,303–305

Quality control of MSC therapies

Although the translation of MSCs from bench to bedside is feasible, most MSC therapies face unsuccessful late-stage clinical trials, with notable safety profiles but often limited efficacy in humans. These failures emphasize the challenges associated with the quality control of MSCs for clinical trials.18 Given the high heterogeneity and complex biology of MSCs in vivo, enhancing manufacturing processes and formulation technologies and establishing standardized production systems and personalized quality control are essential for successful clinical trials.301

The International Society for Cell and Gene Therapy (ISCT) initially established three minimum criteria for human MSCs based on their morphology, surface markers, and trilineage differentiation.306 MSCs are defined as adherent cells with a spindle-shaped morphology under standard culture conditions. These cells exhibited the following characteristics: (1) expression of CD105, CD73, and CD90 but lacking expression of CD45, CD34, CD14, or CD11b, CD79a, CD19, or HLA-DR; and (2) the capacity for differentiation into osteoblasts, adipocytes, and chondrocytes in vitro.307 These criteria reflected the “stemness” of MSCs rather than determining their therapeutic properties. Given the variations that exist at multiple levels, these criteria were insufficient to define MSCs comprehensively. In 2019, ISCT updated its standards for defining MSCs to include tissue origin and relevant functional assays to clarify their associated therapeutic mode. Furthermore, regulatory agencies mandate the identification, viability, purity, potency, proliferative capacity, genomic stability, and microbiological testing of MSCs.308,309

The aforementioned criteria do not encompass the efficacy of MSC therapies; quality control of MSC therapies also includes the following: (1) the source of MSCs, considering the health status, genetics, gender, and age of donors, as well as diverse tissue origins1,310; (2) the methods employed for isolating and obtaining cells from these tissues, whether through enzymatic or mechanical dissociation, which can impact the efficacy of MSCs311; (3) culture conditions, including aspects such as the composition of the culture medium, oxygen levels, flask/bioreactor, passage number, and cell surface modifications, which may similarly affect the efficacy and homing capacity of MSCs308,312; (4) the techniques used for cryopreservation and subsequent thawing/culture rescue, which can influence the viability, function, and homing potential of MSCs313–315; and (5) the expression of biomarkers for efficacy and target tissue homing, such as paracrine effectors and chemokine receptors.316,317

Pharmacokinetics of different sources

The biodistribution of MSCs can be influenced by various factors, such as cell type, route of administration, and host immune status. MSCs from different tissues are capable of trilineage differentiation (osteogenesis, chondrogenesis, and adipogenesis) and exhibit similar surface markers, but significant differences still exist in terms of their biological characteristics and functions.318 MSCs isolated from BM and adipose tissues express the same surface biomarkers but differ in the expression of cell adhesion molecules such as integrin α4, ICAM-1, CD34, and VCAM-1.319 Li et al. compared the proteomes of MSCs derived from the BM, placenta, and umbilical cord to investigate their expression of migration-related proteins, and the results showed that the migration ability of UC-MSCs was weaker than that of MSCs from the BM and placenta (5.9-fold and 3.2-fold, respectively).320 However, Hori et al. reported that UC-MSCs exhibit greater migration toward lymphocytes than do BM and adipose tissue-derived MSCs.321 These differences may be attributed to variations in chemokine receptors among MSCs from distinct tissue sources.

The differences between autologous and allogeneic MSCs extend to their pharmacokinetics. The lower immunogenicity of autologous MSCs enables them to rapidly localize to target tissues or organs without encountering immune rejection. Consequently, they exhibit prolonged survival in the body due to reduced susceptibility to host immune attack and clearance.322,323 However, the application of allogeneic MSCs is encouraged because of factors such as their source and quantity. The industry-sponsored production of allogeneic MSCs enables the manufacture of up to 1 million doses per donor for widespread deployment, far exceeding the capacity of autologous MSCs,324 indicating that this choice is not solely driven by biological advantages.

Preclinical pharmacokinetic research

Pharmacokinetic studies of MSC therapy, which track the biodistribution and fate of cells, play an indispensable role in elucidating the in vivo processes and associated biological actions, as well as in explaining the safety and efficacy of cell therapy products. The pharmacokinetic studies also evaluated the dose concentration, interval and route of administration. The Technical Guidelines for Research and Evaluation of Cell Therapy Products (China) emphasize the application of one or more methods to monitor the dynamic distribution, migration, homing, survival, and extinction of cell therapy products. Additionally, preclinical pharmacokinetic research should focus on the physiological processes of MSC therapy products in vivo, examining their differentiation capabilities and the biological effects related to their biodistribution.303,305 Although none of the agencies recommend methods for analyzing the spatial and temporal distribution of cells, a fundamental principle is that the methods employed should utilize the highest sensitivity currently available. Examples of such methods listed in the guidelines include MRI, PET, SPECT, FLI, autoradiography, PCR, IHC, and in situ hybridization.264 Moreover, the selection of appropriate animal models should align with the pathogenesis and therapeutic mechanism of MSCs.264 In addition to examining the conventional distribution and migration of MSCs, it is important to consider the impact of gene modification or bioengineering approaches on MSCs, their expression or secretion of biomolecules, and their interactions with host cells, which involve the tissue responses induced by the secretion of bioactive molecules from MSCs.304 The preclinical pharmacokinetic characteristics of MSCs can help inform experimental design and patient stratification in clinical pharmacokinetic research.

Clinical pharmacokinetic research

Clinical pharmacokinetic research cannot employ invasive detection methods such as those used in animal experiments. Extrapolating the results of animal studies of MSC therapies to humans is challenging. The mismatch between mouse and human clinical outcomes may arise from differences in immune compatibility, dosage, condition of culture-adapted MSCs, and variations in disease states of the hosts.18 In addition to the aforementioned factors in preclinical pharmacokinetic research, individual variability presents a significant challenge in clinical pharmacokinetic research. The diverse pathological conditions, such as varying levels of inflammation and oxygen, present in clinical subjects greatly impact the pharmacokinetic characteristics of MSCs in the body, thereby influencing the quantity and viability of MSCs that reach specific target organs or tissues.256 Moreover, the interactions between MSCs and host cells lead to variations in their therapeutic efficacy.325 Alsasem et al. developed an advanced, real-time framework for managing MSC transfusions in COVID-19 patients by automatically categorizing patients into various emergency levels and prioritizing them based on their individual status within each level.326 Another important consideration is that the biodistribution of administered MSCs may be influenced by the age of the recipient, which is closely linked to varying metabolic disorders and immunity.327 The pharmacokinetic biomarkers of MSCs identified in preclinical studies can be used to predict and validate clinical pharmacokinetics in patients. The development of therapeutic strategies for individual patients to achieve precise and personalized therapy is emerging as a crucial direction for the future advancement of MSC therapy.

Pharmacokinetics model for systemic administration

To satisfy the clinical requirement for the accuracy of MSC dosage, several pharmacokinetic models have been designed. Previous studies have used a two-compartment pharmacokinetic model, referring to MSCs as inactive and micron-sized nanoparticles, to predict their distribution, yielding remarkably similar data to the actual bioavailability of MSCs post-transplantation.328 However, this model was unable to predict the precise biodistribution of MSCs due to its disregard of MSCs as a dynamic “living therapy”. By integrating anatomical structure into the design, the physiologically based pharmacokinetic (PBPK) model offers greater physiological similarity and prediction accuracy. The first PBPK model of MSCs, reported in 2016, used in vivo optical imaging to track MSC biodistribution and flow cytometry to quantify MSCs.329

Chimeric antigen receptor (CAR)-T cells are recognized as effective therapeutic agents for antitumour applications. Given the similarities between CAR-T cells and MSCs in terms of therapeutic mechanism and cell properties, the model structure and system-specific parameters of the CAR-T-cell PK model can be applied to MSCs. PBPK models of CAR-T cells have been developed that incorporate various parameters, such as tissue volume, blood flow velocity, affinity of CAR-T cells for target cells, antigen abundance, and tumor volume.330 To accurately predict the biodistribution of CAR-T cells in vivo, the types of target cells and the expression of ligands on target cells in different disease stages, which could represent the specific properties of CAR-T cells, should be considered in the development and optimization of models.331 The target organ volume, microenvironment, and interaction between MSCs and other cells can all be considered important parameters or processes for PK models. Furthermore, the physical status of donors, tissue resources, passage number of MSCs, administration route, and dose of MSCs can all be recognized as critical covariates in models because of their unignorable influence on the biodistribution of MSCs.332 To maximize the therapeutic effects and minimize the adverse effects of MSCs, a PK model that has a superior ability to predict the biodistribution and number of MSCs in target organs is urgently needed.

Conclusions

MSC therapy, which has undergone significant progress over the past half-century, has emerged as an effective treatment for major chronic diseases and severe trauma repair in the field of regenerative medicine.27 Although the safety and therapeutic efficacy of MSC therapy have been extensively validated in numerous clinical trials worldwide, only a limited number of MSC products are commercially available in specific regions. This is largely attributed to the challenges associated with pharmacokinetics and the lack of clarity regarding MSC mechanisms, as well as the substantial individualized differences observed in clinical trials. In this review, we discuss MSC homing processes to different organs in vivo and the key regulatory factors involved. We also analyzed MSC fate and evaluated various in vivo tracing methods for detecting MSC homing, highlighting their advantages and disadvantages. Furthermore, we have emphasized the close relationship between the pharmacokinetics of MSCs and their druggability. We have summarized current strategies and suggestions for enhancing the homing capabilities of transplanted MSCs.

MSC therapy products are not subject to conventional pharmacokinetic testing, which is primarily used for conventional drugs. The mode of action of MSCs operates through a “shotgun model” and “hit-and-run” (or “touch-and-go”) mechanism: (1) They exert regulatory effects on the body through multiple targets and mechanisms to maintain homeostasis within niches rather than through single-target and simple inhibitory actions9; (2) Many studies have shown their rapid migration to damaged tissue, where they are quickly cleared after stress-induced release of therapeutic molecules, but their therapeutic effects persist over a long period.12 However, there are still many unanswered questions. First, given the high heterogeneity of MSCs, future research should focus on homing studies for different indications to further standardize quality criteria and production processes, ensuring the consistency of MSC product batches. Second, most studies have not linked the fate of MSCs to persistence in vivo due to limitations in detection and labeling technologies. Combining multiple labeling methods and various imaging techniques will facilitate high-resolution imaging and quantitative spatiotemporal analysis of MSCs in target organs at the single-cell resolution level. Third, it is important to note that preclinical mouse models often do not fully replicate human diseases. Although MSCs exhibit very low immunogenicity, they can trigger varying levels of immune activation in both humans and animals. Additionally, the dosage of MSCs administered to mouse models differs significantly from that administered to clinical patients, which can affect treatment outcomes. Finally, screening response patients based on biomarkers to determine the biodistribution and biological mechanisms of MSCs before clinical application can enhance the efficacy of MSC therapies. On the other hand, combining MSCs with gene modification, click chemistry, and tissue engineering materials hold promise for enhancing the precise biodistribution of MSC therapies. This innovative approach has the potential to accelerate the clinical translation of MSCs and expand their application to new therapeutic frontiers, ultimately benefiting patients with a wide range of medical conditions.

Acknowledgements

Figures were created with BioRender.com. This study was supported by the National Natural Science Foundation of China (82104184, 82073928, 82373949); the Leading Technology Foundation Research Project of Jiangsu Province (BK20192005); the Haihe Laboratory of Cell Ecosystem Innovation Fund (22HHXBSS00005); the Nanjing Scientific and Technological Special Project for Life and Health (202110006); the “Double First-Class” University Project (CPU2018GF01, China); the Jiangsu Province “333” project, China; and the Fundamental Research Funds for the Central Universities (2632023TD03).

Author contributions

Y.S., F.Z. and G.W. conceived and designed the review. Y.S., M.Z., K.H., and E.T. drafted the manuscript text and prepared the tables and figures. J.W., N.W., Y.L., and Q.L. assisted in the literature search. All authors have read and approved the final manuscript.

Competing interests

The authors declare no competing interests.

These authors contributed equally: Yunlong Shan, Mengying Zhang
==== Refs
References

1. Hass R Different populations and sources of human mesenchymal stem cells (MSC): a comparison of adult and neonatal tissue-derived MSC Cell Commun. Signal 2011 9 12 10.1186/1478-811X-9-12 21569606
Hass, R. et al. Different populations and sources of human mesenchymal stem cells (MSC): a comparison of adult and neonatal tissue-derived MSC. Cell Commun. Signal 9, 12 (2011).21569606 10.1186/1478-811X-9-12
2. Zhou T Challenges and advances in clinical applications of mesenchymal stromal cells J. Hematol. Oncol. 2021 14 24 10.1186/s13045-021-01037-x 33579329
Zhou, T. et al. Challenges and advances in clinical applications of mesenchymal stromal cells. J. Hematol. Oncol. 14, 24 (2021).33579329 10.1186/s13045-021-01037-x
3. Han Y The secretion profile of mesenchymal stem cells and potential applications in treating human diseases Signal Transduct. Target Ther. 2022 7 92 10.1038/s41392-022-00932-0 35314676
Han, Y. et al. The secretion profile of mesenchymal stem cells and potential applications in treating human diseases. Signal Transduct. Target Ther. 7, 92 (2022).35314676 10.1038/s41392-022-00932-0
4. Kimbrel EA Lanza R Next-generation stem cells - ushering in a new era of cell-based therapies Nat. Rev. Drug Discov. 2020 19 463 479 10.1038/s41573-020-0064-x 32612263
Kimbrel, E. A. & Lanza, R. Next-generation stem cells - ushering in a new era of cell-based therapies. Nat. Rev. Drug Discov. 19, 463–479 (2020).32612263 10.1038/s41573-020-0064-x
5. Zhuang WZ Mesenchymal stem/stromal cell-based therapy: mechanism, systemic safety and biodistribution for precision clinical applications J. Biomed. Sci. 2021 28 28 10.1186/s12929-021-00725-7 33849537
Zhuang, W. Z. et al. Mesenchymal stem/stromal cell-based therapy: mechanism, systemic safety and biodistribution for precision clinical applications. J. Biomed. Sci. 28, 28 (2021).33849537 10.1186/s12929-021-00725-7
6. Hao H Insights into drug discovery from natural medicines using reverse pharmacokinetics Trends Pharm. Sci. 2014 35 168 177 10.1016/j.tips.2014.02.001 24582872
Hao, H. et al. Insights into drug discovery from natural medicines using reverse pharmacokinetics. Trends Pharm. Sci. 35, 168–177 (2014).24582872 10.1016/j.tips.2014.02.001
7. Nitzsche F Concise review: MSC adhesion cascade-insights into homing and transendothelial migration Stem Cells 2017 35 1446 1460 10.1002/stem.2614 28316123
Nitzsche, F. et al. Concise review: MSC adhesion cascade-insights into homing and transendothelial migration. Stem Cells 35, 1446–1460 (2017).28316123 10.1002/stem.2614
8. Galleu A Apoptosis in mesenchymal stromal cells induces in vivo recipient-mediated immunomodulation Sci. Transl. Med. 2017 9 eaam7828 10.1126/scitranslmed.aam7828 29141887
Galleu, A. et al. Apoptosis in mesenchymal stromal cells induces in vivo recipient-mediated immunomodulation. Sci. Transl. Med. 9, eaam7828 (2017).29141887 10.1126/scitranslmed.aam7828
9. Song N Mesenchymal stem cell immunomodulation: mechanisms and therapeutic potential Trends Pharm. Sci. 2020 41 653 664 10.1016/j.tips.2020.06.009 32709406
Song, N. et al. Mesenchymal stem cell immunomodulation: mechanisms and therapeutic potential. Trends Pharm. Sci. 41, 653–664 (2020).32709406 10.1016/j.tips.2020.06.009
10. Lin RZ Mitochondrial transfer mediates endothelial cell engraftment through mitophagy Nature 2024 629 660 668 10.1038/s41586-024-07340-0 38693258
Lin, R. Z. et al. Mitochondrial transfer mediates endothelial cell engraftment through mitophagy. Nature 629, 660–668 (2024).38693258 10.1038/s41586-024-07340-0
11. Islam MN Mitochondrial transfer from bone-marrow-derived stromal cells to pulmonary alveoli protects against acute lung injury Nat. Med. 2012 18 759 765 10.1038/nm.2736 22504485
Islam, M. N. et al. Mitochondrial transfer from bone-marrow-derived stromal cells to pulmonary alveoli protects against acute lung injury. Nat. Med. 18, 759–765 (2012).22504485 10.1038/nm.2736
12. Uccelli A Mesenchymal stem cells in health and disease Nat. Rev. Immunol. 2008 8 726 736 10.1038/nri2395 19172693
Uccelli, A. et al. Mesenchymal stem cells in health and disease. Nat. Rev. Immunol. 8, 726–736 (2008).19172693 10.1038/nri2395
13. Yu S Enhancing mesenchymal stem cell survival and homing capability to improve cell engraftment efficacy for liver diseases Stem Cell Res. Ther. 2023 14 235 10.1186/s13287-023-03476-4 37667383
Yu, S. et al. Enhancing mesenchymal stem cell survival and homing capability to improve cell engraftment efficacy for liver diseases. Stem Cell Res. Ther. 14, 235 (2023).37667383 10.1186/s13287-023-03476-4
14. van Griensven M Balmayor ER Extracellular vesicles are key players in mesenchymal stem cells’ dual potential to regenerate and modulate the immune system Adv. Drug Deliv. Rev. 2024 207 115203 10.1016/j.addr.2024.115203 38342242
van Griensven, M. & Balmayor, E. R. Extracellular vesicles are key players in mesenchymal stem cells’ dual potential to regenerate and modulate the immune system. Adv. Drug Deliv. Rev. 207, 115203 (2024).38342242 10.1016/j.addr.2024.115203
15. Che Shaffi S Unlocking the potential of extracellular vesicles as the next generation therapy: challenges and opportunities Tissue Eng. Regen. Med. 2024 21 513 527 10.1007/s13770-024-00634-4 38598059
Che Shaffi, S. et al. Unlocking the potential of extracellular vesicles as the next generation therapy: challenges and opportunities. Tissue Eng. Regen. Med. 21, 513–527 (2024).38598059 10.1007/s13770-024-00634-4
16. Abdulmalek O Therapeutic applications of stem cell-derived exosomes Int. J. Mol. Sci. 2024 25 3562 10.3390/ijms25063562 38542535
Abdulmalek, O. et al. Therapeutic applications of stem cell-derived exosomes. Int. J. Mol. Sci. 25, 3562 (2024).38542535 10.3390/ijms25063562
17. Li X Umbilical cord-derived mesenchymal stem cell secretome promotes skin regeneration and rejuvenation: from mechanism to therapeutics Cell Prolif. 2024 57 e13586 10.1111/cpr.13586 38148579
Li, X. et al. Umbilical cord-derived mesenchymal stem cell secretome promotes skin regeneration and rejuvenation: from mechanism to therapeutics. Cell Prolif. 57, e13586 (2024).38148579 10.1111/cpr.13586
18. Galipeau J Sensébé L Mesenchymal stromal cells: clinical challenges and therapeutic opportunities Cell Stem Cell 2018 22 824 833 10.1016/j.stem.2018.05.004 29859173
Galipeau, J. & Sensébé, L. Mesenchymal stromal cells: clinical challenges and therapeutic opportunities. Cell Stem Cell 22, 824–833 (2018).29859173 10.1016/j.stem.2018.05.004
19. Kabat M Trends in mesenchymal stem cell clinical trials 2004-2018: Is efficacy optimal in a narrow dose range Stem Cells Transl. Med 2020 9 17 27 10.1002/sctm.19-0202 31804767
Kabat, M. et al. Trends in mesenchymal stem cell clinical trials 2004-2018: Is efficacy optimal in a narrow dose range. Stem Cells Transl. Med 9, 17–27 (2020).31804767 10.1002/sctm.19-0202
20. Wang Y Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications Nat. Immunol. 2014 15 1009 1016 10.1038/ni.3002 25329189
Wang, Y. et al. Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications. Nat. Immunol. 15, 1009–1016 (2014).25329189 10.1038/ni.3002
21. L PK The mesenchymal stem cell secretome: a new paradigm towards cell-free therapeutic mode in regenerative medicine Cytokine Growth Factor Rev. 2019 46 1 9 10.1016/j.cytogfr.2019.04.002 30954374
L, P. K. et al. The mesenchymal stem cell secretome: a new paradigm towards cell-free therapeutic mode in regenerative medicine. Cytokine Growth Factor Rev. 46, 1–9 (2019).30954374 10.1016/j.cytogfr.2019.04.002
22. Watanabe Y The development of mesenchymal stem cell therapy in the present, and the perspective of cell-free therapy in the future Clin. Mol. Hepatol. 2021 27 70 80 10.3350/cmh.2020.0194 33317249
Watanabe, Y. et al. The development of mesenchymal stem cell therapy in the present, and the perspective of cell-free therapy in the future. Clin. Mol. Hepatol. 27, 70–80 (2021).33317249 10.3350/cmh.2020.0194
23. Varderidou-Minasian S Lorenowicz MJ Mesenchymal stromal/stem cell-derived extracellular vesicles in tissue repair: challenges and opportunities Theranostics 2020 10 5979 5997 10.7150/thno.40122 32483432
Varderidou-Minasian, S. & Lorenowicz, M. J. Mesenchymal stromal/stem cell-derived extracellular vesicles in tissue repair: challenges and opportunities. Theranostics 10, 5979–5997 (2020).32483432 10.7150/thno.40122
24. Antunes MA Effects of different mesenchymal stromal cell sources and delivery routes in experimental emphysema Respir. Res. 2014 15 118 10.1186/s12931-014-0118-x 25272959
Antunes, M. A. et al. Effects of different mesenchymal stromal cell sources and delivery routes in experimental emphysema. Respir. Res. 15, 118 (2014).25272959 10.1186/s12931-014-0118-x
25. Tan F Clinical applications of stem cell-derived exosomes Signal Transduct. Target Ther. 2024 9 17 10.1038/s41392-023-01704-0 38212307
Tan, F. et al. Clinical applications of stem cell-derived exosomes. Signal Transduct. Target Ther. 9, 17 (2024).38212307 10.1038/s41392-023-01704-0
26. Moll G Intravascular mesenchymal stromal/stem cell therapy product diversification: time for new clinical guidelines Trends Mol. Med. 2019 25 149 163 10.1016/j.molmed.2018.12.006 30711482
Moll, G. et al. Intravascular mesenchymal stromal/stem cell therapy product diversification: time for new clinical guidelines. Trends Mol. Med. 25, 149–163 (2019).30711482 10.1016/j.molmed.2018.12.006
27. Levy O Shattering barriers toward clinically meaningful MSC therapies Sci. Adv. 2020 6 eaba6884 10.1126/sciadv.aba6884 32832666
Levy, O. et al. Shattering barriers toward clinically meaningful MSC therapies. Sci. Adv. 6, eaba6884 (2020).32832666 10.1126/sciadv.aba6884
28. Kanelidis AJ Route of delivery modulates the efficacy of mesenchymal stem cell therapy for myocardial infarction: a meta-analysis of preclinical studies and clinical trials Circ. Res. 2017 120 1139 1150 10.1161/CIRCRESAHA.116.309819 28031416
Kanelidis, A. J. et al. Route of delivery modulates the efficacy of mesenchymal stem cell therapy for myocardial infarction: a meta-analysis of preclinical studies and clinical trials. Circ. Res. 120, 1139–1150 (2017).28031416 10.1161/CIRCRESAHA.116.309819
29. Burdick JA To serve and protect: hydrogels to improve stem cell-based therapies Cell Stem Cell 2016 18 13 15 10.1016/j.stem.2015.12.004 26748751
Burdick, J. A. et al. To serve and protect: hydrogels to improve stem cell-based therapies. Cell Stem Cell 18, 13–15 (2016).26748751 10.1016/j.stem.2015.12.004
30. Hofmann M Monitoring of bone marrow cell homing into the infarcted human myocardium Circulation 2005 111 2198 2202 10.1161/01.CIR.0000163546.27639.AA 15851598
Hofmann, M. et al. Monitoring of bone marrow cell homing into the infarcted human myocardium. Circulation 111, 2198–2202 (2005).15851598 10.1161/01.CIR.0000163546.27639.AA
31. Madl CM Bioengineering strategies to accelerate stem cell therapeutics Nature 2018 557 335 342 10.1038/s41586-018-0089-z 29769665
Madl, C. M. et al. Bioengineering strategies to accelerate stem cell therapeutics. Nature 557, 335–342 (2018).29769665 10.1038/s41586-018-0089-z
32. Karp JM Leng Teo GS Mesenchymal stem cell homing: the devil is in the details Cell Stem Cell 2009 4 206 216 10.1016/j.stem.2009.02.001 19265660
Karp, J. M. & Leng Teo, G. S. Mesenchymal stem cell homing: the devil is in the details. Cell Stem Cell 4, 206–216 (2009).19265660 10.1016/j.stem.2009.02.001
33. Scarfe L Non-invasive imaging reveals conditions that impact distribution and persistence of cells after in vivo administration Stem Cell Res Ther. 2018 9 332 10.1186/s13287-018-1076-x 30486897
Scarfe, L. et al. Non-invasive imaging reveals conditions that impact distribution and persistence of cells after in vivo administration. Stem Cell Res Ther. 9, 332 (2018).30486897 10.1186/s13287-018-1076-x
34. Grégoire C Review article: mesenchymal stromal cell therapy for inflammatory bowel diseases Aliment. Pharm. Ther. 2017 45 205 221 10.1111/apt.13864
Grégoire, C. et al. Review article: mesenchymal stromal cell therapy for inflammatory bowel diseases. Aliment. Pharm. Ther. 45, 205–221 (2017).10.1111/apt.13864
35. Voswinkel J Gastro-intestinal autoimmunity: preclinical experiences and successful therapy of fistulizing bowel diseases and gut Graft versus host disease by mesenchymal stromal cells Immunol. Res. 2013 56 241 248 10.1007/s12026-013-8397-8 23564182
Voswinkel, J. et al. Gastro-intestinal autoimmunity: preclinical experiences and successful therapy of fistulizing bowel diseases and gut Graft versus host disease by mesenchymal stromal cells. Immunol. Res. 56, 241–248 (2013).23564182 10.1007/s12026-013-8397-8
36. Devine SM Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates Blood 2003 101 2999 3001 10.1182/blood-2002-06-1830 12480709
Devine, S. M. et al. Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. Blood 101, 2999–3001 (2003).12480709 10.1182/blood-2002-06-1830
37. Sackstein R The lymphocyte homing receptors: gatekeepers of the multistep paradigm Curr. Opin. Hematol. 2005 12 444 450 10.1097/01.moh.0000177827.78280.79 16217160
Sackstein, R. The lymphocyte homing receptors: gatekeepers of the multistep paradigm. Curr. Opin. Hematol. 12, 444–450 (2005).16217160 10.1097/01.moh.0000177827.78280.79
38. Ullah M Mesenchymal stromal cell homing: mechanisms and strategies for improvement iScience 2019 15 421 438 10.1016/j.isci.2019.05.004 31121468
Ullah, M. et al. Mesenchymal stromal cell homing: mechanisms and strategies for improvement. iScience 15, 421–438 (2019).31121468 10.1016/j.isci.2019.05.004
39. Rüster B Mesenchymal stem cells display coordinated rolling and adhesion behavior on endothelial cells Blood 2006 108 3938 3944 10.1182/blood-2006-05-025098 16896152
Rüster, B. et al. Mesenchymal stem cells display coordinated rolling and adhesion behavior on endothelial cells. Blood 108, 3938–3944 (2006).16896152 10.1182/blood-2006-05-025098
40. Aldridge V Human mesenchymal stem cells are recruited to injured liver in a β1-integrin and CD44 dependent manner Hepatology 2012 56 1063 1073 10.1002/hep.25716 22422467
Aldridge, V. et al. Human mesenchymal stem cells are recruited to injured liver in a β1-integrin and CD44 dependent manner. Hepatology 56, 1063–1073 (2012).22422467 10.1002/hep.25716
41. Sackstein R Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone Nat. Med. 2008 14 181 187 10.1038/nm1703 18193058
Sackstein, R. et al. Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone. Nat. Med. 14, 181–187 (2008).18193058 10.1038/nm1703
42. Geng JG P-selectin cell adhesion molecule in inflammation, thrombosis, cancer growth and metastasis Curr. Med. Chem. 2004 11 2153 2160 10.2174/0929867043364720 15279555
Geng, J. G. et al. P-selectin cell adhesion molecule in inflammation, thrombosis, cancer growth and metastasis. Curr. Med. Chem. 11, 2153–2160 (2004).15279555 10.2174/0929867043364720
43. Suila H Human umbilical cord blood-derived mesenchymal stromal cells display a novel interaction between P-selectin and galectin-1 Scand. J. Immunol. 2014 80 12 21 10.1111/sji.12179 24684681
Suila, H. et al. Human umbilical cord blood-derived mesenchymal stromal cells display a novel interaction between P-selectin and galectin-1. Scand. J. Immunol. 80, 12–21 (2014).24684681 10.1111/sji.12179
44. Olivares-Navarrete R Role of integrin subunits in mesenchymal stem cell differentiation and osteoblast maturation on graphitic carbon-coated microstructured surfaces Biomaterials 2015 51 69 79 10.1016/j.biomaterials.2015.01.035 25770999
Olivares-Navarrete, R. et al. Role of integrin subunits in mesenchymal stem cell differentiation and osteoblast maturation on graphitic carbon-coated microstructured surfaces. Biomaterials 51, 69–79 (2015).25770999 10.1016/j.biomaterials.2015.01.035
45. Semon JA Integrin expression and integrin-mediated adhesion in vitro of human multipotent stromal cells (MSCs) to endothelial cells from various blood vessels Cell Tissue Res. 2010 341 147 158 10.1007/s00441-010-0994-4 20563599
Semon, J. A. et al. Integrin expression and integrin-mediated adhesion in vitro of human multipotent stromal cells (MSCs) to endothelial cells from various blood vessels. Cell Tissue Res. 341, 147–158 (2010).20563599 10.1007/s00441-010-0994-4
46. Brooke G Molecular trafficking mechanisms of multipotent mesenchymal stem cells derived from human bone marrow and placenta Stem Cells Dev. 2008 17 929 940 10.1089/scd.2007.0156 18564033
Brooke, G. et al. Molecular trafficking mechanisms of multipotent mesenchymal stem cells derived from human bone marrow and placenta. Stem Cells Dev. 17, 929–940 (2008).18564033 10.1089/scd.2007.0156
47. Moursi AM Interactions between integrin receptors and fibronectin are required for calvarial osteoblast differentiation in vitro J. Cell Sci. 1997 110 2187 2196 10.1242/jcs.110.18.2187 9378768
Moursi, A. M. et al. Interactions between integrin receptors and fibronectin are required for calvarial osteoblast differentiation in vitro. J. Cell Sci. 110, 2187–2196 (1997).9378768 10.1242/jcs.110.18.2187
48. Cui LL Integrin α4 overexpression on rat mesenchymal stem cells enhances transmigration and reduces cerebral embolism after intracarotid injection Stroke 2017 48 2895 2900 10.1161/STROKEAHA.117.017809 28916665
Cui, L. L. et al. Integrin α4 overexpression on rat mesenchymal stem cells enhances transmigration and reduces cerebral embolism after intracarotid injection. Stroke 48, 2895–2900 (2017).28916665 10.1161/STROKEAHA.117.017809
49. Kumar S Ponnazhagan S Bone homing of mesenchymal stem cells by ectopic alpha 4 integrin expression FASEB J. 2007 21 3917 3927 10.1096/fj.07-8275com 17622670
Kumar, S. & Ponnazhagan, S. Bone homing of mesenchymal stem cells by ectopic alpha 4 integrin expression. FASEB J. 21, 3917–3927 (2007).17622670 10.1096/fj.07-8275com
50. Zlotnik A Homeostatic chemokine receptors and organ-specific metastasis Nat. Rev. Immunol. 2011 11 597 606 10.1038/nri3049 21866172
Zlotnik, A. et al. Homeostatic chemokine receptors and organ-specific metastasis. Nat. Rev. Immunol. 11, 597–606 (2011).21866172 10.1038/nri3049
51. Moser B Chemokines: multiple levels of leukocyte migration control Trends Immunol. 2004 25 75 84 10.1016/j.it.2003.12.005 15102366
Moser, B. et al. Chemokines: multiple levels of leukocyte migration control. Trends Immunol. 25, 75–84 (2004).15102366 10.1016/j.it.2003.12.005
52. Cuesta-Gomez N Chemokines and their receptors: predictors of the therapeutic potential of mesenchymal stromal cells J. Transl. Med. 2021 19 156 10.1186/s12967-021-02822-5 33865426
Cuesta-Gomez, N. et al. Chemokines and their receptors: predictors of the therapeutic potential of mesenchymal stromal cells. J. Transl. Med. 19, 156 (2021).33865426 10.1186/s12967-021-02822-5
53. Zlotnik A Yoshie O The chemokine superfamily revisited Immunity 2012 36 705 716 10.1016/j.immuni.2012.05.008 22633458
Zlotnik, A. & Yoshie, O. The chemokine superfamily revisited. Immunity 36, 705–716 (2012).22633458 10.1016/j.immuni.2012.05.008
54. Springer TA Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm Cell 1994 76 301 314 10.1016/0092-8674(94)90337-9 7507411
Springer, T. A. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 76, 301–314 (1994).7507411 10.1016/0092-8674(94)90337-9
55. Constantin G Chemokines trigger immediate beta2 integrin affinity and mobility changes: differential regulation and roles in lymphocyte arrest under flow Immunity 2000 13 759 769 10.1016/S1074-7613(00)00074-1 11163192
Constantin, G. et al. Chemokines trigger immediate beta2 integrin affinity and mobility changes: differential regulation and roles in lymphocyte arrest under flow. Immunity 13, 759–769 (2000).11163192 10.1016/S1074-7613(00)00074-1
56. Honczarenko M Human bone marrow stromal cells express a distinct set of biologically functional chemokine receptors Stem Cells 2006 24 1030 1041 10.1634/stemcells.2005-0319 16253981
Honczarenko, M. et al. Human bone marrow stromal cells express a distinct set of biologically functional chemokine receptors. Stem Cells 24, 1030–1041 (2006).16253981 10.1634/stemcells.2005-0319
57. Von Lüttichau I Human adult CD34- progenitor cells functionally express the chemokine receptors CCR1, CCR4, CCR7, CXCR5, and CCR10 but not CXCR4 Stem Cells Dev. 2005 14 329 336 10.1089/scd.2005.14.329 15969628
Von Lüttichau, I. et al. Human adult CD34- progenitor cells functionally express the chemokine receptors CCR1, CCR4, CCR7, CXCR5, and CCR10 but not CXCR4. Stem Cells Dev. 14, 329–336 (2005).15969628 10.1089/scd.2005.14.329
58. Sordi V Bone marrow mesenchymal stem cells express a restricted set of functionally active chemokine receptors capable of promoting migration to pancreatic islets Blood 2005 106 419 427 10.1182/blood-2004-09-3507 15784733
Sordi, V. et al. Bone marrow mesenchymal stem cells express a restricted set of functionally active chemokine receptors capable of promoting migration to pancreatic islets. Blood 106, 419–427 (2005).15784733 10.1182/blood-2004-09-3507
59. Hassanshahi G Involvement of various chemokine/chemokine receptor axes in trafficking and oriented locomotion of mesenchymal stem cells in multiple sclerosis patients Cytokine 2021 148 155706 10.1016/j.cyto.2021.155706 34583254
Hassanshahi, G. et al. Involvement of various chemokine/chemokine receptor axes in trafficking and oriented locomotion of mesenchymal stem cells in multiple sclerosis patients. Cytokine 148, 155706 (2021).34583254 10.1016/j.cyto.2021.155706
60. Cornelissen AS Organ-specific migration of mesenchymal stromal cells: who, when, where and why Immunol. Lett. 2015 168 159 169 10.1016/j.imlet.2015.06.019 26187508
Cornelissen, A. S. et al. Organ-specific migration of mesenchymal stromal cells: who, when, where and why. Immunol. Lett. 168, 159–169 (2015).26187508 10.1016/j.imlet.2015.06.019
61. Rombouts WJ Ploemacher RE Primary murine MSC show highly efficient homing to the bone marrow but lose homing ability following culture Leukemia 2003 17 160 170 10.1038/sj.leu.2402763 12529674
Rombouts, W. J. & Ploemacher, R. E. Primary murine MSC show highly efficient homing to the bone marrow but lose homing ability following culture. Leukemia 17, 160–170 (2003).12529674 10.1038/sj.leu.2402763
62. Wang M Calcium phosphate altered the cytokine secretion of macrophages and influenced the homing of mesenchymal stem cells J. Mater. Chem. B 2018 6 4765 4774 10.1039/C8TB01201F 32254303
Wang, M. et al. Calcium phosphate altered the cytokine secretion of macrophages and influenced the homing of mesenchymal stem cells. J. Mater. Chem. B 6, 4765–4774 (2018).32254303 10.1039/C8TB01201F
63. Huang J Genetic modification of mesenchymal stem cells overexpressing CCR1 increases cell viability, migration, engraftment, and capillary density in the injured myocardium Circ. Res. 2010 106 1753 1762 10.1161/CIRCRESAHA.109.196030 20378860
Huang, J. et al. Genetic modification of mesenchymal stem cells overexpressing CCR1 increases cell viability, migration, engraftment, and capillary density in the injured myocardium. Circ. Res. 106, 1753–1762 (2010).20378860 10.1161/CIRCRESAHA.109.196030
64. Jiang HH Combined treatment with CCR1-overexpressing mesenchymal stem cells and CCL7 enhances engraftment and promotes the recovery of simulated birth injury-induced stress urinary incontinence in rats Front. Surg. 2020 7 40 10.3389/fsurg.2020.00040 32850943
Jiang, H. H. et al. Combined treatment with CCR1-overexpressing mesenchymal stem cells and CCL7 enhances engraftment and promotes the recovery of simulated birth injury-induced stress urinary incontinence in rats. Front. Surg. 7, 40 (2020).32850943 10.3389/fsurg.2020.00040
65. Girard SD From blood to lesioned brain: an in vitro study on migration mechanisms of human nasal olfactory stem cells Stem Cells Int. 2017 2017 1478606 10.1155/2017/1478606 28698717
Girard, S. D. et al. From blood to lesioned brain: an in vitro study on migration mechanisms of human nasal olfactory stem cells. Stem Cells Int. 2017, 1478606 (2017).28698717 10.1155/2017/1478606
66. Mossanen JC Chemokine (C-C motif) receptor 2-positive monocytes aggravate the early phase of acetaminophen-induced acute liver injury Hepatology 2016 64 1667 1682 10.1002/hep.28682 27302828
Mossanen, J. C. et al. Chemokine (C-C motif) receptor 2-positive monocytes aggravate the early phase of acetaminophen-induced acute liver injury. Hepatology 64, 1667–1682 (2016).27302828 10.1002/hep.28682
67. Kuang S CCR2-engineered mesenchymal stromal cells accelerate diabetic wound healing by restoring immunological homeostasis Biomaterials 2021 275 120963 10.1016/j.biomaterials.2021.120963 34153785
Kuang, S. et al. CCR2-engineered mesenchymal stromal cells accelerate diabetic wound healing by restoring immunological homeostasis. Biomaterials 275, 120963 (2021).34153785 10.1016/j.biomaterials.2021.120963
68. Xu R CCR2-overexpressing mesenchymal stem cells targeting damaged liver enhance recovery of acute liver failure Stem Cell Res. Ther. 2022 13 55 10.1186/s13287-022-02729-y 35123561
Xu, R. et al. CCR2-overexpressing mesenchymal stem cells targeting damaged liver enhance recovery of acute liver failure. Stem Cell Res. Ther. 13, 55 (2022).35123561 10.1186/s13287-022-02729-y
69. Huang Y Targeted homing of CCR2-overexpressing mesenchymal stromal cells to ischemic brain enhances post-stroke recovery partially through PRDX4-mediated blood-brain barrier preservation Theranostics 2018 8 5929 5944 10.7150/thno.28029 30613272
Huang, Y. et al. Targeted homing of CCR2-overexpressing mesenchymal stromal cells to ischemic brain enhances post-stroke recovery partially through PRDX4-mediated blood-brain barrier preservation. Theranostics 8, 5929–5944 (2018).30613272 10.7150/thno.28029
70. Pavon LF Tropism of mesenchymal stem cell toward CD133(+) stem cell of glioblastoma in vitro and promote tumor proliferation in vivo Stem Cell Res Ther. 2018 9 310 10.1186/s13287-018-1049-0 30413179
Pavon, L. F. et al. Tropism of mesenchymal stem cell toward CD133(+) stem cell of glioblastoma in vitro and promote tumor proliferation in vivo. Stem Cell Res Ther. 9, 310 (2018).30413179 10.1186/s13287-018-1049-0
71. Schenk S Monocyte chemotactic protein-3 is a myocardial mesenchymal stem cell homing factor Stem Cells 2007 25 245 251 10.1634/stemcells.2006-0293 17053210
Schenk, S. et al. Monocyte chemotactic protein-3 is a myocardial mesenchymal stem cell homing factor. Stem Cells 25, 245–251 (2007).17053210 10.1634/stemcells.2006-0293
72. He X Spontaneous apoptosis of cells in therapeutic stem cell preparation exert immunomodulatory effects through release of phosphatidylserine Signal Transduct. Target Ther. 2021 6 270 10.1038/s41392-021-00688-z 34262012
He, X. et al. Spontaneous apoptosis of cells in therapeutic stem cell preparation exert immunomodulatory effects through release of phosphatidylserine. Signal Transduct. Target Ther. 6, 270 (2021).34262012 10.1038/s41392-021-00688-z
73. Wang X KSHV enhances mesenchymal stem cell homing and promotes KS-like pathogenesis Virology 2020 549 5 12 10.1016/j.virol.2020.07.012 32777727
Wang, X. et al. KSHV enhances mesenchymal stem cell homing and promotes KS-like pathogenesis. Virology 549, 5–12 (2020).32777727 10.1016/j.virol.2020.07.012
74. Schäfer R Modulating endothelial adhesion and migration impacts stem cell therapies efficacy EBioMedicine 2020 60 102987 10.1016/j.ebiom.2020.102987 32942121
Schäfer, R. et al. Modulating endothelial adhesion and migration impacts stem cell therapies efficacy. EBioMedicine 60, 102987 (2020).32942121 10.1016/j.ebiom.2020.102987
75. Dhoke NR Cxcr6-based mesenchymal stem cell gene therapy potentiates skin regeneration in murine diabetic wounds Mol. Ther. 2020 28 1314 1326 10.1016/j.ymthe.2020.02.014 32112713
Dhoke, N. R. et al. Cxcr6-based mesenchymal stem cell gene therapy potentiates skin regeneration in murine diabetic wounds. Mol. Ther. 28, 1314–1326 (2020).32112713 10.1016/j.ymthe.2020.02.014
76. Chamberlain G Mesenchymal stem cells exhibit firm adhesion, crawling, spreading and transmigration across aortic endothelial cells: effects of chemokines and shear PLoS One 2011 6 e25663 10.1371/journal.pone.0025663 21980522
Chamberlain, G. et al. Mesenchymal stem cells exhibit firm adhesion, crawling, spreading and transmigration across aortic endothelial cells: effects of chemokines and shear. PLoS One 6, e25663 (2011).21980522 10.1371/journal.pone.0025663
77. Li H CCR7 guides migration of mesenchymal stem cell to secondary lymphoid organs: a novel approach to separate GvHD from GvL effect Stem Cells 2014 32 1890 1903 10.1002/stem.1656 24496849
Li, H. et al. CCR7 guides migration of mesenchymal stem cell to secondary lymphoid organs: a novel approach to separate GvHD from GvL effect. Stem Cells 32, 1890–1903 (2014).24496849 10.1002/stem.1656
78. Sasaki M Mesenchymal stem cells are recruited into wounded skin and contribute to wound repair by transdifferentiation into multiple skin cell type J. Immunol. 2008 180 2581 2587 10.4049/jimmunol.180.4.2581 18250469
Sasaki, M. et al. Mesenchymal stem cells are recruited into wounded skin and contribute to wound repair by transdifferentiation into multiple skin cell type. J. Immunol. 180, 2581–2587 (2008).18250469 10.4049/jimmunol.180.4.2581
79. Murphy PM International union of pharmacology. XXII. Nomenclature for chemokine receptors Pharm. Rev. 2000 52 145 176 10699158
Murphy, P. M. et al. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharm. Rev. 52, 145–176 (2000).10699158
80. Ullah M Mesenchymal stem cells and their chondrogenic differentiated and dedifferentiated progeny express chemokine receptor CCR9 and chemotactically migrate toward CCL25 or serum Stem Cell Res. Ther. 2013 4 99 10.1186/scrt310 23958031
Ullah, M. et al. Mesenchymal stem cells and their chondrogenic differentiated and dedifferentiated progeny express chemokine receptor CCR9 and chemotactically migrate toward CCL25 or serum. Stem Cell Res. Ther. 4, 99 (2013).23958031 10.1186/scrt310
81. Hocking AM The role of chemokines in mesenchymal stem cell homing to wounds Adv. Wound Care 2015 4 623 630 10.1089/wound.2014.0579
Hocking, A. M. The role of chemokines in mesenchymal stem cell homing to wounds. Adv. Wound Care 4, 623–630 (2015).10.1089/wound.2014.0579
82. Alexeev V Analysis of chemotactic molecules in bone marrow-derived mesenchymal stem cells and the skin: Ccl27-Ccr10 axis as a basis for targeting to cutaneous tissues Cytotherapy 2013 15 171 184.e1 10.1016/j.jcyt.2012.11.006 23321329
Alexeev, V. et al. Analysis of chemotactic molecules in bone marrow-derived mesenchymal stem cells and the skin: Ccl27-Ccr10 axis as a basis for targeting to cutaneous tissues. Cytotherapy 15, 171–184.e1 (2013).23321329 10.1016/j.jcyt.2012.11.006
83. Ringe J Towards in situ tissue repair: human mesenchymal stem cells express chemokine receptors CXCR1, CXCR2 and CCR2, and migrate upon stimulation with CXCL8 but not CCL2 J. Cell Biochem. 2007 101 135 146 10.1002/jcb.21172 17295203
Ringe, J. et al. Towards in situ tissue repair: human mesenchymal stem cells express chemokine receptors CXCR1, CXCR2 and CCR2, and migrate upon stimulation with CXCL8 but not CCL2. J. Cell Biochem. 101, 135–146 (2007).17295203 10.1002/jcb.21172
84. Bayo J IL-8, GRO and MCP-1 produced by hepatocellular carcinoma microenvironment determine the migratory capacity of human bone marrow-derived mesenchymal stromal cells without affecting tumor aggressiveness Oncotarget 2017 8 80235 80248 10.18632/oncotarget.10288 29113298
Bayo, J. et al. IL-8, GRO and MCP-1 produced by hepatocellular carcinoma microenvironment determine the migratory capacity of human bone marrow-derived mesenchymal stromal cells without affecting tumor aggressiveness. Oncotarget 8, 80235–80248 (2017).29113298 10.18632/oncotarget.10288
85. Kim SM CXC chemokine receptor 1 enhances the ability of human umbilical cord blood-derived mesenchymal stem cells to migrate toward gliomas Biochem Biophys. Res. Commun. 2011 407 741 746 10.1016/j.bbrc.2011.03.093 21439934
Kim, S. M. et al. CXC chemokine receptor 1 enhances the ability of human umbilical cord blood-derived mesenchymal stem cells to migrate toward gliomas. Biochem Biophys. Res. Commun. 407, 741–746 (2011).21439934 10.1016/j.bbrc.2011.03.093
86. Kobayashi Y The role of chemokines in neutrophil biology Front. Biosci. 2008 13 2400 2407 10.2741/2853 17981721
Kobayashi, Y. The role of chemokines in neutrophil biology. Front. Biosci. 13, 2400–2407 (2008).17981721 10.2741/2853
87. Li Q mRNA-engineered mesenchymal stromal cells expressing CXCR2 enhances cell migration and improves recovery in IBD Mol. Ther. Nucleic Acids 2021 26 222 236 10.1016/j.omtn.2021.07.009 34513306
Li, Q. et al. mRNA-engineered mesenchymal stromal cells expressing CXCR2 enhances cell migration and improves recovery in IBD. Mol. Ther. Nucleic Acids 26, 222–236 (2021).34513306 10.1016/j.omtn.2021.07.009
88. Shen Z Genetic modification to induce CXCR2 overexpression in mesenchymal stem cells enhances treatment benefits in radiation-induced oral mucositis Cell Death Dis. 2018 9 229 10.1038/s41419-018-0310-x 29445104
Shen, Z. et al. Genetic modification to induce CXCR2 overexpression in mesenchymal stem cells enhances treatment benefits in radiation-induced oral mucositis. Cell Death Dis. 9, 229 (2018).29445104 10.1038/s41419-018-0310-x
89. Kalwitz G Gene expression profile of adult human bone marrow-derived mesenchymal stem cells stimulated by the chemokine CXCL7 Int. J. Biochem. Cell Biol. 2009 41 649 658 10.1016/j.biocel.2008.07.011 18707017
Kalwitz, G. et al. Gene expression profile of adult human bone marrow-derived mesenchymal stem cells stimulated by the chemokine CXCL7. Int. J. Biochem. Cell Biol. 41, 649–658 (2009).18707017 10.1016/j.biocel.2008.07.011
90. Hajinejad M Resveratrol pretreatment enhanced homing of SDF-1α-preconditioned bone marrow-derived mesenchymal stem cells in a rat model of liver cirrhosis J. Cell Biochem. 2018 119 2939 2950 10.1002/jcb.26500 29130552
Hajinejad, M. et al. Resveratrol pretreatment enhanced homing of SDF-1α-preconditioned bone marrow-derived mesenchymal stem cells in a rat model of liver cirrhosis. J. Cell Biochem. 119, 2939–2950 (2018).29130552 10.1002/jcb.26500
91. He X Mesenchymal stem cells inhibited the apoptosis of alveolar epithelial cells caused by ARDS through CXCL12/CXCR4 axis Bioengineered 2022 13 9060 9070 10.1080/21655979.2022.2052652 35301927
He, X. et al. Mesenchymal stem cells inhibited the apoptosis of alveolar epithelial cells caused by ARDS through CXCL12/CXCR4 axis. Bioengineered 13, 9060–9070 (2022).35301927 10.1080/21655979.2022.2052652
92. Ling L Important role of the SDF-1/CXCR4 axis in the homing of systemically transplanted human amnion-derived mesenchymal stem cells (hAD-MSCs) to ovaries in rats with chemotherapy-induced premature ovarian insufficiency (POI) Stem Cell Res. Ther. 2022 13 79 10.1186/s13287-022-02759-6 35197118
Ling, L. et al. Important role of the SDF-1/CXCR4 axis in the homing of systemically transplanted human amnion-derived mesenchymal stem cells (hAD-MSCs) to ovaries in rats with chemotherapy-induced premature ovarian insufficiency (POI). Stem Cell Res. Ther. 13, 79 (2022).35197118 10.1186/s13287-022-02759-6
93. Naderi-Meshkin H Strategies to improve homing of mesenchymal stem cells for greater efficacy in stem cell therapy Cell Biol. Int. 2015 39 23 34 10.1002/cbin.10378 25231104
Naderi-Meshkin, H. et al. Strategies to improve homing of mesenchymal stem cells for greater efficacy in stem cell therapy. Cell Biol. Int. 39, 23–34 (2015).25231104 10.1002/cbin.10378
94. Meng SS LincRNA-p21 promotes mesenchymal stem cell migration capacity and survival through hypoxic preconditioning Stem Cell Res. Ther. 2018 9 280 10.1186/s13287-018-1031-x 30359325
Meng, S. S. et al. LincRNA-p21 promotes mesenchymal stem cell migration capacity and survival through hypoxic preconditioning. Stem Cell Res. Ther. 9, 280 (2018).30359325 10.1186/s13287-018-1031-x
95. Liu X SDF-1/CXCR4 axis modulates bone marrow mesenchymal stem cell apoptosis, migration and cytokine secretion Protein Cell 2011 2 845 854 10.1007/s13238-011-1097-z 22058039
Liu, X. et al. SDF-1/CXCR4 axis modulates bone marrow mesenchymal stem cell apoptosis, migration and cytokine secretion. Protein Cell 2, 845–854 (2011).22058039 10.1007/s13238-011-1097-z
96. Pesaresi M The chemokine receptors Ccr5 and Cxcr6 enhance migration of mesenchymal stem cells into the degenerating retina Mol. Ther. 2021 29 804 821 10.1016/j.ymthe.2020.10.026 33264643
Pesaresi, M. et al. The chemokine receptors Ccr5 and Cxcr6 enhance migration of mesenchymal stem cells into the degenerating retina. Mol. Ther. 29, 804–821 (2021).33264643 10.1016/j.ymthe.2020.10.026
97. Zhang X CXCR5-overexpressing mesenchymal stromal cells exhibit enhanced homing and can decrease contact hypersensitivity Mol. Ther. 2017 25 1434 1447 10.1016/j.ymthe.2017.04.004 28454789
Zhang, X. et al. CXCR5-overexpressing mesenchymal stromal cells exhibit enhanced homing and can decrease contact hypersensitivity. Mol. Ther. 25, 1434–1447 (2017).28454789 10.1016/j.ymthe.2017.04.004
98. Hung SC Short-term exposure of multipotent stromal cells to low oxygen increases their expression of CX3CR1 and CXCR4 and their engraftment in vivo PLoS One 2007 2 e416 10.1371/journal.pone.0000416 17476338
Hung, S. C. et al. Short-term exposure of multipotent stromal cells to low oxygen increases their expression of CX3CR1 and CXCR4 and their engraftment in vivo. PLoS One 2, e416 (2007).17476338 10.1371/journal.pone.0000416
99. Fu Y Dual-functionalized MSCs that express CX3CR1 and IL-25 exhibit enhanced therapeutic effects on inflammatory bowel disease Mol. Ther. 2020 28 1214 1228 10.1016/j.ymthe.2020.01.020 32087149
Fu, Y. et al. Dual-functionalized MSCs that express CX3CR1 and IL-25 exhibit enhanced therapeutic effects on inflammatory bowel disease. Mol. Ther. 28, 1214–1228 (2020).32087149 10.1016/j.ymthe.2020.01.020
100. Kalluri R Basement membranes: structure, assembly and role in tumour angiogenesis Nat. Rev. Cancer 2003 3 422 433 10.1038/nrc1094 12778132
Kalluri, R. Basement membranes: structure, assembly and role in tumour angiogenesis. Nat. Rev. Cancer 3, 422–433 (2003).12778132 10.1038/nrc1094
101. Steingen C Characterization of key mechanisms in transmigration and invasion of mesenchymal stem cells J. Mol. Cell Cardiol. 2008 44 1072 1084 10.1016/j.yjmcc.2008.03.010 18462748
Steingen, C. et al. Characterization of key mechanisms in transmigration and invasion of mesenchymal stem cells. J. Mol. Cell Cardiol. 44, 1072–1084 (2008).18462748 10.1016/j.yjmcc.2008.03.010
102. Visse R Nagase H Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry Circ. Res. 2003 92 827 839 10.1161/01.RES.0000070112.80711.3D 12730128
Visse, R. & Nagase, H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ. Res. 92, 827–839 (2003).12730128 10.1161/01.RES.0000070112.80711.3D
103. de Almeida L Matrix metalloproteinases: from molecular mechanisms to physiology, pathophysiology, and pharmacology Pharm. Rev. 2022 74 712 768 10.1124/pharmrev.121.000349 35738680
de Almeida, L. et al. Matrix metalloproteinases: from molecular mechanisms to physiology, pathophysiology, and pharmacology. Pharm. Rev. 74, 712–768 (2022).35738680 10.1124/pharmrev.121.000349
104. De Becker A Migration of culture-expanded human mesenchymal stem cells through bone marrow endothelium is regulated by matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-3 Haematologica 2007 92 440 449 10.3324/haematol.10475 17488654
De Becker, A. et al. Migration of culture-expanded human mesenchymal stem cells through bone marrow endothelium is regulated by matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-3. Haematologica 92, 440–449 (2007).17488654 10.3324/haematol.10475
105. Kim I Discovery of chemerin as the new chemoattractant of human mesenchymal stem cells Cell Biosci. 2021 11 120 10.1186/s13578-021-00631-3 34210352
Kim, I. et al. Discovery of chemerin as the new chemoattractant of human mesenchymal stem cells. Cell Biosci. 11, 120 (2021).34210352 10.1186/s13578-021-00631-3
106. Lu C MT1-MMP controls human mesenchymal stem cell trafficking and differentiation Blood 2010 115 221 229 10.1182/blood-2009-06-228494 19901267
Lu, C. et al. MT1-MMP controls human mesenchymal stem cell trafficking and differentiation. Blood 115, 221–229 (2010).19901267 10.1182/blood-2009-06-228494
107. Sun X PDGF-BB-induced MT1-MMP expression regulates proliferation and invasion of mesenchymal stem cells in 3-dimensional collagen via MEK/ERK1/2 and PI3K/AKT signaling Cell Signal 2013 25 1279 1287 10.1016/j.cellsig.2013.01.029 23415772
Sun, X. et al. PDGF-BB-induced MT1-MMP expression regulates proliferation and invasion of mesenchymal stem cells in 3-dimensional collagen via MEK/ERK1/2 and PI3K/AKT signaling. Cell Signal 25, 1279–1287 (2013).23415772 10.1016/j.cellsig.2013.01.029
108. Murphy G Tissue inhibitors of metalloproteinases Genome Biol. 2011 12 233 10.1186/gb-2011-12-11-233 22078297
Murphy, G. Tissue inhibitors of metalloproteinases. Genome Biol. 12, 233 (2011).22078297 10.1186/gb-2011-12-11-233
109. Ries C MMP-2, MT1-MMP, and TIMP-2 are essential for the invasive capacity of human mesenchymal stem cells: differential regulation by inflammatory cytokines Blood 2007 109 4055 4063 10.1182/blood-2006-10-051060 17197427
Ries, C. et al. MMP-2, MT1-MMP, and TIMP-2 are essential for the invasive capacity of human mesenchymal stem cells: differential regulation by inflammatory cytokines. Blood 109, 4055–4063 (2007).17197427 10.1182/blood-2006-10-051060
110. Zanotti L Mouse mesenchymal stem cells inhibit high endothelial cell activation and lymphocyte homing to lymph nodes by releasing TIMP-1 Leukemia 2016 30 1143 1154 10.1038/leu.2016.33 26898191
Zanotti, L. et al. Mouse mesenchymal stem cells inhibit high endothelial cell activation and lymphocyte homing to lymph nodes by releasing TIMP-1. Leukemia 30, 1143–1154 (2016).26898191 10.1038/leu.2016.33
111. Menge T Human mesenchymal stem cells inhibit endothelial proliferation and angiogenesis via cell-cell contact through modulation of the VE-Cadherin/β-catenin signaling pathway Stem Cells Dev. 2013 22 148 157 10.1089/scd.2012.0165 22734943
Menge, T. et al. Human mesenchymal stem cells inhibit endothelial proliferation and angiogenesis via cell-cell contact through modulation of the VE-Cadherin/β-catenin signaling pathway. Stem Cells Dev. 22, 148–157 (2013).22734943 10.1089/scd.2012.0165
112. Tondreau T In vitro study of matrix metalloproteinase/tissue inhibitor of metalloproteinase production by mesenchymal stromal cells in response to inflammatory cytokines: the role of their migration in injured tissues Cytotherapy 2009 11 559 569 10.1080/14653240903051541 19551542
Tondreau, T. et al. In vitro study of matrix metalloproteinase/tissue inhibitor of metalloproteinase production by mesenchymal stromal cells in response to inflammatory cytokines: the role of their migration in injured tissues. Cytotherapy 11, 559–569 (2009).19551542 10.1080/14653240903051541
113. Teo GS Mesenchymal stem cells transmigrate between and directly through tumor necrosis factor-α-activated endothelial cells via both leukocyte-like and novel mechanisms Stem Cells 2012 30 2472 2486 10.1002/stem.1198 22887987
Teo, G. S. et al. Mesenchymal stem cells transmigrate between and directly through tumor necrosis factor-α-activated endothelial cells via both leukocyte-like and novel mechanisms. Stem Cells 30, 2472–2486 (2012).22887987 10.1002/stem.1198
114. Abdi R HCELL expression on murine MSC licenses pancreatotropism and confers durable reversal of autoimmune diabetes in NOD mice Stem Cells 2015 33 1523 1531 10.1002/stem.1948 25641589
Abdi, R. et al. HCELL expression on murine MSC licenses pancreatotropism and confers durable reversal of autoimmune diabetes in NOD mice. Stem Cells 33, 1523–1531 (2015).25641589 10.1002/stem.1948
115. Ko IK Targeting mesenchymal stem cells to activated endothelial cells Biomaterials 2009 30 3702 3710 10.1016/j.biomaterials.2009.03.038 19375791
Ko, I. K. et al. Targeting mesenchymal stem cells to activated endothelial cells. Biomaterials 30, 3702–3710 (2009).19375791 10.1016/j.biomaterials.2009.03.038
116. Ko IK Targeting improves MSC treatment of inflammatory bowel disease Mol. Ther. 2010 18 1365 1372 10.1038/mt.2010.54 20389289
Ko, I. K. et al. Targeting improves MSC treatment of inflammatory bowel disease. Mol. Ther. 18, 1365–1372 (2010).20389289 10.1038/mt.2010.54
117. Cheng H Stem cell membrane engineering for cell rolling using peptide conjugation and tuning of cell-selectin interaction kinetics Biomaterials 2012 33 5004 5012 10.1016/j.biomaterials.2012.03.065 22494889
Cheng, H. et al. Stem cell membrane engineering for cell rolling using peptide conjugation and tuning of cell-selectin interaction kinetics. Biomaterials 33, 5004–5012 (2012).22494889 10.1016/j.biomaterials.2012.03.065
118. Gundlach CW 4th Synthesis and evaluation of an anti-MLC1 × anti-CD90 bispecific antibody for targeting and retaining bone-marrow-derived multipotent stromal cells in infarcted myocardium Bioconjug. Chem. 2011 22 1706 1714 10.1021/bc200309h 21749133
Gundlach, C. W. 4th et al. Synthesis and evaluation of an anti-MLC1 × anti-CD90 bispecific antibody for targeting and retaining bone-marrow-derived multipotent stromal cells in infarcted myocardium. Bioconjug. Chem. 22, 1706–1714 (2011).21749133 10.1021/bc200309h
119. Tsai LK Mesenchymal stem cells primed with valproate and lithium robustly migrate to infarcted regions and facilitate recovery in a stroke model Stroke 2011 42 2932 2939 10.1161/STROKEAHA.110.612788 21836090
Tsai, L. K. et al. Mesenchymal stem cells primed with valproate and lithium robustly migrate to infarcted regions and facilitate recovery in a stroke model. Stroke 42, 2932–2939 (2011).21836090 10.1161/STROKEAHA.110.612788
120. Mao AS Programmable microencapsulation for enhanced mesenchymal stem cell persistence and immunomodulation Proc. Natl Acad. Sci. USA 2019 116 15392 15397 10.1073/pnas.1819415116 31311862
Mao, A. S. et al. Programmable microencapsulation for enhanced mesenchymal stem cell persistence and immunomodulation. Proc. Natl Acad. Sci. USA 116, 15392–15397 (2019).31311862 10.1073/pnas.1819415116
121. Yanai A Focused magnetic stem cell targeting to the retina using superparamagnetic iron oxide nanoparticles Cell Transpl. 2012 21 1137 1148 10.3727/096368911X627435
Yanai, A. et al. Focused magnetic stem cell targeting to the retina using superparamagnetic iron oxide nanoparticles. Cell Transpl. 21, 1137–1148 (2012).10.3727/096368911X627435
122. Ding DC Mesenchymal stem cells Cell Transpl. 2011 20 5 14 10.3727/096368910X
Ding, D. C. et al. Mesenchymal stem cells. Cell Transpl. 20, 5–14 (2011).10.3727/096368910X
123. Bajetto A Cross-talk between mesenchymal and glioblastoma stem cells: communication beyond controversies Stem Cells Transl. Med. 2020 9 1310 1330 10.1002/sctm.20-0161 32543030
Bajetto, A. et al. Cross-talk between mesenchymal and glioblastoma stem cells: communication beyond controversies. Stem Cells Transl. Med. 9, 1310–1330 (2020).32543030 10.1002/sctm.20-0161
124. Acosta SA Intravenous bone marrow stem cell grafts preferentially migrate to spleen and abrogate chronic inflammation in stroke Stroke 2015 46 2616 2627 10.1161/STROKEAHA.115.009854 26219646
Acosta, S. A. et al. Intravenous bone marrow stem cell grafts preferentially migrate to spleen and abrogate chronic inflammation in stroke. Stroke 46, 2616–2627 (2015).26219646 10.1161/STROKEAHA.115.009854
125. Andrzejewska A Mesenchymal stem cells injected into carotid artery to target focal brain injury home to perivascular space Theranostics 2020 10 6615 6628 10.7150/thno.43169 32550893
Andrzejewska, A. et al. Mesenchymal stem cells injected into carotid artery to target focal brain injury home to perivascular space. Theranostics 10, 6615–6628 (2020).32550893 10.7150/thno.43169
126. Cerri S Intracarotid infusion of mesenchymal stem cells in an animal model of Parkinson’s disease, focusing on cell distribution and neuroprotective and behavioral effects Stem Cells Transl. Med. 2015 4 1073 1085 10.5966/sctm.2015-0023 26198165
Cerri, S. et al. Intracarotid infusion of mesenchymal stem cells in an animal model of Parkinson’s disease, focusing on cell distribution and neuroprotective and behavioral effects. Stem Cells Transl. Med. 4, 1073–1085 (2015).26198165 10.5966/sctm.2015-0023
127. Yu Q SDF-1α/CXCR4 axis mediates the migration of mesenchymal stem cells to the hypoxic-ischemic brain lesion in a rat model Cell J. 2015 16 440 447 25685734
Yu, Q. et al. SDF-1α/CXCR4 axis mediates the migration of mesenchymal stem cells to the hypoxic-ischemic brain lesion in a rat model. Cell J. 16, 440–447 (2015).25685734
128. Wang Z Engineered mesenchymal stem cells with enhanced tropism and paracrine secretion of cytokines and growth factors to treat traumatic brain injury Stem Cells 2015 33 456 467 10.1002/stem.1878 25346537
Wang, Z. et al. Engineered mesenchymal stem cells with enhanced tropism and paracrine secretion of cytokines and growth factors to treat traumatic brain injury. Stem Cells 33, 456–467 (2015).25346537 10.1002/stem.1878
129. Chen H Zhou L Treatment of ischemic stroke with modified mesenchymal stem cells Int. J. Med. Sci. 2022 19 1155 1162 10.7150/ijms.74161 35919816
Chen, H. & Zhou, L. Treatment of ischemic stroke with modified mesenchymal stem cells. Int. J. Med. Sci. 19, 1155–1162 (2022).35919816 10.7150/ijms.74161
130. Bang OY The effect of CXCR4 overexpression on mesenchymal stem cell transplantation in ischemic stroke Cell Med. 2012 4 65 76 10.3727/215517912X647172 26858855
Bang, O. Y. et al. The effect of CXCR4 overexpression on mesenchymal stem cell transplantation in ischemic stroke. Cell Med. 4, 65–76 (2012).26858855 10.3727/215517912X647172
131. Shahror RA Enhanced homing of mesenchymal stem cells overexpressing fibroblast growth factor 21 to injury site in a mouse model of traumatic brain injury Int. J. Mol. Sci. 2019 20 2624 10.3390/ijms20112624 31142002
Shahror, R. A. et al. Enhanced homing of mesenchymal stem cells overexpressing fibroblast growth factor 21 to injury site in a mouse model of traumatic brain injury. Int. J. Mol. Sci. 20, 2624 (2019).31142002 10.3390/ijms20112624
132. Hou Y IL-8 enhances the angiogenic potential of human bone marrow mesenchymal stem cells by increasing vascular endothelial growth factor Cell Biol. Int. 2014 38 1050 1059 10.1002/cbin.10294 24797366
Hou, Y. et al. IL-8 enhances the angiogenic potential of human bone marrow mesenchymal stem cells by increasing vascular endothelial growth factor. Cell Biol. Int. 38, 1050–1059 (2014).24797366 10.1002/cbin.10294
133. Andrzejewska A Mesenchymal stem cells for neurological disorders Adv. Sci. 2021 8 2002944 10.1002/advs.202002944
Andrzejewska, A. et al. Mesenchymal stem cells for neurological disorders. Adv. Sci. 8, 2002944 (2021).10.1002/advs.202002944
134. Ahn YJ Biodistribution of poly clustered superparamagnetic iron oxide nanoparticle labeled mesenchymal stem cells in aminoglycoside-induced ototoxic mouse model Biomed. Eng. Lett. 2021 11 39 53 10.1007/s13534-020-00181-6 33747602
Ahn, Y. J. et al. Biodistribution of poly clustered superparamagnetic iron oxide nanoparticle labeled mesenchymal stem cells in aminoglycoside-induced ototoxic mouse model. Biomed. Eng. Lett. 11, 39–53 (2021).33747602 10.1007/s13534-020-00181-6
135. da Costa Gonçalves F Paz AH Cell membrane and bioactive factors derived from mesenchymal stromal cells: cell-free based therapy for inflammatory bowel diseases World J. Stem Cells 2019 11 618 633 10.4252/wjsc.v11.i9.618 31616539
da Costa Gonçalves, F. & Paz, A. H. Cell membrane and bioactive factors derived from mesenchymal stromal cells: cell-free based therapy for inflammatory bowel diseases. World J. Stem Cells 11, 618–633 (2019).31616539 10.4252/wjsc.v11.i9.618
136. He XW Systemic infusion of bone marrow-derived mesenchymal stem cells for treatment of experimental colitis in mice Dig. Dis. Sci. 2012 57 3136 3144 10.1007/s10620-012-2290-5 22752635
He, X. W. et al. Systemic infusion of bone marrow-derived mesenchymal stem cells for treatment of experimental colitis in mice. Dig. Dis. Sci. 57, 3136–3144 (2012).22752635 10.1007/s10620-012-2290-5
137. Lopez-Santalla M Biodistribution and efficacy of human adipose-derived mesenchymal stem cells following intranodal administration in experimental colitis Front. Immunol. 2017 8 638 10.3389/fimmu.2017.00638 28642759
Lopez-Santalla, M. et al. Biodistribution and efficacy of human adipose-derived mesenchymal stem cells following intranodal administration in experimental colitis. Front. Immunol. 8, 638 (2017).28642759 10.3389/fimmu.2017.00638
138. Zheng XB Bone marrow-derived CXCR4-overexpressing MSCs display increased homing to intestine and ameliorate colitis-associated tumorigenesis in mice Gastroenterol. Rep. 2019 7 127 138 10.1093/gastro/goy017
Zheng, X. B. et al. Bone marrow-derived CXCR4-overexpressing MSCs display increased homing to intestine and ameliorate colitis-associated tumorigenesis in mice. Gastroenterol. Rep. 7, 127–138 (2019).10.1093/gastro/goy017
139. Chen Q Anti-VCAM 1 antibody-coated mesenchymal stromal cells attenuate experimental colitis via immunomodulation Med. Sci. Monit. 2019 25 4457 4468 10.12659/MSM.914238 31201771
Chen, Q. et al. Anti-VCAM 1 antibody-coated mesenchymal stromal cells attenuate experimental colitis via immunomodulation. Med. Sci. Monit. 25, 4457–4468 (2019).31201771 10.12659/MSM.914238
140. Fan H Pre-treatment with IL-1β enhances the efficacy of MSC transplantation in DSS-induced colitis Cell Mol. Immunol. 2012 9 473 481 10.1038/cmi.2012.40 23085948
Fan, H. et al. Pre-treatment with IL-1β enhances the efficacy of MSC transplantation in DSS-induced colitis. Cell Mol. Immunol. 9, 473–481 (2012).23085948 10.1038/cmi.2012.40
141. Hidalgo-Garcia L Can a conversation between mesenchymal stromal cells and macrophages solve the crisis in the inflamed intestine Front. Pharm. 2018 9 179 10.3389/fphar.2018.00179
Hidalgo-Garcia, L. et al. Can a conversation between mesenchymal stromal cells and macrophages solve the crisis in the inflamed intestine. Front. Pharm. 9, 179 (2018).10.3389/fphar.2018.00179
142. Zhao ML H19 overexpression improved efficacy of mesenchymal stem cells in ulcerative colitis by modulating the miR-141/ICAM-1 and miR-139/CXCR4 axes Dis. Markers 2021 2021 7107705 10.1155/2021/7107705 34630738
Zhao, M. L. et al. H19 overexpression improved efficacy of mesenchymal stem cells in ulcerative colitis by modulating the miR-141/ICAM-1 and miR-139/CXCR4 axes. Dis. Markers 2021, 7107705 (2021).34630738 10.1155/2021/7107705
143. Qiu Y TLR3 preconditioning enhances the therapeutic efficacy of umbilical cord mesenchymal stem cells in TNBS-induced colitis via the TLR3-Jagged-1-Notch-1 pathway Mucosal Immunol. 2017 10 727 742 10.1038/mi.2016.78 27649928
Qiu, Y. et al. TLR3 preconditioning enhances the therapeutic efficacy of umbilical cord mesenchymal stem cells in TNBS-induced colitis via the TLR3-Jagged-1-Notch-1 pathway. Mucosal Immunol. 10, 727–742 (2017).27649928 10.1038/mi.2016.78
144. Ma J Time course of myocardial stromal cell-derived factor 1 expression and beneficial effects of intravenously administered bone marrow stem cells in rats with experimental myocardial infarction Basic Res. Cardiol. 2005 100 217 223 10.1007/s00395-005-0521-z 15754085
Ma, J. et al. Time course of myocardial stromal cell-derived factor 1 expression and beneficial effects of intravenously administered bone marrow stem cells in rats with experimental myocardial infarction. Basic Res. Cardiol. 100, 217–223 (2005).15754085 10.1007/s00395-005-0521-z
145. Hale SL Mesenchymal stem cell administration at coronary artery reperfusion in the rat by two delivery routes: a quantitative assessment Life Sci. 2008 83 511 515 10.1016/j.lfs.2008.07.020 18755200
Hale, S. L. et al. Mesenchymal stem cell administration at coronary artery reperfusion in the rat by two delivery routes: a quantitative assessment. Life Sci. 83, 511–515 (2008).18755200 10.1016/j.lfs.2008.07.020
146. Zhang SJ Effect of TGF-β1/SDF-1/CXCR4 signal on BM-MSCs homing in rat heart of ischemia/perfusion injury Eur. Rev. Med. Pharm. Sci. 2016 20 899 905
Zhang, S. J. et al. Effect of TGF-β1/SDF-1/CXCR4 signal on BM-MSCs homing in rat heart of ischemia/perfusion injury. Eur. Rev. Med. Pharm. Sci. 20, 899–905 (2016).
147. Unzek S SDF-1 recruits cardiac stem cell-like cells that depolarize in vivo Cell Transpl. 2007 16 879 886 10.3727/096368907783338271
Unzek, S. et al. SDF-1 recruits cardiac stem cell-like cells that depolarize in vivo. Cell Transpl. 16, 879–886 (2007).10.3727/096368907783338271
148. Schmidt-Lucke C Cardiac migration of endogenous mesenchymal stromal cells in patients with inflammatory cardiomyopathy Mediators Inflamm. 2015 2015 308185 10.1155/2015/308185 25814787
Schmidt-Lucke, C. et al. Cardiac migration of endogenous mesenchymal stromal cells in patients with inflammatory cardiomyopathy. Mediators Inflamm. 2015, 308185 (2015).25814787 10.1155/2015/308185
149. Wu Y Zhao RC The role of chemokines in mesenchymal stem cell homing to myocardium Stem Cell Rev. Rep. 2012 8 243 250 10.1007/s12015-011-9293-z 21706142
Wu, Y. & Zhao, R. C. The role of chemokines in mesenchymal stem cell homing to myocardium. Stem Cell Rev. Rep. 8, 243–250 (2012).21706142 10.1007/s12015-011-9293-z
150. He H Overexpression of protein kinase C ɛ improves retention and survival of transplanted mesenchymal stem cells in rat acute myocardial infarction Cell Death Dis. 2016 7 e2056 10.1038/cddis.2015.417 26775707
He, H. et al. Overexpression of protein kinase C ɛ improves retention and survival of transplanted mesenchymal stem cells in rat acute myocardial infarction. Cell Death Dis. 7, e2056 (2016).26775707 10.1038/cddis.2015.417
151. Kean TJ Development of a peptide-targeted, myocardial ischemia-homing, mesenchymal stem cell J. Drug Target 2012 20 23 32 10.3109/1061186X.2011.622398 22047107
Kean, T. J. et al. Development of a peptide-targeted, myocardial ischemia-homing, mesenchymal stem cell. J. Drug Target 20, 23–32 (2012).22047107 10.3109/1061186X.2011.622398
152. Cheng K Transplantation of bone marrow-derived MSCs improves cisplatinum-induced renal injury through paracrine mechanisms Exp. Mol. Pathol. 2013 94 466 473 10.1016/j.yexmp.2013.03.002 23534987
Cheng, K. et al. Transplantation of bone marrow-derived MSCs improves cisplatinum-induced renal injury through paracrine mechanisms. Exp. Mol. Pathol. 94, 466–473 (2013).23534987 10.1016/j.yexmp.2013.03.002
153. Tögel F Bioluminescence imaging to monitor the in vivo distribution of administered mesenchymal stem cells in acute kidney injury Am. J. Physiol. Ren. Physiol. 2008 295 F315 F321 10.1152/ajprenal.00098.2008
Tögel, F. et al. Bioluminescence imaging to monitor the in vivo distribution of administered mesenchymal stem cells in acute kidney injury. Am. J. Physiol. Ren. Physiol. 295, F315–F321 (2008).10.1152/ajprenal.00098.2008
154. Taylor A Multimodal imaging techniques show differences in homing capacity between mesenchymal stromal cells and macrophages in mouse renal injury models Mol. Imaging Biol. 2020 22 904 913 10.1007/s11307-019-01458-8 31823201
Taylor, A. et al. Multimodal imaging techniques show differences in homing capacity between mesenchymal stromal cells and macrophages in mouse renal injury models. Mol. Imaging Biol. 22, 904–913 (2020).31823201 10.1007/s11307-019-01458-8
155. Luk F Inactivated mesenchymal stem cells maintain immunomodulatory capacity Stem Cells Dev. 2016 25 1342 1354 10.1089/scd.2016.0068 27349989
Luk, F. et al. Inactivated mesenchymal stem cells maintain immunomodulatory capacity. Stem Cells Dev. 25, 1342–1354 (2016).27349989 10.1089/scd.2016.0068
156. Hauger O MR evaluation of the glomerular homing of magnetically labeled mesenchymal stem cells in a rat model of nephropathy Radiology 2006 238 200 210 10.1148/radiol.2381041668 16373768
Hauger, O. et al. MR evaluation of the glomerular homing of magnetically labeled mesenchymal stem cells in a rat model of nephropathy. Radiology 238, 200–210 (2006).16373768 10.1148/radiol.2381041668
157. Li W An update for mesenchymal stem cell therapy in lupus nephritis Kidney Dis. 2021 7 79 89 10.1159/000513741
Li, W. et al. An update for mesenchymal stem cell therapy in lupus nephritis. Kidney Dis. 7, 79–89 (2021).10.1159/000513741
158. Liu N Migration of CXCR4 gene-modified bone marrow-derived mesenchymal stem cells to the acute injured kidney J. Cell Biochem. 2013 114 2677 2689 10.1002/jcb.24615 23794207
Liu, N. et al. Migration of CXCR4 gene-modified bone marrow-derived mesenchymal stem cells to the acute injured kidney. J. Cell Biochem. 114, 2677–2689 (2013).23794207 10.1002/jcb.24615
159. Zou X Targeting murine mesenchymal stem cells to kidney injury molecule-1 improves their therapeutic efficacy in chronic ischemic kidney injury Stem Cells Transl. Med. 2018 7 394 403 10.1002/sctm.17-0186 29446551
Zou, X. et al. Targeting murine mesenchymal stem cells to kidney injury molecule-1 improves their therapeutic efficacy in chronic ischemic kidney injury. Stem Cells Transl. Med. 7, 394–403 (2018).29446551 10.1002/sctm.17-0186
160. Xinaris C A novel strategy to enhance mesenchymal stem cell migration capacity and promote tissue repair in an injury-specific fashion Cell Transpl. 2013 22 423 436 10.3727/096368912X653246
Xinaris, C. et al. A novel strategy to enhance mesenchymal stem cell migration capacity and promote tissue repair in an injury-specific fashion. Cell Transpl. 22, 423–436 (2013).10.3727/096368912X653246
161. Si X Transforming growth factor-β1 promotes homing of bone marrow mesenchymal stem cells in renal ischemia-reperfusion injury Int. J. Clin. Exp. Pathol. 2015 8 12368 12378 26722423
Si, X. et al. Transforming growth factor-β1 promotes homing of bone marrow mesenchymal stem cells in renal ischemia-reperfusion injury. Int. J. Clin. Exp. Pathol. 8, 12368–12378 (2015).26722423
162. Zhou S Bone mesenchymal stem cells pretreated with erythropoietin enhance the effect to ameliorate cyclosporine A-induced nephrotoxicity in rats J. Cell Biochem. 2018 119 8220 8232 10.1002/jcb.26833 29932236
Zhou, S. et al. Bone mesenchymal stem cells pretreated with erythropoietin enhance the effect to ameliorate cyclosporine A-induced nephrotoxicity in rats. J. Cell Biochem. 119, 8220–8232 (2018).29932236 10.1002/jcb.26833
163. Burks SR Mesenchymal stromal cell potency to treat acute kidney injury increased by ultrasound-activated interferon-γ/interleukin-10 axis J. Cell Mol. Med. 2018 22 6015 6025 10.1111/jcmm.13874 30216653
Burks, S. R. et al. Mesenchymal stromal cell potency to treat acute kidney injury increased by ultrasound-activated interferon-γ/interleukin-10 axis. J. Cell Mol. Med. 22, 6015–6025 (2018).30216653 10.1111/jcmm.13874
164. Ullah M Reversing acute kidney injury using pulsed focused ultrasound and MSC therapy: a role for HSP-Mediated PI3K/AKT signaling Mol. Ther. Methods Clin. Dev. 2020 17 683 694 10.1016/j.omtm.2020.03.023 32346546
Ullah, M. et al. Reversing acute kidney injury using pulsed focused ultrasound and MSC therapy: a role for HSP-Mediated PI3K/AKT signaling. Mol. Ther. Methods Clin. Dev. 17, 683–694 (2020).32346546 10.1016/j.omtm.2020.03.023
165. Park M Tonsil-derived mesenchymal stem cells ameliorate CCl4-induced liver fibrosis in mice via autophagy activation Sci. Rep. 2015 5 8616 10.1038/srep08616 25722117
Park, M. et al. Tonsil-derived mesenchymal stem cells ameliorate CCl4-induced liver fibrosis in mice via autophagy activation. Sci. Rep. 5, 8616 (2015).25722117 10.1038/srep08616
166. Milosavljevic N Mesenchymal stem cells attenuate liver fibrosis by suppressing Th17 cells—an experimental study Transpl. Int. 2018 31 102 115 10.1111/tri.13023 28805262
Milosavljevic, N. et al. Mesenchymal stem cells attenuate liver fibrosis by suppressing Th17 cells—an experimental study. Transpl. Int. 31, 102–115 (2018).28805262 10.1111/tri.13023
167. Ye Z Mesenchymal stem cells overexpressing hepatocyte nuclear factor-4 alpha alleviate liver injury by modulating anti-inflammatory functions in mice Stem Cell Res. Ther. 2019 10 149 10.1186/s13287-019-1260-7 31133062
Ye, Z. et al. Mesenchymal stem cells overexpressing hepatocyte nuclear factor-4 alpha alleviate liver injury by modulating anti-inflammatory functions in mice. Stem Cell Res. Ther. 10, 149 (2019).31133062 10.1186/s13287-019-1260-7
168. Cao Y Mesenchymal stem cell therapy for liver fibrosis/cirrhosis Ann. Transl. Med. 2020 8 562 10.21037/atm.2020.02.119 32775363
Cao, Y. et al. Mesenchymal stem cell therapy for liver fibrosis/cirrhosis. Ann. Transl. Med. 8, 562 (2020).32775363 10.21037/atm.2020.02.119
169. Ahmed SK Role of bone marrow mesenchymal stem cells in the treatment of CCL4 induced liver fibrosis in albino rats: a histological and immunohistochemical study Int. J. Stem Cells 2014 7 87 97 10.15283/ijsc.2014.7.2.87 25473446
Ahmed, S. K. et al. Role of bone marrow mesenchymal stem cells in the treatment of CCL4 induced liver fibrosis in albino rats: a histological and immunohistochemical study. Int. J. Stem Cells 7, 87–97 (2014).25473446 10.15283/ijsc.2014.7.2.87
170. Zheng J Preconditioning of umbilical cord-derived mesenchymal stem cells by rapamycin increases cell migration and ameliorates liver ischaemia/reperfusion injury in mice via the CXCR4/CXCL12 axis Cell Prolif. 2019 52 e12546 10.1111/cpr.12546 30537044
Zheng, J. et al. Preconditioning of umbilical cord-derived mesenchymal stem cells by rapamycin increases cell migration and ameliorates liver ischaemia/reperfusion injury in mice via the CXCR4/CXCL12 axis. Cell Prolif. 52, e12546 (2019).30537044 10.1111/cpr.12546
171. Hu C Genetic modification by overexpression of target gene in mesenchymal stromal cell for treating liver diseases J. Mol. Med. 2021 99 179 192 10.1007/s00109-020-02031-5 33388882
Hu, C. et al. Genetic modification by overexpression of target gene in mesenchymal stromal cell for treating liver diseases. J. Mol. Med. 99, 179–192 (2021).33388882 10.1007/s00109-020-02031-5
172. Hu C Pre-treatments enhance the therapeutic effects of mesenchymal stem cells in liver diseases J. Cell Mol. Med. 2020 24 40 49 10.1111/jcmm.14788 31691463
Hu, C. et al. Pre-treatments enhance the therapeutic effects of mesenchymal stem cells in liver diseases. J. Cell Mol. Med. 24, 40–49 (2020).31691463 10.1111/jcmm.14788
173. Hu C Li L The immunoregulation of mesenchymal stem cells plays a critical role in improving the prognosis of liver transplantation J. Transl. Med. 2019 17 412 10.1186/s12967-019-02167-0 31823784
Hu, C. & Li, L. The immunoregulation of mesenchymal stem cells plays a critical role in improving the prognosis of liver transplantation. J. Transl. Med. 17, 412 (2019).31823784 10.1186/s12967-019-02167-0
174. Nasir GA Mesenchymal stem cells and Interleukin-6 attenuate liver fibrosis in mice J. Transl. Med. 2013 11 78 10.1186/1479-5876-11-78 23531302
Nasir, G. A. et al. Mesenchymal stem cells and Interleukin-6 attenuate liver fibrosis in mice. J. Transl. Med. 11, 78 (2013).23531302 10.1186/1479-5876-11-78
175. Hu C Mesenchymal stromal cells promote liver regeneration through regulation of immune cells Int. J. Biol. Sci. 2020 16 893 903 10.7150/ijbs.39725 32071558
Hu, C. et al. Mesenchymal stromal cells promote liver regeneration through regulation of immune cells. Int. J. Biol. Sci. 16, 893–903 (2020).32071558 10.7150/ijbs.39725
176. Ali G Nitric oxide augments mesenchymal stem cell ability to repair liver fibrosis J. Transl. Med. 2012 10 75 10.1186/1479-5876-10-75 22533821
Ali, G. et al. Nitric oxide augments mesenchymal stem cell ability to repair liver fibrosis. J. Transl. Med. 10, 75 (2012).22533821 10.1186/1479-5876-10-75
177. Al-Dhamin Z Therapeutic efficiency of bone marrow-derived mesenchymal stem cells for liver fibrosis: a systematic review of in vivo studies World J. Gastroenterol. 2020 26 7444 7469 10.3748/wjg.v26.i47.7444 33384547
Al-Dhamin, Z. et al. Therapeutic efficiency of bone marrow-derived mesenchymal stem cells for liver fibrosis: a systematic review of in vivo studies. World J. Gastroenterol. 26, 7444–7469 (2020).33384547 10.3748/wjg.v26.i47.7444
178. Xu J Prevention of endotoxin-induced systemic response by bone marrow-derived mesenchymal stem cells in mice Am. J. Physiol. Lung Cell Mol. Physiol. 2007 293 L131 L141 10.1152/ajplung.00431.2006 17416739
Xu, J. et al. Prevention of endotoxin-induced systemic response by bone marrow-derived mesenchymal stem cells in mice. Am. J. Physiol. Lung Cell Mol. Physiol. 293, L131–L141 (2007).17416739 10.1152/ajplung.00431.2006
179. Jiang X Intravenous delivery of adipose-derived mesenchymal stromal cells attenuates acute radiation-induced lung injury in rats Cytotherapy 2015 17 560 570 10.1016/j.jcyt.2015.02.011 25791071
Jiang, X. et al. Intravenous delivery of adipose-derived mesenchymal stromal cells attenuates acute radiation-induced lung injury in rats. Cytotherapy 17, 560–570 (2015).25791071 10.1016/j.jcyt.2015.02.011
180. Reddy M Human adipose-derived mesenchymal stem cells attenuate early stage of bleomycin-induced pulmonary fibrosis: comparison with pirfenidone Int. J. Stem Cells 2016 9 192 206 10.15283/ijsc16041 27871152
Reddy, M. et al. Human adipose-derived mesenchymal stem cells attenuate early stage of bleomycin-induced pulmonary fibrosis: comparison with pirfenidone. Int. J. Stem Cells 9, 192–206 (2016).27871152 10.15283/ijsc16041
181. Li L Mesenchymal stem cells with downregulated Hippo signaling attenuate lung injury in mice with lipopolysaccharide‑induced acute respiratory distress syndrome Int. J. Mol. Med. 2019 43 1241 1252 30628652
Li, L. et al. Mesenchymal stem cells with downregulated Hippo signaling attenuate lung injury in mice with lipopolysaccharide‑induced acute respiratory distress syndrome. Int. J. Mol. Med. 43, 1241–1252 (2019).30628652
182. Wang K Vimentin-Rab7a pathway mediates the migration of MSCs and lead to therapeutic effects on ARDS Stem Cells Int. 2021 2021 9992381 10.1155/2021/9992381 34367295
Wang, K. et al. Vimentin-Rab7a pathway mediates the migration of MSCs and lead to therapeutic effects on ARDS. Stem Cells Int. 2021, 9992381 (2021).34367295 10.1155/2021/9992381
183. Han J E-Prostanoid 2 receptor overexpression promotes mesenchymal stem cell attenuated lung injury Hum. Gene Ther. 2016 27 621 630 10.1089/hum.2016.003 27158855
Han, J. et al. E-Prostanoid 2 receptor overexpression promotes mesenchymal stem cell attenuated lung injury. Hum. Gene Ther. 27, 621–630 (2016).27158855 10.1089/hum.2016.003
184. Zhao F Pretreatment with G-CSF could enhance the antifibrotic effect of BM-MSCs on pulmonary fibrosis Stem Cells Int. 2019 2019 1726743 10.1155/2019/1726743 30719047
Zhao, F. et al. Pretreatment with G-CSF could enhance the antifibrotic effect of BM-MSCs on pulmonary fibrosis. Stem Cells Int. 2019, 1726743 (2019).30719047 10.1155/2019/1726743
185. Wang H Hepatocyte growth factor gene-modified mesenchymal stem cells reduce radiation-induced lung injury Hum. Gene Ther. 2013 24 343 353 10.1089/hum.2012.177 23458413
Wang, H. et al. Hepatocyte growth factor gene-modified mesenchymal stem cells reduce radiation-induced lung injury. Hum. Gene Ther. 24, 343–353 (2013).23458413 10.1089/hum.2012.177
186. Inokuma D CTACK/CCL27 accelerates skin regeneration via accumulation of bone marrow-derived keratinocytes Stem Cells 2006 24 2810 2816 10.1634/stemcells.2006-0264 16931770
Inokuma, D. et al. CTACK/CCL27 accelerates skin regeneration via accumulation of bone marrow-derived keratinocytes. Stem Cells 24, 2810–2816 (2006).16931770 10.1634/stemcells.2006-0264
187. Maeda A Recruitment of mesenchymal stem cells to damaged sites by plant-derived components Front. Cell Dev. Biol. 2020 8 437 10.3389/fcell.2020.00437 32582713
Maeda, A. Recruitment of mesenchymal stem cells to damaged sites by plant-derived components. Front. Cell Dev. Biol. 8, 437 (2020).32582713 10.3389/fcell.2020.00437
188. Ma T Interleukin 17 (il-17)-induced mesenchymal stem cells prolong the survival of allogeneic skin grafts Ann. Transpl. 2018 23 615 621 10.12659/AOT.909381
Ma, T. et al. Interleukin 17 (il-17)-induced mesenchymal stem cells prolong the survival of allogeneic skin grafts. Ann. Transpl. 23, 615–621 (2018).10.12659/AOT.909381
189. Wu M JAM-A promotes wound healing by enhancing both homing and secretory activities of mesenchymal stem cells Clin. Sci. 2015 129 575 588 10.1042/CS20140735
Wu, M. et al. JAM-A promotes wound healing by enhancing both homing and secretory activities of mesenchymal stem cells. Clin. Sci. 129, 575–588 (2015).10.1042/CS20140735
190. Ling L Human amnion-derived mesenchymal stem cell (hAD-MSC) transplantation improves ovarian function in rats with premature ovarian insufficiency (POI) at least partly through a paracrine mechanism Stem Cell Res. Ther. 2019 10 46 10.1186/s13287-019-1136-x 30683144
Ling, L. et al. Human amnion-derived mesenchymal stem cell (hAD-MSC) transplantation improves ovarian function in rats with premature ovarian insufficiency (POI) at least partly through a paracrine mechanism. Stem Cell Res. Ther. 10, 46 (2019).30683144 10.1186/s13287-019-1136-x
191. Feng X Effects of human amnion-derived mesenchymal stem cell (hAD-MSC) transplantation in situ on primary ovarian insufficiency in SD rats Reprod. Sci. 2020 27 1502 1512 10.1007/s43032-020-00147-0 31953773
Feng, X. et al. Effects of human amnion-derived mesenchymal stem cell (hAD-MSC) transplantation in situ on primary ovarian insufficiency in SD rats. Reprod. Sci. 27, 1502–1512 (2020).31953773 10.1007/s43032-020-00147-0
192. Corradetti B Hyaluronic acid coatings as a simple and efficient approach to improve MSC homing toward the site of inflammation Sci. Rep. 2017 7 7991 10.1038/s41598-017-08687-3 28801676
Corradetti, B. et al. Hyaluronic acid coatings as a simple and efficient approach to improve MSC homing toward the site of inflammation. Sci. Rep. 7, 7991 (2017).28801676 10.1038/s41598-017-08687-3
193. Layek B Glycoengineered mesenchymal stem cells as an enabling platform for two-step targeting of solid tumors Biomaterials 2016 88 97 109 10.1016/j.biomaterials.2016.02.024 26946263
Layek, B. et al. Glycoengineered mesenchymal stem cells as an enabling platform for two-step targeting of solid tumors. Biomaterials 88, 97–109 (2016).26946263 10.1016/j.biomaterials.2016.02.024
194. Gholamrezanezhad A In vivo tracking of 111In-oxine labeled mesenchymal stem cells following infusion in patients with advanced cirrhosis Nucl. Med. Biol. 2011 38 961 967 10.1016/j.nucmedbio.2011.03.008 21810549
Gholamrezanezhad, A. et al. In vivo tracking of 111In-oxine labeled mesenchymal stem cells following infusion in patients with advanced cirrhosis. Nucl. Med. Biol. 38, 961–967 (2011).21810549 10.1016/j.nucmedbio.2011.03.008
195. de Witte S Immunomodulation by therapeutic mesenchymal stromal cells (MSC) is triggered through phagocytosis of MSC by monocytic Cells Stem Cells 2018 36 602 615 10.1002/stem.2779 29341339
de Witte, S. et al. Immunomodulation by therapeutic mesenchymal stromal cells (MSC) is triggered through phagocytosis of MSC by monocytic Cells. Stem Cells 36, 602–615 (2018).29341339 10.1002/stem.2779
196. Amadeo F Firefly luciferase offers superior performance to AkaLuc for tracking the fate of administered cell therapies Eur. J. Nucl. Med. Mol. Imaging 2022 49 796 808 10.1007/s00259-021-05439-4 34313817
Amadeo, F. et al. Firefly luciferase offers superior performance to AkaLuc for tracking the fate of administered cell therapies. Eur. J. Nucl. Med. Mol. Imaging 49, 796–808 (2022).34313817 10.1007/s00259-021-05439-4
197. Zangi L Direct imaging of immune rejection and memory induction by allogeneic mesenchymal stromal cells Stem Cells 2009 27 2865 2874 10.1002/stem.217 19750539
Zangi, L. et al. Direct imaging of immune rejection and memory induction by allogeneic mesenchymal stromal cells. Stem Cells 27, 2865–2874 (2009).19750539 10.1002/stem.217
198. Carneiro BA El-Deiry WS Targeting apoptosis in cancer therapy Nat. Rev. Clin. Oncol. 2020 17 395 417 10.1038/s41571-020-0341-y 32203277
Carneiro, B. A. & El-Deiry, W. S. Targeting apoptosis in cancer therapy. Nat. Rev. Clin. Oncol. 17, 395–417 (2020).32203277 10.1038/s41571-020-0341-y
199. Pang S Mesenchymal stromal cell apoptosis is required for their therapeutic function Nat. Commun. 2021 12 6495 10.1038/s41467-021-26834-3 34764248
Pang, S. et al. Mesenchymal stromal cell apoptosis is required for their therapeutic function. Nat. Commun. 12, 6495 (2021).34764248 10.1038/s41467-021-26834-3
200. Li X IFNγ and TNFα synergistically induce apoptosis of mesenchymal stem/stromal cells via the induction of nitric oxide Stem Cell Res. Ther. 2019 10 18 10.1186/s13287-018-1102-z 30635041
Li, X. et al. IFNγ and TNFα synergistically induce apoptosis of mesenchymal stem/stromal cells via the induction of nitric oxide. Stem Cell Res. Ther. 10, 18 (2019).30635041 10.1186/s13287-018-1102-z
201. Gu Y The deubiquitinating enzyme UCHL1 negatively regulates the immunosuppressive capacity and survival of multipotent mesenchymal stromal cells Cell Death Dis. 2018 9 459 10.1038/s41419-018-0532-y 29686406
Gu, Y. et al. The deubiquitinating enzyme UCHL1 negatively regulates the immunosuppressive capacity and survival of multipotent mesenchymal stromal cells. Cell Death Dis. 9, 459 (2018).29686406 10.1038/s41419-018-0532-y
202. Zhang F Nicorandil protects mesenchymal stem cells against hypoxia and serum deprivation-induced apoptosis Int. J. Mol. Med. 2015 36 415 423 10.3892/ijmm.2015.2229 26035532
Zhang, F. et al. Nicorandil protects mesenchymal stem cells against hypoxia and serum deprivation-induced apoptosis. Int. J. Mol. Med. 36, 415–423 (2015).26035532 10.3892/ijmm.2015.2229
203. Hou M C1q tumor necrosis factor-related protein-3 protects mesenchymal stem cells against hypoxia- and serum deprivation-induced apoptosis through the phosphoinositide 3-kinase/Akt pathway Int. J. Mol. Med. 2014 33 97 104 10.3892/ijmm.2013.1550 24212403
Hou, M. et al. C1q tumor necrosis factor-related protein-3 protects mesenchymal stem cells against hypoxia- and serum deprivation-induced apoptosis through the phosphoinositide 3-kinase/Akt pathway. Int. J. Mol. Med. 33, 97–104 (2014).24212403 10.3892/ijmm.2013.1550
204. Si H Overexpression of adrenomedullin protects mesenchymal stem cells against hypoxia and serum deprivation‑induced apoptosis via the Akt/GSK3β and Bcl‑2 signaling pathways Int. J. Mol. Med. 2018 41 3342 3352 29512737
Si, H. et al. Overexpression of adrenomedullin protects mesenchymal stem cells against hypoxia and serum deprivation‑induced apoptosis via the Akt/GSK3β and Bcl‑2 signaling pathways. Int. J. Mol. Med. 41, 3342–3352 (2018).29512737
205. Zhang Z Asprosin improves the survival of mesenchymal stromal cells in myocardial infarction by inhibiting apoptosis via the activated ERK1/2-SOD2 pathway Life Sci. 2019 231 116554 10.1016/j.lfs.2019.116554 31194992
Zhang, Z. et al. Asprosin improves the survival of mesenchymal stromal cells in myocardial infarction by inhibiting apoptosis via the activated ERK1/2-SOD2 pathway. Life Sci. 231, 116554 (2019).31194992 10.1016/j.lfs.2019.116554
206. Wang Y miRNA-98-5p targeting IGF2BP1 induces mesenchymal stem cell apoptosis by modulating PI3K/Akt and p53 in immune thrombocytopenia Mol. Ther. Nucleic Acids 2020 20 764 776 10.1016/j.omtn.2020.04.013 32428701
Wang, Y. et al. miRNA-98-5p targeting IGF2BP1 induces mesenchymal stem cell apoptosis by modulating PI3K/Akt and p53 in immune thrombocytopenia. Mol. Ther. Nucleic Acids 20, 764–776 (2020).32428701 10.1016/j.omtn.2020.04.013
207. Xu J High-density lipoprotein protects mesenchymal stem cells from oxidative stress-induced apoptosis via activation of the PI3K/Akt pathway and suppression of reactive oxygen species Int. J. Mol. Sci. 2012 13 17104 17120 10.3390/ijms131217104 23443132
Xu, J. et al. High-density lipoprotein protects mesenchymal stem cells from oxidative stress-induced apoptosis via activation of the PI3K/Akt pathway and suppression of reactive oxygen species. Int. J. Mol. Sci. 13, 17104–17120 (2012).23443132 10.3390/ijms131217104
208. Zhang Q Dissecting molecular mechanisms underlying H(2)O(2)-induced apoptosis of mouse bone marrow mesenchymal stem cell: role of Mst1 inhibition Stem Cell Res. Ther. 2020 11 526 10.1186/s13287-020-02041-7 33298178
Zhang, Q. et al. Dissecting molecular mechanisms underlying H(2)O(2)-induced apoptosis of mouse bone marrow mesenchymal stem cell: role of Mst1 inhibition. Stem Cell Res. Ther. 11, 526 (2020).33298178 10.1186/s13287-020-02041-7
209. Zhang F AT1R-mediated apoptosis of bone marrow mesenchymal stem cells is associated with mtROS production and mtDNA reduction Oxid. Med. Cell Longev. 2019 2019 4608165 10.1155/2019/4608165 31772704
Zhang, F. et al. AT1R-mediated apoptosis of bone marrow mesenchymal stem cells is associated with mtROS production and mtDNA reduction. Oxid. Med. Cell Longev. 2019, 4608165 (2019).31772704 10.1155/2019/4608165
210. Ren W High glucose mediates apoptosis and osteogenesis of MSCs via downregulation of AKT-Sirt1-TWIST Mol. Biol. Rep. 2022 49 2723 2733 10.1007/s11033-021-07082-6 35037196
Ren, W. et al. High glucose mediates apoptosis and osteogenesis of MSCs via downregulation of AKT-Sirt1-TWIST. Mol. Biol. Rep. 49, 2723–2733 (2022).35037196 10.1007/s11033-021-07082-6
211. Dregalla RC Red blood cells and their releases compromise bone marrow-derived human mesenchymal stem/stromal cell survival in vitro Stem Cell Res. Ther. 2021 12 547 10.1186/s13287-021-02610-4 34674751
Dregalla, R. C. et al. Red blood cells and their releases compromise bone marrow-derived human mesenchymal stem/stromal cell survival in vitro. Stem Cell Res. Ther. 12, 547 (2021).34674751 10.1186/s13287-021-02610-4
212. Chen XD Autophagy in fate determination of mesenchymal stem cells and bone remodeling World J. Stem Cells 2020 12 776 786 10.4252/wjsc.v12.i8.776 32952858
Chen, X. D. et al. Autophagy in fate determination of mesenchymal stem cells and bone remodeling. World J. Stem Cells 12, 776–786 (2020).32952858 10.4252/wjsc.v12.i8.776
213. Mizushima N Komatsu M Autophagy: renovation of cells and tissues Cell 2011 147 728 741 10.1016/j.cell.2011.10.026 22078875
Mizushima, N. & Komatsu, M. Autophagy: renovation of cells and tissues. Cell 147, 728–741 (2011).22078875 10.1016/j.cell.2011.10.026
214. Menshikov M Autophagy, mesenchymal stem cell differentiation, and secretion Biomedicines 2021 9 1178 10.3390/biomedicines9091178 34572364
Menshikov, M. et al. Autophagy, mesenchymal stem cell differentiation, and secretion. Biomedicines 9, 1178 (2021).34572364 10.3390/biomedicines9091178
215. Dang S Autophagy regulates the therapeutic potential of mesenchymal stem cells in experimental autoimmune encephalomyelitis Autophagy 2014 10 1301 1315 10.4161/auto.28771 24905997
Dang, S. et al. Autophagy regulates the therapeutic potential of mesenchymal stem cells in experimental autoimmune encephalomyelitis. Autophagy 10, 1301–1315 (2014).24905997 10.4161/auto.28771
216. Yang M Knockdown of insulin-like growth factor 1 exerts a protective effect on hypoxic injury of aged BM-MSCs: role of autophagy Stem Cell Res. Ther. 2018 9 284 10.1186/s13287-018-1028-5 30359321
Yang, M. et al. Knockdown of insulin-like growth factor 1 exerts a protective effect on hypoxic injury of aged BM-MSCs: role of autophagy. Stem Cell Res. Ther. 9, 284 (2018).30359321 10.1186/s13287-018-1028-5
217. Lv B Hypoxia-inducible factor 1α protects mesenchymal stem cells against oxygen-glucose deprivation-induced injury via autophagy induction and PI3K/AKT/mTOR signaling pathway Am. J. Transl. Res. 2017 9 2492 2499 28559999
Lv, B. et al. Hypoxia-inducible factor 1α protects mesenchymal stem cells against oxygen-glucose deprivation-induced injury via autophagy induction and PI3K/AKT/mTOR signaling pathway. Am. J. Transl. Res. 9, 2492–2499 (2017).28559999
218. Zhang Q Autophagy activation: a novel mechanism of atorvastatin to protect mesenchymal stem cells from hypoxia and serum deprivation via AMP-activated protein kinase/mammalian target of rapamycin pathway Stem Cells Dev. 2012 21 1321 1332 10.1089/scd.2011.0684 22356678
Zhang, Q. et al. Autophagy activation: a novel mechanism of atorvastatin to protect mesenchymal stem cells from hypoxia and serum deprivation via AMP-activated protein kinase/mammalian target of rapamycin pathway. Stem Cells Dev. 21, 1321–1332 (2012).22356678 10.1089/scd.2011.0684
219. Regmi S Enhanced viability and function of mesenchymal stromal cell spheroids is mediated via autophagy induction Autophagy 2021 17 2991 3010 10.1080/15548627.2020.1850608 33206581
Regmi, S. et al. Enhanced viability and function of mesenchymal stromal cell spheroids is mediated via autophagy induction. Autophagy 17, 2991–3010 (2021).33206581 10.1080/15548627.2020.1850608
220. Liao W Therapeutic effect of human umbilical cord multipotent mesenchymal stromal cells in a rat model of stroke Transplantation 2009 87 350 359 10.1097/TP.0b013e318195742e 19202439
Liao, W. et al. Therapeutic effect of human umbilical cord multipotent mesenchymal stromal cells in a rat model of stroke. Transplantation 87, 350–359 (2009).19202439 10.1097/TP.0b013e318195742e
221. Leong WK Human adult dental pulp stem cells enhance poststroke functional recovery through non-neural replacement mechanisms Stem Cells Transl. Med. 2012 1 177 187 10.5966/sctm.2011-0039 23197777
Leong, W. K. et al. Human adult dental pulp stem cells enhance poststroke functional recovery through non-neural replacement mechanisms. Stem Cells Transl. Med. 1, 177–187 (2012).23197777 10.5966/sctm.2011-0039
222. Sacchetti B No identical “mesenchymal stem cells” at different times and sites: human committed progenitors of distinct origin and differentiation potential are incorporated as adventitial cells in microvessels Stem Cell Rep. 2016 6 897 913 10.1016/j.stemcr.2016.05.011
Sacchetti, B. et al. No identical “mesenchymal stem cells” at different times and sites: human committed progenitors of distinct origin and differentiation potential are incorporated as adventitial cells in microvessels. Stem Cell Rep. 6, 897–913 (2016).10.1016/j.stemcr.2016.05.011
223. Li Y IFT20 governs mesenchymal stem cell fate through positively regulating TGF-β-Smad2/3-Glut1 signaling mediated glucose metabolism Redox Biol. 2022 54 102373 10.1016/j.redox.2022.102373 35751983
Li, Y. et al. IFT20 governs mesenchymal stem cell fate through positively regulating TGF-β-Smad2/3-Glut1 signaling mediated glucose metabolism. Redox Biol. 54, 102373 (2022).35751983 10.1016/j.redox.2022.102373
224. Stöckl S Sox9 modulates cell survival and adipogenic differentiation of multipotent adult rat mesenchymal stem cells J. Cell Sci. 2013 126 2890 2902 23606745
Stöckl, S. et al. Sox9 modulates cell survival and adipogenic differentiation of multipotent adult rat mesenchymal stem cells. J. Cell Sci. 126, 2890–2902 (2013).23606745
225. Liu Y INTS7-ABCD3 interaction stimulates the proliferation and osteoblastic differentiation of mouse bone marrow mesenchymal stem cells by suppressing oxidative stress Front Physiol. 2021 12 758607 10.3389/fphys.2021.758607 34880777
Liu, Y. et al. INTS7-ABCD3 interaction stimulates the proliferation and osteoblastic differentiation of mouse bone marrow mesenchymal stem cells by suppressing oxidative stress. Front Physiol. 12, 758607 (2021).34880777 10.3389/fphys.2021.758607
226. Crane JL IGF-1 signaling is essential for differentiation of mesenchymal stem cells for peak bone mass Bone Res. 2013 1 186 194 10.4248/BR201302007 26273502
Crane, J. L. et al. IGF-1 signaling is essential for differentiation of mesenchymal stem cells for peak bone mass. Bone Res. 1, 186–194 (2013).26273502 10.4248/BR201302007
227. Dixon SJ Ferroptosis: an iron-dependent form of nonapoptotic cell death Cell 2012 149 1060 1072 10.1016/j.cell.2012.03.042 22632970
Dixon, S. J. et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149, 1060–1072 (2012).22632970 10.1016/j.cell.2012.03.042
228. Sang M Mitochondrial membrane anchored photosensitive nano-device for lipid hydroperoxides burst and inducing ferroptosis to surmount therapy-resistant cancer Theranostics 2019 9 6209 6223 10.7150/thno.36283 31534546
Sang, M. et al. Mitochondrial membrane anchored photosensitive nano-device for lipid hydroperoxides burst and inducing ferroptosis to surmount therapy-resistant cancer. Theranostics 9, 6209–6223 (2019).31534546 10.7150/thno.36283
229. Sang M BHQ-cyanine-based “off-on” long-circulating assembly as a ferroptosis amplifier for cancer treatment: a lipid-peroxidation burst device ACS Appl. Mater. Interfaces 2019 11 42873 42884 10.1021/acsami.9b12469 31553151
Sang, M. et al. BHQ-cyanine-based “off-on” long-circulating assembly as a ferroptosis amplifier for cancer treatment: a lipid-peroxidation burst device. ACS Appl. Mater. Interfaces 11, 42873–42884 (2019).31553151 10.1021/acsami.9b12469
230. Liu J The NSUN5-FTH1/FTL pathway mediates ferroptosis in bone marrow-derived mesenchymal stem cells Cell Death Discov. 2022 8 99 10.1038/s41420-022-00902-z 35249107
Liu, J. et al. The NSUN5-FTH1/FTL pathway mediates ferroptosis in bone marrow-derived mesenchymal stem cells. Cell Death Discov. 8, 99 (2022).35249107 10.1038/s41420-022-00902-z
231. Xu Y Tert-butyl hydroperoxide induces ferroptosis of bone mesenchymal stem cells by repressing the prominin2/BACH1/ROS axis Am. J. Physiol. Cell Physiol. 2023 325 C1212 C1227 10.1152/ajpcell.00224.2023 37721001
Xu, Y. et al. Tert-butyl hydroperoxide induces ferroptosis of bone mesenchymal stem cells by repressing the prominin2/BACH1/ROS axis. Am. J. Physiol. Cell Physiol. 325, C1212–C1227 (2023).37721001 10.1152/ajpcell.00224.2023
232. Song M N6 methyladenosine eraser FTO suppresses Staphylococcus aureus-induced ferroptosis of bone marrow mesenchymal stem cells to ameliorate osteomyelitis through regulating the MDM2/TLR4/SLC7A11 signaling pathway Cell Biol. Int. 2024 48 450 460 10.1002/cbin.12115 38165230
Song, M. et al. N6 methyladenosine eraser FTO suppresses Staphylococcus aureus-induced ferroptosis of bone marrow mesenchymal stem cells to ameliorate osteomyelitis through regulating the MDM2/TLR4/SLC7A11 signaling pathway. Cell Biol. Int. 48, 450–460 (2024).38165230 10.1002/cbin.12115
233. Chen P Overexpression of PRDX2 in adipose-derived mesenchymal stem cells enhances the therapeutic effect in a neurogenic erectile dysfunction rat model by inhibiting ferroptosis Oxid. Med. Cell Longev. 2023 2023 4952857 10.1155/2023/4952857 36819780
Chen, P. et al. Overexpression of PRDX2 in adipose-derived mesenchymal stem cells enhances the therapeutic effect in a neurogenic erectile dysfunction rat model by inhibiting ferroptosis. Oxid. Med. Cell Longev. 2023, 4952857 (2023).36819780 10.1155/2023/4952857
234. Hu G Suppressing mesenchymal stromal cell ferroptosis via targeting a metabolism-epigenetics axis corrects their poor retention and insufficient healing benefits in the injured liver milieu Adv. Sci. 2023 10 e2206439 10.1002/advs.202206439
Hu, G. et al. Suppressing mesenchymal stromal cell ferroptosis via targeting a metabolism-epigenetics axis corrects their poor retention and insufficient healing benefits in the injured liver milieu. Adv. Sci. 10, e2206439 (2023).10.1002/advs.202206439
235. Li M Melatonin inhibits the ferroptosis pathway in rat bone marrow mesenchymal stem cells by activating the PI3K/AKT/mTOR signaling axis to attenuate steroid-induced osteoporosis Oxid. Med. Cell Longev. 2022 2022 8223737 36035224
Li, M. et al. Melatonin inhibits the ferroptosis pathway in rat bone marrow mesenchymal stem cells by activating the PI3K/AKT/mTOR signaling axis to attenuate steroid-induced osteoporosis. Oxid. Med. Cell Longev. 2022, 8223737 (2022).36035224
236. Zineldeen DH Cellular preconditioning and mesenchymal stem cell ferroptosis World J. Stem Cells 2024 16 64 69 10.4252/wjsc.v16.i2.64 38455100
Zineldeen, D. H. et al. Cellular preconditioning and mesenchymal stem cell ferroptosis. World J. Stem Cells 16, 64–69 (2024).38455100 10.4252/wjsc.v16.i2.64
237. Galipeau J Macrophages at the nexus of mesenchymal stromal cell potency: the emerging role of chemokine cooperativity Stem Cells 2021 39 1145 1154 10.1002/stem.3380 33786935
Galipeau, J. Macrophages at the nexus of mesenchymal stromal cell potency: the emerging role of chemokine cooperativity. Stem Cells 39, 1145–1154 (2021).33786935 10.1002/stem.3380
238. Li Y Lin F Mesenchymal stem cells are injured by complement after their contact with serum Blood 2012 120 3436 3443 10.1182/blood-2012-03-420612 22966167
Li, Y. & Lin, F. Mesenchymal stem cells are injured by complement after their contact with serum. Blood 120, 3436–3443 (2012).22966167 10.1182/blood-2012-03-420612
239. Gavin C The complement system is essential for the phagocytosis of mesenchymal stromal cells by monocytes Front. Immunol. 2019 10 2249 10.3389/fimmu.2019.02249 31616424
Gavin, C. et al. The complement system is essential for the phagocytosis of mesenchymal stromal cells by monocytes. Front. Immunol. 10, 2249 (2019).31616424 10.3389/fimmu.2019.02249
240. Braza F Mesenchymal stem cells induce suppressive macrophages through phagocytosis in a mouse model of asthma Stem Cells 2016 34 1836 1845 10.1002/stem.2344 26891455
Braza, F. et al. Mesenchymal stem cells induce suppressive macrophages through phagocytosis in a mouse model of asthma. Stem Cells 34, 1836–1845 (2016).26891455 10.1002/stem.2344
241. Hasgur S Splenic macrophage phagocytosis of intravenously infused mesenchymal stromal cells attenuates tumor localization Cytotherapy 2021 23 411 422 10.1016/j.jcyt.2020.04.102 33781710
Hasgur, S. et al. Splenic macrophage phagocytosis of intravenously infused mesenchymal stromal cells attenuates tumor localization. Cytotherapy 23, 411–422 (2021).33781710 10.1016/j.jcyt.2020.04.102
242. Fafián-Labora JA Effect of aging on behaviour of mesenchymal stem cells World J. Stem Cells 2019 11 337 346 10.4252/wjsc.v11.i6.337 31293716
Fafián-Labora, J. A. et al. Effect of aging on behaviour of mesenchymal stem cells. World J. Stem Cells 11, 337–346 (2019).31293716 10.4252/wjsc.v11.i6.337
243. Jung YH EphB2 signaling-mediated Sirt3 expression reduces MSC senescence by maintaining mitochondrial ROS homeostasis Free Radic. Biol. Med. 2017 110 368 380 10.1016/j.freeradbiomed.2017.07.001 28687409
Jung, Y. H. et al. EphB2 signaling-mediated Sirt3 expression reduces MSC senescence by maintaining mitochondrial ROS homeostasis. Free Radic. Biol. Med. 110, 368–380 (2017).28687409 10.1016/j.freeradbiomed.2017.07.001
244. Yang M Ascorbic acid inhibits senescence in mesenchymal stem cells through ROS and AKT/mTOR signaling Cytotechnology 2018 70 1301 1313 10.1007/s10616-018-0220-x 29777434
Yang, M. et al. Ascorbic acid inhibits senescence in mesenchymal stem cells through ROS and AKT/mTOR signaling. Cytotechnology 70, 1301–1313 (2018).29777434 10.1007/s10616-018-0220-x
245. Zhang D Coenzyme Q10 inhibits the aging of mesenchymal stem cells induced by D-galactose through Akt/mTOR signaling Oxid. Med. Cell Longev. 2015 2015 867293 10.1155/2015/867293 25789082
Zhang, D. et al. Coenzyme Q10 inhibits the aging of mesenchymal stem cells induced by D-galactose through Akt/mTOR signaling. Oxid. Med. Cell Longev. 2015, 867293 (2015).25789082 10.1155/2015/867293
246. Hong Y miR-155-5p inhibition rejuvenates aged mesenchymal stem cells and enhances cardioprotection following infarction Aging Cell 2020 19 e13128 10.1111/acel.13128 32196916
Hong, Y. et al. miR-155-5p inhibition rejuvenates aged mesenchymal stem cells and enhances cardioprotection following infarction. Aging Cell 19, e13128 (2020).32196916 10.1111/acel.13128
247. Li X MiR-495 promotes senescence of mesenchymal stem cells by targeting Bmi-1 Cell Physiol. Biochem. 2017 42 780 796 10.1159/000478069 28628915
Li, X. et al. MiR-495 promotes senescence of mesenchymal stem cells by targeting Bmi-1. Cell Physiol. Biochem. 42, 780–796 (2017).28628915 10.1159/000478069
248. Zhang H Apelin rejuvenates aged human mesenchymal stem cells by regulating autophagy and improves cardiac protection after infarction Front. Cell Dev. Biol. 2021 9 628463 10.3389/fcell.2021.628463 33738284
Zhang, H. et al. Apelin rejuvenates aged human mesenchymal stem cells by regulating autophagy and improves cardiac protection after infarction. Front. Cell Dev. Biol. 9, 628463 (2021).33738284 10.3389/fcell.2021.628463
249. Liang X Overexpression of ERBB4 rejuvenates aged mesenchymal stem cells and enhances angiogenesis via PI3K/AKT and MAPK/ERK pathways FASEB J. 2019 33 4559 4570 10.1096/fj.201801690R 30566395
Liang, X. et al. Overexpression of ERBB4 rejuvenates aged mesenchymal stem cells and enhances angiogenesis via PI3K/AKT and MAPK/ERK pathways. FASEB J. 33, 4559–4570 (2019).30566395 10.1096/fj.201801690R
250. Kim M CD26 inhibition potentiates the therapeutic effects of human umbilical cord blood-derived mesenchymal stem cells by delaying cellular senescence Front. Cell Dev. Biol. 2021 9 803645 10.3389/fcell.2021.803645 35178399
Kim, M. et al. CD26 inhibition potentiates the therapeutic effects of human umbilical cord blood-derived mesenchymal stem cells by delaying cellular senescence. Front. Cell Dev. Biol. 9, 803645 (2021).35178399 10.3389/fcell.2021.803645
251. Al-Azab M Indian Hedgehog regulates senescence in bone marrow-derived mesenchymal stem cell through modulation of ROS/mTOR/4EBP1, p70S6K1/2 pathway Aging 2020 12 5693 5715 10.18632/aging.102958 32235006
Al-Azab, M. et al. Indian Hedgehog regulates senescence in bone marrow-derived mesenchymal stem cell through modulation of ROS/mTOR/4EBP1, p70S6K1/2 pathway. Aging 12, 5693–5715 (2020).32235006 10.18632/aging.102958
252. Chang TC 5-methoxytryptophan protects MSCs from stress-induced premature senescence by upregulating FoxO3a and mTOR Sci. Rep. 2017 7 11133 10.1038/s41598-017-11077-4 28894133
Chang, T. C. et al. 5-methoxytryptophan protects MSCs from stress-induced premature senescence by upregulating FoxO3a and mTOR. Sci. Rep. 7, 11133 (2017).28894133 10.1038/s41598-017-11077-4
253. Elsied MA Walnut kernel oil and defatted extracts enhance mesenchymal stem cell stemness and delay senescence Molecules 2023 28 6281 10.3390/molecules28176281 37687109
Elsied, M. A. et al. Walnut kernel oil and defatted extracts enhance mesenchymal stem cell stemness and delay senescence. Molecules 28, 6281 (2023).37687109 10.3390/molecules28176281
254. Lee JY GATA4-dependent regulation of the secretory phenotype via MCP-1 underlies lamin A-mediated human mesenchymal stem cell aging Exp. Mol. Med. 2018 50 1 12 10.1038/s12276-018-0187-x 30523262
Lee, J. Y. et al. GATA4-dependent regulation of the secretory phenotype via MCP-1 underlies lamin A-mediated human mesenchymal stem cell aging. Exp. Mol. Med. 50, 1–12 (2018).30523262 10.1038/s12276-018-0187-x
255. Yang J Optical and MRI multimodal tracing of stem cells in vivo Mol. Imaging 2023 2023 4223485 10.1155/2023/4223485 38148836
Yang, J. et al. Optical and MRI multimodal tracing of stem cells in vivo. Mol. Imaging 2023, 4223485 (2023).38148836 10.1155/2023/4223485
256. Salvadori M Dissecting the pharmacodynamics and pharmacokinetics of MSCs to overcome limitations in their clinical translation Mol. Ther. Methods Clin. Dev. 2019 14 1 15 10.1016/j.omtm.2019.05.004 31236426
Salvadori, M. et al. Dissecting the pharmacodynamics and pharmacokinetics of MSCs to overcome limitations in their clinical translation. Mol. Ther. Methods Clin. Dev. 14, 1–15 (2019).31236426 10.1016/j.omtm.2019.05.004
257. Xu L Umbilical cord artery-derived perivascular stem cells for treatment of ovarian failure through CD146 signaling Signal Transduct. Target Ther. 2022 7 223 10.1038/s41392-022-01029-4 35821199
Xu, L. et al. Umbilical cord artery-derived perivascular stem cells for treatment of ovarian failure through CD146 signaling. Signal Transduct. Target Ther. 7, 223 (2022).35821199 10.1038/s41392-022-01029-4
258. Tappenbeck N In vivo safety profile and biodistribution of GMP-manufactured human skin-derived ABCB5-positive mesenchymal stromal cells for use in clinical trials Cytotherapy 2019 21 546 560 10.1016/j.jcyt.2018.12.005 30878384
Tappenbeck, N. et al. In vivo safety profile and biodistribution of GMP-manufactured human skin-derived ABCB5-positive mesenchymal stromal cells for use in clinical trials. Cytotherapy 21, 546–560 (2019).30878384 10.1016/j.jcyt.2018.12.005
259. Kim SM In vivo near-infrared imaging for the tracking of systemically delivered mesenchymal stem cells: tropism for brain tumors and biodistribution Int. J. Nanomed. 2016 11 13 23
Kim, S. M. et al. In vivo near-infrared imaging for the tracking of systemically delivered mesenchymal stem cells: tropism for brain tumors and biodistribution. Int. J. Nanomed. 11, 13–23 (2016).
260. Liang Z Preclinical short-term and long-term safety of human bone marrow mesenchymal stem cells Cell Transpl. 2023 32 9636897231213271 10.1177/09636897231213271
Liang, Z. et al. Preclinical short-term and long-term safety of human bone marrow mesenchymal stem cells. Cell Transpl. 32, 9636897231213271 (2023).10.1177/09636897231213271
261. Wang F Route of delivery influences biodistribution of human bone marrow-derived mesenchymal stromal cells following experimental bone marrow transplantation J. Stem Cells Regen. Med. 2015 11 34 43 10.46582/jsrm.1102007 27330253
Wang, F. et al. Route of delivery influences biodistribution of human bone marrow-derived mesenchymal stromal cells following experimental bone marrow transplantation. J. Stem Cells Regen. Med. 11, 34–43 (2015).27330253 10.46582/jsrm.1102007
262. Ye D Optical imaging and high-accuracy quantification of intracellular iron contents Small 2021 17 e2005474 10.1002/smll.202005474 33306269
Ye, D. et al. Optical imaging and high-accuracy quantification of intracellular iron contents. Small 17, e2005474 (2021).33306269 10.1002/smll.202005474
263. Wang H Magnetic sensor based on image processing for dynamically tracking magnetic moment of single magnetic mesenchymal stem cell Biosens. Bioelectron. 2020 169 112593 10.1016/j.bios.2020.112593 32966950
Wang, H. et al. Magnetic sensor based on image processing for dynamically tracking magnetic moment of single magnetic mesenchymal stem cell. Biosens. Bioelectron. 169, 112593 (2020).32966950 10.1016/j.bios.2020.112593
264. Kamiyama Y Biodistribution studies for cell therapy products: current status and issues Regen. Ther. 2021 18 202 216 10.1016/j.reth.2021.06.005 34307798
Kamiyama, Y. et al. Biodistribution studies for cell therapy products: current status and issues. Regen. Ther. 18, 202–216 (2021).34307798 10.1016/j.reth.2021.06.005
265. Yeh HW Red-shifted luciferase-luciferin pairs for enhanced bioluminescence imaging Nat. Methods 2017 14 971 974 10.1038/nmeth.4400 28869756
Yeh, H. W. et al. Red-shifted luciferase-luciferin pairs for enhanced bioluminescence imaging. Nat. Methods 14, 971–974 (2017).28869756 10.1038/nmeth.4400
266. Kundrotas G Uptake and distribution of carboxylated quantum dots in human mesenchymal stem cells: cell growing density matters J. Nanobiotechnol. 2019 17 39 10.1186/s12951-019-0470-6
Kundrotas, G. et al. Uptake and distribution of carboxylated quantum dots in human mesenchymal stem cells: cell growing density matters. J. Nanobiotechnol. 17, 39 (2019).10.1186/s12951-019-0470-6
267. Bertolini M Smart probes for optical imaging of T cells and screening of anti-cancer immunotherapies Chem. Soc. Rev. 2023 52 5352 5372 10.1039/D2CS00928E 37376918
Bertolini, M. et al. Smart probes for optical imaging of T cells and screening of anti-cancer immunotherapies. Chem. Soc. Rev. 52, 5352–5372 (2023).37376918 10.1039/D2CS00928E
268. Benson S Miniaturized chemical tags for optical imaging Angew. Chem. Int. Ed. Engl. 2022 61 e202204788 10.1002/anie.202204788 35704518
Benson, S. et al. Miniaturized chemical tags for optical imaging. Angew. Chem. Int. Ed. Engl. 61, e202204788 (2022).35704518 10.1002/anie.202204788
269. Lin CS Commonly used mesenchymal stem cell markers and tracking labels: Limitations and challenges Histol. Histopathol. 2013 28 1109 1116 23588700
Lin, C. S. et al. Commonly used mesenchymal stem cell markers and tracking labels: Limitations and challenges. Histol. Histopathol. 28, 1109–1116 (2013).23588700
270. Hossain MA Imaging modalities for the in vivo surveillance of mesenchymal stromal cells J. Tissue Eng. Regen. Med. 2015 9 1217 1224 10.1002/term.1907 24917526
Hossain, M. A. et al. Imaging modalities for the in vivo surveillance of mesenchymal stromal cells. J. Tissue Eng. Regen. Med. 9, 1217–1224 (2015).24917526 10.1002/term.1907
271. Liu S Long-term tracking mesenchymal stem cell differentiation with photostable fluorescent nanoparticles ACS Appl Mater. Interfaces 2016 8 11925 11933 10.1021/acsami.5b12371 27124820
Liu, S. et al. Long-term tracking mesenchymal stem cell differentiation with photostable fluorescent nanoparticles. ACS Appl Mater. Interfaces 8, 11925–11933 (2016).27124820 10.1021/acsami.5b12371
272. Nowlan B Human bone marrow-derived stromal cell behavior when injected directly into the bone marrow of NOD-scid-gamma mice pre-conditioned with sub-lethal irradiation Stem Cell Res Ther. 2021 12 231 10.1186/s13287-021-02297-7 33845908
Nowlan, B. et al. Human bone marrow-derived stromal cell behavior when injected directly into the bone marrow of NOD-scid-gamma mice pre-conditioned with sub-lethal irradiation. Stem Cell Res Ther. 12, 231 (2021).33845908 10.1186/s13287-021-02297-7
273. Yu HY Intravital imaging and single-cell transcriptomic analysis for engraftment of mesenchymal stem cells in an animal model of interstitial cystitis/bladder pain syndrome Biomaterials 2022 280 121277 10.1016/j.biomaterials.2021.121277 34861510
Yu, H. Y. et al. Intravital imaging and single-cell transcriptomic analysis for engraftment of mesenchymal stem cells in an animal model of interstitial cystitis/bladder pain syndrome. Biomaterials 280, 121277 (2022).34861510 10.1016/j.biomaterials.2021.121277
274. Cai W NIR-II FL/PA dual-modal imaging long-term tracking of human umbilical cord-derived mesenchymal stem cells labeled with melanin nanoparticles and visible HUMSC-based liver regeneration for acute liver failure Biomater. Sci. 2020 8 6592 6602 10.1039/D0BM01221A 33231594
Cai, W. et al. NIR-II FL/PA dual-modal imaging long-term tracking of human umbilical cord-derived mesenchymal stem cells labeled with melanin nanoparticles and visible HUMSC-based liver regeneration for acute liver failure. Biomater. Sci. 8, 6592–6602 (2020).33231594 10.1039/D0BM01221A
275. Hu B Dissecting molecular mechanisms underlying ferroptosis in human umbilical cord mesenchymal stem cells: Role of cystathionine γ-lyase/hydrogen sulfide pathway World J. Stem Cells 2023 15 1017 1034 10.4252/wjsc.v15.i11.1017 38058959
Hu, B. et al. Dissecting molecular mechanisms underlying ferroptosis in human umbilical cord mesenchymal stem cells: Role of cystathionine γ-lyase/hydrogen sulfide pathway. World J. Stem Cells 15, 1017–1034 (2023).38058959 10.4252/wjsc.v15.i11.1017
276. Uchibori R NF-κB activity regulates mesenchymal stem cell accumulation at tumor sites Cancer Res. 2013 73 364 372 10.1158/0008-5472.CAN-12-0088 23066037
Uchibori, R. et al. NF-κB activity regulates mesenchymal stem cell accumulation at tumor sites. Cancer Res. 73, 364–372 (2013).23066037 10.1158/0008-5472.CAN-12-0088
277. Nucci MP Effect of cell therapy and exercise training in a stroke model, considering the cell track by molecular image and behavioral analysis Cells 2022 11 485 10.3390/cells11030485 35159294
Nucci, M. P. et al. Effect of cell therapy and exercise training in a stroke model, considering the cell track by molecular image and behavioral analysis. Cells 11, 485 (2022).35159294 10.3390/cells11030485
278. Wang L Application of bioluminescence resonance energy transfer-based cell tracking approach in bone tissue engineering J. Tissue Eng. 2021 12 2041731421995465 10.1177/2041731421995465 33643604
Wang, L. et al. Application of bioluminescence resonance energy transfer-based cell tracking approach in bone tissue engineering. J. Tissue Eng. 12, 2041731421995465 (2021).33643604 10.1177/2041731421995465
279. Gawne PJ Direct cell radiolabeling for in vivo cell tracking with PET and SPECT imaging Chem. Rev. 2022 122 10266 10318 10.1021/acs.chemrev.1c00767 35549242
Gawne, P. J. et al. Direct cell radiolabeling for in vivo cell tracking with PET and SPECT imaging. Chem. Rev. 122, 10266–10318 (2022).35549242 10.1021/acs.chemrev.1c00767
280. Li X Hacker M Molecular imaging in stem cell-based therapies of cardiac diseases Adv. Drug Deliv. Rev. 2017 120 71 88 10.1016/j.addr.2017.07.012 28734900
Li, X. & Hacker, M. Molecular imaging in stem cell-based therapies of cardiac diseases. Adv. Drug Deliv. Rev. 120, 71–88 (2017).28734900 10.1016/j.addr.2017.07.012
281. Bindslev L Labelling of human mesenchymal stem cells with indium-111 for SPECT imaging: effect on cell proliferation and differentiation Eur. J. Nucl. Med. Mol. Imaging 2006 33 1171 1177 10.1007/s00259-006-0093-7 16763813
Bindslev, L. et al. Labelling of human mesenchymal stem cells with indium-111 for SPECT imaging: effect on cell proliferation and differentiation. Eur. J. Nucl. Med. Mol. Imaging 33, 1171–1177 (2006).16763813 10.1007/s00259-006-0093-7
282. Meseguer-Olmo L Intraarticular and intravenous administration of (99M)Tc-HMPAO-labeled human mesenchymal stem cells ((99M)TC-AH-MSC(S)): In vivo imaging and biodistribution Nucl. Med. Biol. 2017 46 36 42 10.1016/j.nucmedbio.2016.12.003 28013120
Meseguer-Olmo, L. et al. Intraarticular and intravenous administration of (99M)Tc-HMPAO-labeled human mesenchymal stem cells ((99M)TC-AH-MSC(S)): In vivo imaging and biodistribution. Nucl. Med. Biol. 46, 36–42 (2017).28013120 10.1016/j.nucmedbio.2016.12.003
283. Gyöngyösi M Serial noninvasive in vivo positron emission tomographic tracking of percutaneously intramyocardially injected autologous porcine mesenchymal stem cells modified for transgene reporter gene expression Circ. Cardiovasc. Imaging 2008 1 94 103 10.1161/CIRCIMAGING.108.797449 19808526
Gyöngyösi, M. et al. Serial noninvasive in vivo positron emission tomographic tracking of percutaneously intramyocardially injected autologous porcine mesenchymal stem cells modified for transgene reporter gene expression. Circ. Cardiovasc. Imaging 1, 94–103 (2008).19808526 10.1161/CIRCIMAGING.108.797449
284. Nose N [18F]FDG-labelled stem cell PET imaging in different route of administrations and multiple animal species Sci. Rep. 2021 11 10896 10.1038/s41598-021-90383-4 34035416
Nose, N. et al. [18F]FDG-labelled stem cell PET imaging in different route of administrations and multiple animal species. Sci. Rep. 11, 10896 (2021).34035416 10.1038/s41598-021-90383-4
285. Patrick PS Lung delivery of MSCs expressing anti-cancer protein TRAIL visualised with (89)Zr-oxine PET-CT Stem Cell Res. Ther. 2020 11 256 10.1186/s13287-020-01770-z 32586403
Patrick, P. S. et al. Lung delivery of MSCs expressing anti-cancer protein TRAIL visualised with (89)Zr-oxine PET-CT. Stem Cell Res. Ther. 11, 256 (2020).32586403 10.1186/s13287-020-01770-z
286. Serai SD Components of a magnetic resonance imaging system and their relationship to safety and image quality Pediatr. Radio. 2021 51 716 723 10.1007/s00247-020-04894-9
Serai, S. D. et al. Components of a magnetic resonance imaging system and their relationship to safety and image quality. Pediatr. Radio. 51, 716–723 (2021).10.1007/s00247-020-04894-9
287. Vandeputte C Characterization of the inflammatory response in a photothrombotic stroke model by MRI: implications for stem cell transplantation Mol. Imaging Biol. 2011 13 663 671 10.1007/s11307-010-0395-9 20700767
Vandeputte, C. et al. Characterization of the inflammatory response in a photothrombotic stroke model by MRI: implications for stem cell transplantation. Mol. Imaging Biol. 13, 663–671 (2011).20700767 10.1007/s11307-010-0395-9
288. Andreas K Highly efficient magnetic stem cell labeling with citrate-coated superparamagnetic iron oxide nanoparticles for MRI tracking Biomaterials 2012 33 4515 4525 10.1016/j.biomaterials.2012.02.064 22445482
Andreas, K. et al. Highly efficient magnetic stem cell labeling with citrate-coated superparamagnetic iron oxide nanoparticles for MRI tracking. Biomaterials 33, 4515–4525 (2012).22445482 10.1016/j.biomaterials.2012.02.064
289. Sumner JP In vivo labeling of adult neural progenitors for MRI with micron sized particles of iron oxide: quantification of labeled cell phenotype Neuroimage 2009 44 671 678 10.1016/j.neuroimage.2008.07.050 18722534
Sumner, J. P. et al. In vivo labeling of adult neural progenitors for MRI with micron sized particles of iron oxide: quantification of labeled cell phenotype. Neuroimage 44, 671–678 (2009).18722534 10.1016/j.neuroimage.2008.07.050
290. Rizzo S 7-T MRI tracking of mesenchymal stromal cells after lung injection in a rat model Eur. Radio. Exp. 2020 4 54 10.1186/s41747-020-00183-0
Rizzo, S. et al. 7-T MRI tracking of mesenchymal stromal cells after lung injection in a rat model. Eur. Radio. Exp. 4, 54 (2020).10.1186/s41747-020-00183-0
291. Gupta AK Gupta M Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications Biomaterials 2005 26 3995 4021 10.1016/j.biomaterials.2004.10.012 15626447
Gupta, A. K. & Gupta, M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials 26, 3995–4021 (2005).15626447 10.1016/j.biomaterials.2004.10.012
292. Schulze F Amino-polyvinyl alcohol coated superparamagnetic iron oxide nanoparticles are suitable for monitoring of human mesenchymal stromal cells in vivo Small 2014 10 4340 4351 10.1002/smll.201400707 24990430
Schulze, F. et al. Amino-polyvinyl alcohol coated superparamagnetic iron oxide nanoparticles are suitable for monitoring of human mesenchymal stromal cells in vivo. Small 10, 4340–4351 (2014).24990430 10.1002/smll.201400707
293. Xie X Magnetic particle imaging: from tracer design to biomedical applications in vasculature abnormality Adv. Mater. 2024 36 e2306450 10.1002/adma.202306450 37812831
Xie, X. et al. Magnetic particle imaging: from tracer design to biomedical applications in vasculature abnormality. Adv. Mater. 36, e2306450 (2024).37812831 10.1002/adma.202306450
294. Sehl OC Foster PJ The sensitivity of magnetic particle imaging and fluorine-19 magnetic resonance imaging for cell tracking Sci. Rep. 2021 11 22198 10.1038/s41598-021-01642-3 34772991
Sehl, O. C. & Foster, P. J. The sensitivity of magnetic particle imaging and fluorine-19 magnetic resonance imaging for cell tracking. Sci. Rep. 11, 22198 (2021).34772991 10.1038/s41598-021-01642-3
295. Zheng B Quantitative magnetic particle imaging monitors the transplantation, biodistribution, and clearance of stem cells in vivo Theranostics 2016 6 291 301 10.7150/thno.13728 26909106
Zheng, B. et al. Quantitative magnetic particle imaging monitors the transplantation, biodistribution, and clearance of stem cells in vivo. Theranostics 6, 291–301 (2016).26909106 10.7150/thno.13728
296. Li W In vivo photoacoustic imaging of brain injury and rehabilitation by high-efficient near-infrared dye labeled mesenchymal stem cells with enhanced brain barrier permeability Adv. Sci. 2018 5 1700277 10.1002/advs.201700277
Li, W. et al. In vivo photoacoustic imaging of brain injury and rehabilitation by high-efficient near-infrared dye labeled mesenchymal stem cells with enhanced brain barrier permeability. Adv. Sci. 5, 1700277 (2018).10.1002/advs.201700277
297. Dhada KS In vivo photoacoustic tracking of mesenchymal stem cell viability ACS Nano 2019 13 7791 7799 10.1021/acsnano.9b01802 31250647
Dhada, K. S. et al. In vivo photoacoustic tracking of mesenchymal stem cell viability. ACS Nano 13, 7791–7799 (2019).31250647 10.1021/acsnano.9b01802
298. Belmar-López C Mesenchymal stem cells delivery in individuals with different pathologies: multimodal tracking, safety and future applications Int. J. Mol. Sci. 2022 23 1682 10.3390/ijms23031682 35163605
Belmar-López, C. et al. Mesenchymal stem cells delivery in individuals with different pathologies: multimodal tracking, safety and future applications. Int. J. Mol. Sci. 23, 1682 (2022).35163605 10.3390/ijms23031682
299. Yao M Engineering of SPECT/photoacoustic imaging/antioxidative stress triple-function nanoprobe for advanced mesenchymal stem cell therapy of cerebral ischemia ACS Appl. Mater. Interfaces 2020 12 37885 37895 10.1021/acsami.0c10500 32806884
Yao, M. et al. Engineering of SPECT/photoacoustic imaging/antioxidative stress triple-function nanoprobe for advanced mesenchymal stem cell therapy of cerebral ischemia. ACS Appl. Mater. Interfaces 12, 37885–37895 (2020).32806884 10.1021/acsami.0c10500
300. Murata M Teshima T Treatment of steroid-refractory acute graft-versus-host disease using commercial mesenchymal stem cell products Front. Immunol. 2021 12 724380 10.3389/fimmu.2021.724380 34489977
Murata, M. & Teshima, T. Treatment of steroid-refractory acute graft-versus-host disease using commercial mesenchymal stem cell products. Front. Immunol. 12, 724380 (2021).34489977 10.3389/fimmu.2021.724380
301. Wang S Clinical applications of mesenchymal stem cells J. Hematol. Oncol. 2012 5 19 10.1186/1756-8722-5-19 22546280
Wang, S. et al. Clinical applications of mesenchymal stem cells. J. Hematol. Oncol. 5, 19 (2012).22546280 10.1186/1756-8722-5-19
302. Squillaro T Clinical trials with mesenchymal stem cells: an update Cell Transpl. 2016 25 829 848 10.3727/096368915X689622
Squillaro, T. et al. Clinical trials with mesenchymal stem cells: an update. Cell Transpl. 25, 829–848 (2016).10.3727/096368915X689622
303. Zhao Q Development and investigational new drug application of mesenchymal stem/stromal cells products in China Stem Cells Transl. Med. 2021 10 Suppl 2 S18 S30 10.1002/sctm.21-0083 34724720
Zhao, Q. et al. Development and investigational new drug application of mesenchymal stem/stromal cells products in China. Stem Cells Transl. Med. 10(Suppl 2), S18–S30 (2021).34724720 10.1002/sctm.21-0083
304. Hirai T Country-specific regulation and international standardization of cell-based therapeutic products derived from pluripotent stem cells Stem Cell Rep. 2023 18 1573 1591 10.1016/j.stemcr.2023.05.003
Hirai, T. et al. Country-specific regulation and international standardization of cell-based therapeutic products derived from pluripotent stem cells. Stem Cell Rep. 18, 1573–1591 (2023).10.1016/j.stemcr.2023.05.003
305. Wu W Regulatory oversight of cell therapy in China: government’s efforts in patient access and therapeutic innovation Pharm. Res. 2020 158 104889 10.1016/j.phrs.2020.104889
Wu, W. et al. Regulatory oversight of cell therapy in China: government’s efforts in patient access and therapeutic innovation. Pharm. Res. 158, 104889 (2020).10.1016/j.phrs.2020.104889
306. Dominici M Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement Cytotherapy 2006 8 315 317 10.1080/14653240600855905 16923606
Dominici, M. et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8, 315–317 (2006).16923606 10.1080/14653240600855905
307. Tallone T Adult human adipose tissue contains several types of multipotent cells J. Cardiovasc. Transl. Res. 2011 4 200 210 10.1007/s12265-011-9257-3 21327755
Tallone, T. et al. Adult human adipose tissue contains several types of multipotent cells. J. Cardiovasc. Transl. Res. 4, 200–210 (2011).21327755 10.1007/s12265-011-9257-3
308. de Wolf C Regulatory perspective on in vitro potency assays for human mesenchymal stromal cells used in immunotherapy Cytotherapy 2017 19 784 797 10.1016/j.jcyt.2017.03.076 28457740
de Wolf, C. et al. Regulatory perspective on in vitro potency assays for human mesenchymal stromal cells used in immunotherapy. Cytotherapy 19, 784–797 (2017).28457740 10.1016/j.jcyt.2017.03.076
309. Guadix JA Principal criteria for evaluating the quality, safety and efficacy of hMSC-based products in clinical practice: current approaches and challenges Pharmaceutics 2019 11 552 10.3390/pharmaceutics11110552 31652984
Guadix, J. A. et al. Principal criteria for evaluating the quality, safety and efficacy of hMSC-based products in clinical practice: current approaches and challenges. Pharmaceutics 11, 552 (2019).31652984 10.3390/pharmaceutics11110552
310. Shi Y Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases Nat. Rev. Nephrol. 2018 14 493 507 10.1038/s41581-018-0023-5 29895977
Shi, Y. et al. Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases. Nat. Rev. Nephrol. 14, 493–507 (2018).29895977 10.1038/s41581-018-0023-5
311. Juneja SC A simplified method for the aspiration of bone marrow from patients undergoing hip and knee joint replacement for isolating mesenchymal stem cells and in vitro chondrogenesis Bone Marrow Res. 2016 2016 3152065 10.1155/2016/3152065 27057356
Juneja, S. C. et al. A simplified method for the aspiration of bone marrow from patients undergoing hip and knee joint replacement for isolating mesenchymal stem cells and in vitro chondrogenesis. Bone Marrow Res. 2016, 3152065 (2016).27057356 10.1155/2016/3152065
312. Yin JQ Manufacturing of primed mesenchymal stromal cells for therapy Nat. Biomed. Eng. 2019 3 90 104 10.1038/s41551-018-0325-8 30944433
Yin, J. Q. et al. Manufacturing of primed mesenchymal stromal cells for therapy. Nat. Biomed. Eng. 3, 90–104 (2019).30944433 10.1038/s41551-018-0325-8
313. Chinnadurai R Actin cytoskeletal disruption following cryopreservation alters the biodistribution of human mesenchymal stromal cells in vivo Stem Cell Rep. 2014 3 60 72 10.1016/j.stemcr.2014.05.003
Chinnadurai, R. et al. Actin cytoskeletal disruption following cryopreservation alters the biodistribution of human mesenchymal stromal cells in vivo. Stem Cell Rep. 3, 60–72 (2014).10.1016/j.stemcr.2014.05.003
314. Wilson JG Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial Lancet Respir. Med. 2015 3 24 32 10.1016/S2213-2600(14)70291-7 25529339
Wilson, J. G. et al. Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial. Lancet Respir. Med. 3, 24–32 (2015).25529339 10.1016/S2213-2600(14)70291-7
315. François M Cryopreserved mesenchymal stromal cells display impaired immunosuppressive properties as a result of heat-shock response and impaired interferon-γ licensing Cytotherapy 2012 14 147 152 10.3109/14653249.2011.623691 22029655
François, M. et al. Cryopreserved mesenchymal stromal cells display impaired immunosuppressive properties as a result of heat-shock response and impaired interferon-γ licensing. Cytotherapy 14, 147–152 (2012).22029655 10.3109/14653249.2011.623691
316. Conrad C Multipotent mesenchymal stem cells acquire a lymphendothelial phenotype and enhance lymphatic regeneration in vivo Circulation 2009 119 281 289 10.1161/CIRCULATIONAHA.108.793208 19118255
Conrad, C. et al. Multipotent mesenchymal stem cells acquire a lymphendothelial phenotype and enhance lymphatic regeneration in vivo. Circulation 119, 281–289 (2009).19118255 10.1161/CIRCULATIONAHA.108.793208
317. Haga H Tumour cell-derived extracellular vesicles interact with mesenchymal stem cells to modulate the microenvironment and enhance cholangiocarcinoma growth J. Extracell. Vesicles 2015 4 24900 10.3402/jev.v4.24900 25557794
Haga, H. et al. Tumour cell-derived extracellular vesicles interact with mesenchymal stem cells to modulate the microenvironment and enhance cholangiocarcinoma growth. J. Extracell. Vesicles 4, 24900 (2015).25557794 10.3402/jev.v4.24900
318. Li J The heterogeneity of mesenchymal stem cells: an important issue to be addressed in cell therapy Stem Cell Res. Ther. 2023 14 381 10.1186/s13287-023-03587-y 38124129
Li, J. et al. The heterogeneity of mesenchymal stem cells: an important issue to be addressed in cell therapy. Stem Cell Res. Ther. 14, 381 (2023).38124129 10.1186/s13287-023-03587-y
319. De Ugarte DA Differential expression of stem cell mobilization-associated molecules on multi-lineage cells from adipose tissue and bone marrow Immunol. Lett. 2003 89 267 270 10.1016/S0165-2478(03)00108-1 14556988
De Ugarte, D. A. et al. Differential expression of stem cell mobilization-associated molecules on multi-lineage cells from adipose tissue and bone marrow. Immunol. Lett. 89, 267–270 (2003).14556988 10.1016/S0165-2478(03)00108-1
320. Li G Comparative proteomic analysis of mesenchymal stem cells derived from human bone marrow, umbilical cord, and placenta: implication in the migration Proteomics 2009 9 20 30 10.1002/pmic.200701195 19116983
Li, G. et al. Comparative proteomic analysis of mesenchymal stem cells derived from human bone marrow, umbilical cord, and placenta: implication in the migration. Proteomics 9, 20–30 (2009).19116983 10.1002/pmic.200701195
321. Hori A Superior migration ability of umbilical cord-derived mesenchymal stromal cells (MSCs) toward activated lymphocytes in comparison with those of bone marrow and adipose-derived MSCs Front. Cell Dev. Biol. 2024 12 1329218 10.3389/fcell.2024.1329218 38529405
Hori, A. et al. Superior migration ability of umbilical cord-derived mesenchymal stromal cells (MSCs) toward activated lymphocytes in comparison with those of bone marrow and adipose-derived MSCs. Front. Cell Dev. Biol. 12, 1329218 (2024).38529405 10.3389/fcell.2024.1329218
322. Aldrich ED Allogeneic mesenchymal stromal cells for cartilage regeneration: a review of in vitro evaluation, clinical experience, and translational opportunities Stem Cells Transl. Med. 2021 10 1500 1515 10.1002/sctm.20-0552 34387402
Aldrich, E. D. et al. Allogeneic mesenchymal stromal cells for cartilage regeneration: a review of in vitro evaluation, clinical experience, and translational opportunities. Stem Cells Transl. Med. 10, 1500–1515 (2021).34387402 10.1002/sctm.20-0552
323. Arthur A Gronthos S Clinical application of bone marrow mesenchymal stem/stromal cells to repair skeletal tissue Int. J. Mol. Sci. 2020 21 9759 10.3390/ijms21249759 33371306
Arthur, A. & Gronthos, S. Clinical application of bone marrow mesenchymal stem/stromal cells to repair skeletal tissue. Int. J. Mol. Sci. 21, 9759 (2020).33371306 10.3390/ijms21249759
324. Galipeau J The mesenchymal stromal cells dilemma–does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road Cytotherapy 2013 15 2 8 10.1016/j.jcyt.2012.10.002 23260081
Galipeau, J. The mesenchymal stromal cells dilemma–does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road. Cytotherapy 15, 2–8 (2013).23260081 10.1016/j.jcyt.2012.10.002
325. Mendicino M MSC-based product characterization for clinical trials: an FDA perspective Cell Stem Cell 2014 14 141 145 10.1016/j.stem.2014.01.013 24506881
Mendicino, M. et al. MSC-based product characterization for clinical trials: an FDA perspective. Cell Stem Cell 14, 141–145 (2014).24506881 10.1016/j.stem.2014.01.013
326. Alsalem MA Rescuing emergency cases of COVID-19 patients: an intelligent real-time MSC transfusion framework based on multicriteria decision-making methods Appl. Intell. 2022 52 9676 9700 10.1007/s10489-021-02813-5
Alsalem, M. A. et al. Rescuing emergency cases of COVID-19 patients: an intelligent real-time MSC transfusion framework based on multicriteria decision-making methods. Appl. Intell. 52, 9676–9700 (2022).10.1007/s10489-021-02813-5
327. Fabian C Distribution pattern following systemic mesenchymal stem cell injection depends on the age of the recipient and neuronal health Stem Cell Res. Ther. 2017 8 85 10.1186/s13287-017-0533-2 28420415
Fabian, C. et al. Distribution pattern following systemic mesenchymal stem cell injection depends on the age of the recipient and neuronal health. Stem Cell Res. Ther. 8, 85 (2017).28420415 10.1186/s13287-017-0533-2
328. Parekkadan B Milwid JM Mesenchymal stem cells as therapeutics Annu. Rev. Biomed. Eng. 2010 12 87 117 10.1146/annurev-bioeng-070909-105309 20415588
Parekkadan, B. & Milwid, J. M. Mesenchymal stem cells as therapeutics. Annu. Rev. Biomed. Eng. 12, 87–117 (2010).20415588 10.1146/annurev-bioeng-070909-105309
329. Wang H A physiologically based kinetic model for elucidating the in vivo distribution of administered mesenchymal stem cells Sci. Rep. 2016 6 22293 10.1038/srep22293 26924777
Wang, H. et al. A physiologically based kinetic model for elucidating the in vivo distribution of administered mesenchymal stem cells. Sci. Rep. 6, 22293 (2016).26924777 10.1038/srep22293
330. Singh AP Development of a quantitative relationship between CAR-affinity, antigen abundance, tumor cell depletion and CAR-T cell expansion using a multiscale systems PK-PD model MAbs 2020 12 1688616 10.1080/19420862.2019.1688616 31852337
Singh, A. P. et al. Development of a quantitative relationship between CAR-affinity, antigen abundance, tumor cell depletion and CAR-T cell expansion using a multiscale systems PK-PD model. MAbs 12, 1688616 (2020).31852337 10.1080/19420862.2019.1688616
331. Singh AP Bench-to-bedside translation of chimeric antigen receptor (CAR) T cells using a multiscale systems pharmacokinetic-pharmacodynamic model: a case study with anti-BCMA CAR-T CPT Pharmacomet. Syst. Pharm. 2021 10 362 376 10.1002/psp4.12598
Singh, A. P. et al. Bench-to-bedside translation of chimeric antigen receptor (CAR) T cells using a multiscale systems pharmacokinetic-pharmacodynamic model: a case study with anti-BCMA CAR-T. CPT Pharmacomet. Syst. Pharm. 10, 362–376 (2021).10.1002/psp4.12598
332. Brooks A Concise Review: quantitative detection and modeling the in vivo kinetics of therapeutic mesenchymal stem/stromal cells Stem Cells Transl. Med. 2018 7 78 86 10.1002/sctm.17-0209 29210198
Brooks, A. et al. Concise Review: quantitative detection and modeling the in vivo kinetics of therapeutic mesenchymal stem/stromal cells. Stem Cells Transl. Med. 7, 78–86 (2018).29210198 10.1002/sctm.17-0209
333. Kerkelä E Transient proteolytic modification of mesenchymal stromal cells increases lung clearance rate and targeting to injured tissue Stem Cells Transl. Med 2013 2 510 520 10.5966/sctm.2012-0187 23734061
Kerkelä, E. et al. Transient proteolytic modification of mesenchymal stromal cells increases lung clearance rate and targeting to injured tissue. Stem Cells Transl. Med 2, 510–520 (2013).23734061 10.5966/sctm.2012-0187
334. Pachón-Peña G A glycovariant of human CD44 is characteristically expressed on human mesenchymal stem cells Stem Cells 2017 35 1080 1092 10.1002/stem.2549 27888602
Pachón-Peña, G. et al. A glycovariant of human CD44 is characteristically expressed on human mesenchymal stem cells. Stem Cells 35, 1080–1092 (2017).27888602 10.1002/stem.2549
335. Dykstra B Glycoengineering of E-selectin ligands by intracellular versus extracellular fucosylation differentially affects osteotropism of human mesenchymal stem cells Stem Cells 2016 34 2501 2511 10.1002/stem.2435 27335219
Dykstra, B. et al. Glycoengineering of E-selectin ligands by intracellular versus extracellular fucosylation differentially affects osteotropism of human mesenchymal stem cells. Stem Cells 34, 2501–2511 (2016).27335219 10.1002/stem.2435
336. Chou KJ CD44 fucosylation on mesenchymal stem cell enhances homing and macrophage polarization in ischemic kidney injury Exp. Cell Res. 2017 350 91 102 10.1016/j.yexcr.2016.11.010 27871849
Chou, K. J. et al. CD44 fucosylation on mesenchymal stem cell enhances homing and macrophage polarization in ischemic kidney injury. Exp. Cell Res. 350, 91–102 (2017).27871849 10.1016/j.yexcr.2016.11.010
337. Hao D Surface modification of polymeric electrospun scaffolds via a potent and high-affinity integrin α4β1 ligand improved the adhesion, spreading and survival of human chorionic villus-derived mesenchymal stem cells: a new insight for fetal tissue engineering J. Mater. Chem. B 2020 8 1649 1659 10.1039/C9TB02309G 32011618
Hao, D. et al. Surface modification of polymeric electrospun scaffolds via a potent and high-affinity integrin α4β1 ligand improved the adhesion, spreading and survival of human chorionic villus-derived mesenchymal stem cells: a new insight for fetal tissue engineering. J. Mater. Chem. B 8, 1649–1659 (2020).32011618 10.1039/C9TB02309G
338. Meitei HT CCR6-CCL20 axis as a therapeutic target for autoimmune diseases Autoimmun. Rev. 2021 20 102846 10.1016/j.autrev.2021.102846 33971346
Meitei, H. T. et al. CCR6-CCL20 axis as a therapeutic target for autoimmune diseases. Autoimmun. Rev. 20, 102846 (2021).33971346 10.1016/j.autrev.2021.102846
339. Shao Y Overexpression of CXCR7 promotes mesenchymal stem cells to repair phosgene-induced acute lung injury in rats Biomed. Pharmacother. 2019 109 1233 1239 10.1016/j.biopha.2018.10.108 30551373
Shao, Y. et al. Overexpression of CXCR7 promotes mesenchymal stem cells to repair phosgene-induced acute lung injury in rats. Biomed. Pharmacother. 109, 1233–1239 (2019).30551373 10.1016/j.biopha.2018.10.108
340. Zhang X Mesenchymal stromal cells ameliorate chronic GVHD by boosting thymic regeneration in a CCR9-dependent manner in mice Blood Adv. 2023 7 5359 5373 10.1182/bloodadvances.2022009646 37363876
Zhang, X. et al. Mesenchymal stromal cells ameliorate chronic GVHD by boosting thymic regeneration in a CCR9-dependent manner in mice. Blood Adv. 7, 5359–5373 (2023).37363876 10.1182/bloodadvances.2022009646
341. Lin Y Unveiling the improved targeting migration of mesenchymal stem cells with CXC chemokine receptor 3-modification using intravital NIR-II photoacoustic imaging J. Nanobiotechnol. 2022 20 307 10.1186/s12951-022-01513-7
Lin, Y. et al. Unveiling the improved targeting migration of mesenchymal stem cells with CXC chemokine receptor 3-modification using intravital NIR-II photoacoustic imaging. J. Nanobiotechnol. 20, 307 (2022).10.1186/s12951-022-01513-7
342. Sanghani A CXCR4 has the potential to enhance bone formation in osteopenic rats Tissue Eng. Part A 2018 24 1775 1783 10.1089/ten.tea.2018.0121 29882473
Sanghani, A. et al. CXCR4 has the potential to enhance bone formation in osteopenic rats. Tissue Eng. Part A 24, 1775–1783 (2018).29882473 10.1089/ten.tea.2018.0121
343. Bobis-Wozowicz S Genetically modified adipose tissue-derived mesenchymal stem cells overexpressing CXCR4 display increased motility, invasiveness, and homing to bone marrow of NOD/SCID mice Exp. Hematol. 2011 39 686 696.e4 10.1016/j.exphem.2011.03.004 21426925
Bobis-Wozowicz, S. et al. Genetically modified adipose tissue-derived mesenchymal stem cells overexpressing CXCR4 display increased motility, invasiveness, and homing to bone marrow of NOD/SCID mice. Exp. Hematol. 39, 686–696.e4 (2011).21426925 10.1016/j.exphem.2011.03.004
344. Ye D Short-wave enhances mesenchymal stem cell recruitment in fracture healing by increasing HIF-1 in callus Stem Cell Res Ther. 2020 11 382 10.1186/s13287-020-01888-0 32894200
Ye, D. et al. Short-wave enhances mesenchymal stem cell recruitment in fracture healing by increasing HIF-1 in callus. Stem Cell Res Ther. 11, 382 (2020).32894200 10.1186/s13287-020-01888-0
345. Jin W Modelling of the SDF-1/CXCR4 regulated in vivo homing of therapeutic mesenchymal stem/stromal cells in mice PeerJ 2018 6 e6072 10.7717/peerj.6072 30564525
Jin, W. et al. Modelling of the SDF-1/CXCR4 regulated in vivo homing of therapeutic mesenchymal stem/stromal cells in mice. PeerJ 6, e6072 (2018).30564525 10.7717/peerj.6072
346. Yang JX CXCR4 receptor overexpression in mesenchymal stem cells facilitates treatment of acute lung injury in rats J. Biol. Chem. 2015 290 1994 2006 10.1074/jbc.M114.605063 25492872
Yang, J. X. et al. CXCR4 receptor overexpression in mesenchymal stem cells facilitates treatment of acute lung injury in rats. J. Biol. Chem. 290, 1994–2006 (2015).25492872 10.1074/jbc.M114.605063
347. Song C Li G CXCR4 and matrix metalloproteinase-2 are involved in mesenchymal stromal cell homing and engraftment to tumors Cytotherapy 2011 13 549 561 10.3109/14653249.2010.542457 21171825
Song, C. & Li, G. CXCR4 and matrix metalloproteinase-2 are involved in mesenchymal stromal cell homing and engraftment to tumors. Cytotherapy 13, 549–561 (2011).21171825 10.3109/14653249.2010.542457
348. Yu X Hypoxic preconditioning with cobalt of bone marrow mesenchymal stem cells improves cell migration and enhances therapy for treatment of ischemic acute kidney injury PLoS One 2013 8 e62703 10.1371/journal.pone.0062703 23671625
Yu, X. et al. Hypoxic preconditioning with cobalt of bone marrow mesenchymal stem cells improves cell migration and enhances therapy for treatment of ischemic acute kidney injury. PLoS One 8, e62703 (2013).23671625 10.1371/journal.pone.0062703
349. Liu H The role of SDF-1-CXCR4/CXCR7 axis in the therapeutic effects of hypoxia-preconditioned mesenchymal stem cells for renal ischemia/reperfusion injury PLoS One 2012 7 e34608 10.1371/journal.pone.0034608 22511954
Liu, H. et al. The role of SDF-1-CXCR4/CXCR7 axis in the therapeutic effects of hypoxia-preconditioned mesenchymal stem cells for renal ischemia/reperfusion injury. PLoS One 7, e34608 (2012).22511954 10.1371/journal.pone.0034608
350. Hu C CXCL12/CXCR4 axis promotes mesenchymal stem cell mobilization to burn wounds and contributes to wound repair J. Surg. Res. 2013 183 427 434 10.1016/j.jss.2013.01.019 23462453
Hu, C. et al. CXCL12/CXCR4 axis promotes mesenchymal stem cell mobilization to burn wounds and contributes to wound repair. J. Surg. Res. 183, 427–434 (2013).23462453 10.1016/j.jss.2013.01.019
351. Lozito TP Tuan RS Mesenchymal stem cells inhibit both endogenous and exogenous MMPs via secreted TIMPs J. Cell Physiol. 2011 226 385 396 10.1002/jcp.22344 20665704
Lozito, T. P. & Tuan, R. S. Mesenchymal stem cells inhibit both endogenous and exogenous MMPs via secreted TIMPs. J. Cell Physiol. 226, 385–396 (2011).20665704 10.1002/jcp.22344
352. Sarkar D Engineered cell homing Blood 2011 118 e184 e191 10.1182/blood-2010-10-311464 22034631
Sarkar, D. et al. Engineered cell homing. Blood 118, e184–e191 (2011).22034631 10.1182/blood-2010-10-311464
353. Yan H Targeted repair of vascular injury by adipose-derived stem cells modified with P-selectin binding peptide Adv. Sci. 2020 7 1903516 10.1002/advs.201903516
Yan, H. et al. Targeted repair of vascular injury by adipose-derived stem cells modified with P-selectin binding peptide. Adv. Sci. 7, 1903516 (2020).10.1002/advs.201903516
354. Conway M Real-time tracking of stem cell viability, proliferation, and differentiation with autonomous bioluminescence imaging BMC Biol. 2020 18 79 10.1186/s12915-020-00815-2 32620121
Conway, M. et al. Real-time tracking of stem cell viability, proliferation, and differentiation with autonomous bioluminescence imaging. BMC Biol. 18, 79 (2020).32620121 10.1186/s12915-020-00815-2
355. Ryu CM Longitudinal intravital imaging of transplanted mesenchymal stem cells elucidates their functional integration and therapeutic potency in an animal model of interstitial cystitis/bladder pain syndrome Theranostics 2018 8 5610 5624 10.7150/thno.27559 30555567
Ryu, C. M. et al. Longitudinal intravital imaging of transplanted mesenchymal stem cells elucidates their functional integration and therapeutic potency in an animal model of interstitial cystitis/bladder pain syndrome. Theranostics 8, 5610–5624 (2018).30555567 10.7150/thno.27559
356. Yan S Extracellular magnetic labeling of biomimetic hydrogel-induced human mesenchymal stem cell spheroids with ferumoxytol for MRI tracking Bioact. Mater. 2023 19 418 428 35574059
Yan, S. et al. Extracellular magnetic labeling of biomimetic hydrogel-induced human mesenchymal stem cell spheroids with ferumoxytol for MRI tracking. Bioact. Mater. 19, 418–428 (2023).35574059
357. Betzer O Nanoparticle-based CT imaging technique for longitudinal and quantitative stem cell tracking within the brain: application in neuropsychiatric disorders ACS Nano 2014 8 9274 9285 10.1021/nn503131h 25133802
Betzer, O. et al. Nanoparticle-based CT imaging technique for longitudinal and quantitative stem cell tracking within the brain: application in neuropsychiatric disorders. ACS Nano 8, 9274–9285 (2014).25133802 10.1021/nn503131h
358. Wu C Polymeric vector-mediated gene transfection of MSCs for dual bioluminescent and MRI tracking in vivo Biomaterials 2014 35 8249 8260 10.1016/j.biomaterials.2014.06.014 24976241
Wu, C. et al. Polymeric vector-mediated gene transfection of MSCs for dual bioluminescent and MRI tracking in vivo. Biomaterials 35, 8249–8260 (2014).24976241 10.1016/j.biomaterials.2014.06.014
359. Huang J CT/NIRF dual-modal imaging tracking and therapeutic efficacy of transplanted mesenchymal stem cells labeled with Au nanoparticles in silica-induced pulmonary fibrosis J. Mater. Chem. B 2020 8 1713 1727 10.1039/C9TB02652E 32022096
Huang, J. et al. CT/NIRF dual-modal imaging tracking and therapeutic efficacy of transplanted mesenchymal stem cells labeled with Au nanoparticles in silica-induced pulmonary fibrosis. J. Mater. Chem. B 8, 1713–1727 (2020).32022096 10.1039/C9TB02652E
360. Tang Y MRI/SPECT/fluorescent tri-modal probe for evaluating the homing and therapeutic efficacy of transplanted mesenchymal stem cells in a rat ischemic stroke model Adv. Funct. Mater. 2015 25 1024 1034 10.1002/adfm.201402930 26290659
Tang, Y. et al. MRI/SPECT/fluorescent tri-modal probe for evaluating the homing and therapeutic efficacy of transplanted mesenchymal stem cells in a rat ischemic stroke model. Adv. Funct. Mater. 25, 1024–1034 (2015).26290659 10.1002/adfm.201402930
361. Ning P Multimodal imaging-guided spatiotemporal tracking of photosensitive stem cells for breast cancer treatment ACS Appl Mater. Interfaces 2022 14 7551 7564 10.1021/acsami.1c13072 35107006
Ning, P. et al. Multimodal imaging-guided spatiotemporal tracking of photosensitive stem cells for breast cancer treatment. ACS Appl Mater. Interfaces 14, 7551–7564 (2022).35107006 10.1021/acsami.1c13072
